TABLE OF CONTENTS

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

SCHEDULE 14A


(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the


Securities Exchange Act of 1934

(Amendment No.    )

Filed by the Registrant   ☒                             Filed by a Party other than the Registrant  ☐

Filed by the Registrant ☒
Filed by a Party other than the Registrant  o

Check the appropriate box:

 o
Preliminary Proxy Statement
 o
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
 o
Definitive Additional Materials
 o
Soliciting Material Pursuant to §240.14a-12

GNC HOLDINGS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

GNC HOLDINGS, INC.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.
 o
Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11.
(1)
(1)

Title of each class of securities to which transaction applies:

(2)
(2)

Aggregate number of securities to which transaction applies:

(3)
(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)
(4)

Proposed maximum aggregate value of transaction:

(5)
(5)

Total fee paid:

 o
Fee paid previously with preliminary materials:
 o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
(1)
(1)

Amount previously paid:

(2)
(2)

Form, Schedule or Registration Statement No.:

(3)

Filing Party:

(3)
(4)
Filing Party:

(4)
Date Filed:

   

TABLE OF CONTENTS



LOGO

300 Sixth Avenue


Pittsburgh, Pennsylvania 15222

March 26, 2018April 11, 2019

Dear Stockholder,

You are cordially invited to attend a Specialthe Annual Meeting of Stockholders of GNC Holdings, Inc. (the “Company”) to be held on April 25, 2018Tuesday, May 21, 2019 at 8:3000 a.m., Eastern Time at the Omni William Penn Hotel, 530 William Penn Place, Sternwheeler Room, Pittsburgh, Pennsylvania 15219 (the “Special Meeting”).15219.

On February 13, 2018,The agenda for the Company entered intoAnnual Meeting includes:

The election of nine (9) directors named in the attached proxy statement to our Board of Directors (Proposal 1);
An advisory vote to approve the compensation paid to our Named Executive Officers disclosed in the attached proxy statement (commonly known as a Securities Purchase Agreement with Harbin Pharmaceutical Group Holdings Co., Ltd. (the “Investor”), pursuant to which the Company agreed to issue“say-on-pay” proposal) (Proposal 2); and sell to the Investor, and the Investor agreed to purchase from the Company, 299,950 shares of a newly created series of convertible preferred stock
The ratification of the Company, to be designatedappointment of PricewaterhouseCoopers LLP as “Series A Convertible Preferred Stock” (the “Convertible Preferred Stock”),our independent registered accounting firm for a purchase price of $1,000 per share, or an aggregate purchase price of approximately $300 million. The Convertible Preferred Stock will be convertible into shares of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”), at an initial conversion price of $5.35 per share, subject to customary antidilution adjustments, and will accrue cumulative preferential dividends, payable quarterly in arrears, at an annual rate of 6.50% of the stated value of the Convertible Preferred Stock. The transaction is subject to customary closing conditions, including receipt of all necessary regulatory and governmental approvals, approval of our stockholders and the entry by the parties into a commercial joint venture in China.

2019 fiscal year (Proposal 3).

At the Special Meeting, you will be asked to consider and vote on a proposal to approve, in accordance with Section 312.03 of the NYSE Listed Company Manual, the issuance of the Convertible Preferred Stock to the Investor, which Convertible Preferred Stock will include the right to (i) at the option of the Investor, convert such Convertible Preferred Stock into shares of the Company’s Common Stock and (ii) receive additional shares of Convertible Preferred Stock or an increase in the stated value of the Convertible Preferred Stock as a result of the payment ofnon-cash dividends (the “Share Issuance”).

Our Board of Directors unanimously recommends that you vote “FOR” the Share Issuance.

Stockholders of record at the close of business on March 23, 2018 are entitled to notice of,FOR Proposals 1, 2, and to vote at, the Special Meeting or any adjournment or postponement thereof.3.

Your interest in the Company and your vote are very important to us. The enclosed proxy materials contain detailed information regarding the proposalbusiness that will be considered at the SpecialAnnual Meeting. We encourage you to read the proxy materials and vote your shares as soon as possible. You may vote your proxy via the Internet or telephone or, if you received a paper copy of the proxy materials, by mail by completing and returning the proxy card in the accompanying prepaid reply envelope.

Whether or not you plan to attend the Special Meeting, please complete, date, sign and return, as promptly as possible, the enclosed proxy card in the accompanying prepaid reply envelope, or submit your proxy by telephone or the Internet. If you attend the Special Meeting and vote in person, your vote by ballot will revoke any proxy previously submitted.

If your shares of Common Stock are held in “street name” by your bank, brokerage firm or other nominee, your bank, brokerage firm or other nominee will be unable to vote your shares of Common Stock without instructions from you. You should instruct your bank, brokerage firm or other nominee to vote your shares of Common Stock in accordance with the procedures provided by your bank, brokerage firm or other nominee.


If you have any questions or need assistance voting your shares of Common Stock, please contact Georgeson LLC, our proxy solicitor, by calling toll-free at (888)607-9107.card.

On behalf of the Company,GNC, I would like to express our appreciation for your ongoing interestinvestment in GNC.the Company.

Live Well,
Very truly yours,

LOGO

Kenneth A. Martindale
Chairman and Chief Executive Officer


LOGO

TABLE OF CONTENTS

GNC HOLDINGS, INC.


NOTICE OF

SPECIAL
2019 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON APRIL 25, 2018

MAY 21, 2019

DATE AND TIME
8:3000 a.m., Eastern Time, on April 25, 2018Tuesday, May 21, 2019
PLACE
Omni William Penn Hotel
530 William Penn Place Sternwheeler Room,
Pittsburgh, Pennsylvania 15219
ITEMS OF BUSINESS
(1)
To considerelect nine (9) directors named in these proxy materials to hold office until our 2020 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal (Proposal 1).
(2)
To approve, by non-binding vote on a proposalan advisory basis, the compensation paid to approve,our Named Executive Officers in accordance with Section 312.03 of the NYSE Listed Company Manual, the issuance by GNC Holdings, Inc. (the “Company”) to Harbin Pharmaceutical Group Holdings Co., Ltd. (the “Investor”)2018, as disclosed in a private placement of 299,950 shares of a newly created series of convertible preferred stock (the “Convertible Preferred Stock”) of the Company, which will include the right to (i) at the option of the Investor, convert such Convertible Preferred Stock into shares of the Company’s Class A common stock, par value $0.001 per share, and (ii) receive additional shares of Convertible Preferred Stock or an increase in the stated value of the Convertible Preferred Stockthese proxy materials (commonly known as a result of the payment ofnon-cash dividends (the “Share Issuance”)“say-on-pay” proposal) (Proposal 2).
(3)
To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our 2019 fiscal year (Proposal 3).
(4)
To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
RECORD DATE
You are entitled to vote only if you were a stockholder of record at the close of business on March 23, 2018.25, 2019, our record date.
PROXY VOTING
It is important that your shares be represented and voted at the SpecialAnnual Meeting. Whether or not you plan to attend the SpecialAnnual Meeting, we urge you to vote online at www.proxyvote.com or via telephone by calling1-800-690-6903, or to complete and return a proxy card in the accompanying prepaid reply envelope (no postage is required).
REQUIRED VOTE
Pursuant to the rules of the New York Stock Exchange, the approval of the Share Issuance requires the
The affirmative vote of a majority of the shares present (invotes cast by our stockholders in person or represented by proxy) and entitled to voteproxy at the Special Meeting.Annual Meeting is required to approve each of the Proposals described in these proxy materials.

March 26,Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on May 21, 2019: As permitted by rules adopted by the Securities and Exchange Commission, rather than mailing a full paper set of these proxy materials, we are mailing to many of our stockholders only a notice of Internet availability of proxy materials containing instructions on how to access these proxy materials and submit their respective proxy votes online. This proxy statement, our 2018 Annual Report on Form 10-K and the proxy card are available at www.proxyvote.com. You will need your notice of Internet availability or proxy card to access these proxy materials.

April 11, 2019

LOGO

Susan M. Canning
Kevin G. Nowe
Senior Vice President, Chief Legal Officer and
Secretary


TABLE OF CONTENTS

i

TABLE OF CONTENTS


- i -


LOGO

300 Sixth Avenue


Pittsburgh, Pennsylvania 15222

PROXY STATEMENT

SPECIAL2019 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON APRIL 25, 2018
May 21, 2019

The Board of Directors (the “Board”) of GNC Holdings, Inc., a Delaware corporation (the “Company,” “we,” “us,” or “our”), has prepared this document to solicit your proxy to vote upon certain matters at a specialour 2019 annual meeting of our stockholders (the “Special“Annual Meeting”).

These proxy materials contain information regarding the SpecialAnnual Meeting, to be held on April 25, 2018,Tuesday, May 21, 2019, beginning at 8:3000 a.m., Eastern Time at the Omni William Penn Hotel, 530 William Penn Place, Sternwheeler Room, Pittsburgh, Pennsylvania 15219, and at any adjournmentsadjournment or postponementspostponement thereof. As permitted by the rules adopted by the Securities and Exchange Commission (the “SEC”), rather than mailing a full paper set of these proxy materials, we are mailing to many of our stockholders only a notice of Internet availability of proxy materials (the “Notice”) containing instructions on how to access and review these proxy materials and submit their respective proxy votes online. If you receive the Notice and would like to receive a paper copy of these proxy materials, you should follow the instructions for requesting such materials located at www.proxyvote.com.

QUESTIONS ABOUT THE ANNUAL MEETING AND THESE PROXY MATERIALS

It is anticipated that we will begin mailing this proxy statement, andthe proxy card, our Annual Report on Form 10-K for the year ended December 31, 2018 (the “Annual Report”) and the Notice, and that these proxy materials will first be made available online to our stockholders, on or about March 26, 2018.April 11, 2019. The information regarding stock ownership and other matters in this proxy statement is as of March 23, 201825, 2019 (the “Record Date”), unless otherwise indicated.

QUESTIONS ABOUT THE SPECIAL MEETING AND THESE PROXY MATERIALSWhat may I vote on?

Why am I receiving this proxy statement?

We are sending you this proxy statement because the Board is soliciting your proxy to vote at the Special Meeting to be held on April 25, 2018, at 8:30 a.m., Eastern Time, at the Omni William Penn, 530 William Penn Place, Sternwheeler Room, Pittsburgh, Pennsylvania 15219, and any adjournments or postponements of the Special Meeting. This proxy statement summarizes information that is intended to assist you in making an informedYou may vote on the proposalfollowing proposals:

the election of nine (9) directors to be considered at serve until our 2020 annual meeting of stockholders (the “2020 Annual Meeting”) and their respective successors have been duly elected and qualified, or their earlier resignation or removal (Proposal 1);
the Special Meeting.

What is the purposeapproval, by non-binding vote, on an advisory basis of the Special Meeting?

On February 13,compensation paid to our Named Executive Officers for 2018, as disclosed in these proxy materials (commonly known as a “say-on-pay” proposal) (Proposal 2); and

the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Harbin Pharmaceutical Group Holdings Co., Ltd. (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor, and the Investor agreed to purchase from the Company, 299,950 shares of a newly created series of convertible preferred stockratification of the Company, to be designatedappointment of PricewaterhouseCoopers LLP (“PwC”) as “Series A Convertible Preferred Stock” (the “Convertible Preferred Stock”), for a purchase price of $1,000 per share, or an aggregate purchase price of approximately $300 million. The transaction is subject to customary closing conditions, including receipt of all necessary regulatory and governmental approvals, approval of our stockholders and entry into the Joint Venture (as defined below). The Convertible Preferred Stock will be convertible into shares of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”), at an initial conversion price of $5.35 per share, subject to customary antidilution adjustments (the “Conversion Price”), and will accrue cumulative preferential dividends, payable quarterly in arrears, at an annual rate of 6.50% of the Stated Value (as defined below). The terms of the Convertible Preferred Stock will be set forth in the certificate of designations of preferences, rights and limitationsindependent registered public accounting firm for the Convertible Preferred Stock (the “Certificate of Designations”2019 fiscal year (Proposal 3).

THE BOARD RECOMMENDS A VOTE (1) FOR THE ELECTION OF EACH OF OUR NOMINEES FOR DIRECTORS (PROPOSAL 1), (2) FOR THE APPROVAL, BY NON-BINDING VOTE ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS FOR 2018 (“SAY-ON-PAY”) to be filed by the Company with the Secretary of State of the State of Delaware prior to the closing of the transaction. The Certificate of Designations is described in more detail in the section entitled“Description of the Convertible Preferred Stock” below.

In connection with the Securities Purchase Agreement, we will enter into a stockholders agreement (the “Stockholders Agreement”) with the Investor, which will provide for certain rights and responsibilities of the

parties in connection with the Investor’s investment and the governance of the Company, and a registration rights agreement (the “Registration Rights Agreement”) with the Investor, which will provide for the obligation of the Company, at the request of the Investor, to register the resale of the Common Stock underlying the Convertible Preferred Stock with the U.S. Securities and Exchange Commission (the “SEC”). In addition, the Securities Purchase Agreement provides for the parties to use reasonable best efforts to negotiate definitive documentation with respect to a commercial joint venture in China (the “Joint Venture”)(PROPOSAL 2), pursuant to which, among other things, the Joint Venture would be granted an exclusive right to use the Company’s trademarks and manufacture and distribute the Company’s products in China (excluding Hong Kong, Taiwan and Macau)AND (3) FOR THE RATIFICATION OF THE APPOINTMENT OF PWC AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PROPOSAL 3). The Company would receive royalties on all products sold by the Joint Venture. The Joint Venture would be owned 65% by the Investor and 35% by the Company. The Stockholders Agreement, the Registration Rights Agreement and the Joint Venture are described in more detail in the section entitled“Description of the Transaction Documents” below.

Additionally, on February 28, 2018, the Company completed the refinancing of the Company’s Existing Credit Agreement (as defined below), which provided for (i) the amendment and restatement of the Company’s Existing Credit Agreement to extend the maturity date of certain term loans of the Company, (ii) the repayment in full and termination of the Company’s revolving credit facility, (iii) the repayment of a portion of the Company’s existing term loans and (iv) the entrance into a new asset-based term loan facility. These financing-related transactions satisfy the condition to completion of the issuance, purchase and sale of the Convertible Preferred Stock with respect to the Credit Agreement Refinancing (as defined in the Securities Purchase Agreement). More information regarding these financing-related transactions can be found in the section entitled “Description of the Share Issuance” below.

In accordance with the Securities Purchase Agreement and applicable rules, regulations and guidance of the New York Stock Exchange (the “NYSE”), the Company is calling the Special Meeting to consider and vote upon a proposal to approve, in accordance with Section 312.03 of the NYSE Listed Company Manual, the issuance of the Convertible Preferred Stock to the Investor, which Convertible Preferred Stock will include the right to (i) at the option of the Investor, convert such Convertible Preferred Stock into shares of the Company’s Common Stock and (ii) receive additional shares of Convertible Preferred Stock or an increase in the stated value of the Convertible Preferred Stock as a result of the payment ofnon-cash dividends (the “Share Issuance”).

How does the Board recommend that I vote?

After consulting with its financial advisors and outside legal counsel and after reviewing and considering the terms and conditions of the Share Issuance and the factors more fully described in this proxy statement, the Board unanimously (i) approved the Securities Purchase Agreement and the other transaction documents and the transactions contemplated thereby, including the Share Issuance; (ii) determined that the terms of the Securities Purchase Agreement and the other transaction documents and the transactions contemplated thereby, including the Share Issuance, are fair to, and in the best interests of, the Company and its stockholders; (iii) directed that the Share Issuance be submitted to the stockholders of the Company for approval; (iv) recommended approval of the Share Issuance by the Company’s stockholders; and (v) declared that the Securities Purchase Agreement and the other transaction documents and the transactions contemplated thereby, including the Share Issuance, are advisable.

The Board unanimously recommends that the Company’s stockholders vote “FOR” the proposal to approve the Share Issuance.

What are the principal conditions to consummation of the Share Issuance?

The obligations of the Company and the Investor to complete the issuance, purchase and sale of the Convertible Preferred Stock are subject to the satisfaction or waiver (to the extent permitted by applicable law) by the Company and the Investor at or prior to the Closing of the following conditions:

the approval of the Share Issuance by the Company’s stockholders;

the receipt of the PRC Approvals and CFIUS Clearance (each as defined below);

the entrance into the Joint Venture; and

other customary conditions, including, among other things, accuracy of representations and warranties and compliance with covenants by the parties.

The Company and the Investor (i) have agreed that the condition that the Company complete the Credit Agreement Refinancing has been satisfied, and (ii) have determined that no filings are required with respect to the Share Issuance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), and that, accordingly, the condition with respect to an HSR Act filing is deemed to be satisfied.

See the section entitled “Description of the Transaction Documents—Securities PurchaseAgreement—Conditions to Completion of the Issuance, Purchase and Sale of the Convertible Preferred Stock” below for a full description of the conditions to consummating the Share Issuance.

What happens if the Share Issuance is not completed?

If the Share Issuance is not approved by the Company’s stockholders, or if another condition to the consummation of the Share Issuance is not satisfied, the Share Issuance will not be completed and the Securities Purchase Agreement may be terminated.

Under specified circumstances following the termination of the Securities Purchase Agreement, we may be required to pay the Investor a termination fee or to reimburse certain of the Investor’s transaction expenses, or we may be entitled to receive a reverse termination fee from the Investor, as described in the section entitled “Description of the Transaction Documents—Securities Purchase Agreement— Termination of the Securities Purchase Agreement” below.

Why is stockholder approval necessary for the Share Issuance?

Our Common Stock is listed on the NYSE and we are subject to the NYSE rules and regulations. Section 312.03(c) of the NYSE Listed Company Manual requires stockholder approval prior to any issuance of common stock, or of securities convertible into common stock, in any transaction or series of related transactions if (1) the common stock to be issued has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such stock or of securities convertible into or exercisable for common stock, or (2) the number of shares of common stock to be issued is, or will be upon issuance, equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of the common stock or of securities convertible into or exercisable for common stock.

At the closing of the Share Issuance, the Convertible Preferred Stock to be sold to the Investor will be convertible, at the option of the Investor, into 56,065,421 shares of Common Stock (subject to adjustment), which represents greater than 20% of both the voting power and number of shares of our Common Stock outstanding prior to the issuance. Because the sale of the Convertible Preferred Stock to the Investor exceeds 20% of both the voting power and number of shares of our Common Stock outstanding prior to the issuance and would implicate Section 312.03(c) of the NYSE Listed Company Manual and, since the NYSE rules do not define “change of control,” possibly 312.03(d) of the NYSE Listed Company Manual, we must seek stockholder approval prior to making such issuance. Further, we are obligated to seek such stockholder approval pursuant to the Securities Purchase Agreement.

When and where is the Special Meeting?

The Special Meeting will take place on April 25, 2018 at 8:30 a.m., Eastern Time, at the Omni William Penn, 530 William Penn Place, Sternwheeler Room, Pittsburgh, Pennsylvania 15219.

Pursuant to our Fifth Amended and Restated Bylaws (the “Bylaws”), either our Board or the presiding person of the Special Meeting has the power to recess and/or adjourn the meeting, for any or no reason, to another place, date and time. We intend to adjourn the Special Meeting to solicit additional proxies if there are insufficient votes at the Special Meeting to approve the Share Issuance.

If the Special Meeting is adjourned to another time or place, the Company may transact any business which might have been transacted at the original meeting. If the meeting is adjourned for 30 days or fewer and no new record date is set for the adjourned meeting, the time and place of the adjourned meeting will be announced at the Special Meeting and no other notice will be sent to stockholders.

Who may vote?

Stockholders of record, of our Common Stock at the close of business on the Record Date are entitled to receive the Notice and these proxy materials and to vote their respective shares at the SpecialAnnual Meeting. Each share of our Class A common stock, par value $0.001 per share (“Common StockStock”) is entitled to one vote on each matter that is properly brought before the SpecialAnnual Meeting. As of the Record Date, there were 83,661,96583,966,049 shares of Common Stock issued and outstanding.

Each share of our Series A Convertible Preferred Stock, par value $0.001 per share (“Preferred Stock”) is entitled to a number of votes equal to the number of shares of Common Stock that such Preferred Stock may convert into as of the

1

TABLE OF CONTENTS

Record Date, calculated by dividing (i) the applicable liquidation preference, which as of the Record Date is $1,000.00 per share, by $5.35 per share, and disregarding any fractional shares into which such aggregate number is convertible. As of the Record Date, there were 299,950 shares of Preferred Stock issued and outstanding, entitling the holder thereof to cast 56,065,420 votes.

Holders of our Common Stock and Preferred Stock vote together as a single class on all matters presented to the stockholders for their vote or approval, except as may otherwise be required by Delaware Law or the terms of our Certificate of Incorporation, as amended and restated. Under the terms of the Stockholders Agreement, entered into November 8, 2018 (the “Stockholders Agreement”) between the Company and Harbin Pharmaceutical Group Co., Ltd. (“Harbin”), the current holder of our Preferred Stock, Harbin has agreed for so long as it holds at least fifteen percent (15%) of the Company’s common stock (on an as-converted basis) to vote either in accordance with the recommendations of the Board or in accordance with the relative percentage votes of the Common Stock.

How do I vote?

We encourage you to vote your shares via the Internet. How you vote will depend on how you hold your shares of Common Stock.

Stockholders of Record

If your Common Stock is registered directly in your name with our transfer agent, American Stock, Transfer & Trust Company, LLC, you are considered a stockholder of record with respect to those shares, and a full paper set of these proxy materials is being sent directly to you. As a stockholder of record, you have the right to vote by proxy.

You may vote by proxy in any of the following three ways:

InternetInternet.. Go to www.proxyvote.com to use the Internet to transmit your voting instructions.instructions and for electronic delivery of information. Have your proxy card in hand when you access the website.

PhonePhone.. Call1-800-690-6903 using any touch-tone telephone to transmit your voting instructions. Have your proxy card in hand when you call.

MailMail.. Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided, or return it in your own envelope to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

Voting by any of these methods will not affect your right to attend the SpecialAnnual Meeting and vote in person. However, for those who will not be voting in person at the SpecialAnnual Meeting, your final voting instructions must be received by no later than 11:59 p.m., Eastern Time on April 24, 2018.May 20, 2019.

Beneficial Owners

Most of our stockholders hold their shares through a broker,stockbroker, bank or other nominee, rather than directly in their own name.names. If you hold your shares in one of these ways, you are considered the beneficial owner of shares held in street name, and the proxy materials areNotice is being forwarded to you by your broker, bank or nominee who is considered, with respect to those shares, the stockholder of record. As the beneficial owner, you have the right to direct your broker, bank or nominee on how to vote. Your broker, bank or nominee has enclosed a voting

instruction form for you to use in directing the broker, bank or nominee on how to vote your shares. If you hold your shares through an NYSEa New York Stock Exchange (“NYSE”) member brokerage firm, that member brokerage firm does not havehas the discretion to vote shares it holds on your behalf without instructions from you with respect to the Share Issuance. ForProposal 3 (the ratification of PwC as our independent registered accounting firm for our 2019 fiscal year), but not with respect to Proposal 1 (the election of directors) or Proposal 2 (the “say-on-pay” proposal) as more information, seefully described under “What is a broker‘non-vote’ ‘non-vote’?” below.

May I attend the Special Meeting and vote in person?

Yes. All stockholders of record as of the Record Date may attend the Special Meeting and vote in person. Stockholders will need to present proof of ownership of our Common Stock as of the Record Date, such as a bank or brokerage account statement, and a form of personal identification to be admitted to the Special Meeting. No cameras, recording equipment, electronic devices, large bags, briefcases or packages will be permitted in the Special Meeting.2

Even if you plan to attend the Special Meeting in person, we encourage you to complete, sign, date and return the enclosed proxy to ensure that your shares of our Common Stock will be represented at the Special Meeting. If you attend the Special Meeting and vote in person, your vote by ballot will revoke any proxy previously submitted.TABLE OF CONTENTS

If you are a beneficial owner and hold your shares of Common Stock in “street name” through a broker, bank or nominee, you should instruct your broker, bank or nominee on how you wish to vote your shares of Common Stock using the instructions provided by your broker, bank or nominee. Your broker, bank or nominee cannot vote on the proposal to approve the Share Issuance without your instructions. If you hold your shares of Common Stock in “street name,” because you are not the stockholder of record, you may not vote your shares of Common Stock in person at the Special Meeting unless you request and obtain a valid proxy in your name from your broker, bank or nominee.

Can I change my vote?

Yes. If you are the stockholder of record, you may revoke your proxy before it is exercised by doing any of the following:

voting again over the Internet or by telephone prior to 11:59 p.m., Eastern Time on April 24, 2018;May 20, 2019;

timely sending a letter to us stating that your proxy is revoked;

signing a new proxy and timely sending it to us; or

attending the SpecialAnnual Meeting and voting by ballot.

Beneficial owners should contact their broker, bank or nominee for instructions on changing their votes.

How many votes must be present to hold the SpecialAnnual Meeting?

A “quorum” is necessary to hold the SpecialAnnual Meeting. A quorum is considered present if a majority of the votes entitled to be cast by the stockholders entitled to vote at the Special Meeting are represented in person or by proxyAnnual Meeting. They may be present at the Special Meeting.Annual Meeting or represented by proxy. Abstentions and broker “non-votes” are counted as present and entitled to vote for purposes of determining a quorum. Broker“non-votes” will not be counted as present and entitled to vote for purposes of determining a quorum at the Special Meeting.

How many votes are needed to approve the Share Issuance?proposals?

Pursuant toAt the rules of the NYSE, the approval of the Share Issuance requires the affirmativeAnnual Meeting, a “FOR” vote ofby a majority of votes cast is required for each of the shares present (in person orproposals described in this proxy statement: Proposal 1 (the election of directors), Proposal 2 (the “say-on-pay” proposal), and Proposal 3 (the ratification of PwC as independent registered accounting firm for our 2019 fiscal year).

For Proposals 1, 2 and 3, a “FOR” vote by proxy) and entitled to vote at the Special Meeting. Thisa “majority of votes cast” means that there must be more votes “FORthe proposal thannumber of shares voted “FOR” exceeds the aggregatenumber of votes “AGAINSTshares voted “AGAINST. the proposal plus abstentions at the Special Meeting. Broker“non-votes” will have no effect on the outcome of this vote.

What is an abstention?

An abstention is a properly signed proxy card that is marked ABSTAIN.“ABSTAIN. In the case of Proposals 1, 2 and 3, abstentions do not constitute votes “FOR” or votes “AGAINST” and, therefore, will have no effect on the outcome of any of those proposals.

Pursuant to the rules of the NYSE, abstentions are counted as present for purposes of determining a quorum, but will be counted as votes “AGAINST” the proposal to approve the Share Issuance.

What is a broker“non-vote? “non-vote?

A broker“non-vote” “non-vote” occurs when a broker, bank or nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary voting power for that particular item and has not received timely instructions from the beneficial owner. Under current applicable rules, the proposal to approve the Share Issuance at the Special MeetingProposal 3 (the ratification of PwC as independent registered accounting firm for our 2019 fiscal year) is not a “discretionary” item upon which NYSE member brokerage firms that hold shares as nominee may vote on behalf of the beneficial owners if such beneficial owners have not furnished voting instructions by the tenth day before the SpecialAnnual Meeting. Therefore,

However, NYSE member brokerage firms that hold shares as a nominee may not vote on behalf of the beneficial owners on the Share IssuanceProposal 1 (the election of directors) or Proposal 2 (the “say-on-pay” proposal) unless you provide voting instructions.

If an Therefore, if a NYSE member brokerage firm holds your Common Stock as a nominee, please instruct your broker how to vote your Common Stock.Stock on each of these proposals. This will ensure that your shares are counted.

counted with respect to each of these proposals. Broker“non-votes” will “non-votes” do not be counted as presentconstitute votes “FOR” or votes “AGAINST” and entitled to vote for purposes of determining a quorum at the Special Meeting andtherefore will have no effect on the vote to approveoutcome of any of the Share Issuance.

What should I do if I receive more than one set of voting materials?

You may receive more than one set of voting materials, including multiple copies of this proxy statement and multiple proxy cards or voting instruction cards. For example, if you hold your shares of our Common Stock in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. If you are a stockholder of record and your shares of Common Stock are registered in more than one name, you will receive more than one proxy card. Please complete, date, sign and return each proxy card and voting instruction card that you receive. Each proxy card you receive comes with its own prepaid return envelope; if you submit a proxy by mail, make sure you return each proxy card in the return envelope that accompanies that proxy card or return it in your own envelope to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.proposals.

Will any other matters be acted on at the SpecialAnnual Meeting?

Pursuant to our Bylaws, only such business as is specified in this proxy statement will be conductedIf any other matters are properly presented at the Special Meeting.

Where can I findAnnual Meeting or any adjournment or postponement thereof, the voting resultspersons named in the proxy will have discretion to vote on those matters. As of December 11, 2018, the date by which any proposal for consideration at the Annual Meeting submitted by a stockholder must have been received by us to be presented at the Annual Meeting, and as of the Special Meeting?

The Company intendsdate of these proxy materials, we did not know of any other matters to announce preliminary voting resultsbe presented at the Special Meeting and publish final results in a Current Report on Form8-K that will be filed with the SEC following the SpecialAnnual Meeting. All reports that the Company files with the SEC are publicly available when filed. See the section entitled “Where You Can Find More Information” below.

3

TABLE OF CONTENTS

Who pays for this proxy solicitation?

We will pay the expenses of soliciting proxies. In addition to solicitation by mail, proxies may be solicited in person or by telephone or other means by our directors or associates for no additional compensation. We will reimburse brokerage firms and other nominees, custodians and fiduciaries for costs incurred by them in mailing these proxy materials to the beneficial owners of Common Stock held of record by such persons.

In addition, we have retained Georgeson LLC to assist in the solicitation of proxies and otherwise in connection with the Special Meeting for an estimated fee of $8,500, plus reimbursement of certain reasonable expenses.

WhoWhom should I call with other questions?

If you have additional questions about these proxy materials or the SpecialAnnual Meeting, please contact: GNC Holdings, Inc., 300 Sixth Avenue, Pittsburgh, Pennsylvania, 15222, Attention: Secretary; Telephone: (412) 288-4600.

4

TABLE OF CONTENTS

ELECTION OF DIRECTORS
(PROPOSAL 1)

LOGO

1290 AvenueThe Board proposes that each of the Americas, 9th Floornine (9) director nominees described below (the “Nominees”), who currently are members of our Board, be re-elected for a one-year term expiring at our 2020 Annual Meeting and to serve until the due election and qualification of his or her successor, or until his or her earlier resignation or removal.

New York, NY 10104

Banks, BrokersIn November of 2018, the Board adopted resolutions to increase the size of the Board to ten (10) members. In addition to the eight (8) then existing directors, upon designation by Harbin and Shareholders

Call Toll-Free (888)607-9107

DESCRIPTION OF THE SHARE ISSUANCE

While we believe thatbased on the summary below describesrecommendation of the materialBoard’s Nominating and Corporate Governance Committee, the Board appointed Hsing Chow and Yong Kai Wong to the Board, effective January 22, 2019, in accordance with the terms of the Share Issuance,Stockholders Agreement. Messrs. Chow and Wong are included in the nominees for re-election below. In February 2019 the Board size was further increased to eleven (11) members, and in April 2019, upon designation by Harbin and based on the recommendation of the Board’s Nominating and Corporate Governance Committee, the Board appointed Michele S. Meyer to the Board, effective immediately, in accordance with the terms of the Stockholders Agreement. Ms. Meyer is included in the nominees for re-election below. Harbin has additional contractual rights to nominate up to two (2) additional directors to the Board, provided that each such additional nominee satisfies the requirements set forth in the Stockholders Agreement. As of the date of this Proxy Statement, Harbin has not yet exercised this optional right with respect to the final two positions.

Two of the Company’s current directors, Jeffrey Berger and Richard Wallace, have notified the Company of their intention to retire from the Board as of the date of the Annual Meeting, and as such are not included in this proxy statement as Nominees for re-election. The Company thanks them for their service. The Board’s Nominating and Corporate Governance Committee is working collaboratively with Harbin to fill the remaining board seats as soon as qualified candidates, as outlined in the Company’s governance documents and the Stockholders Agreement, are found.

All of the Nominees have indicated their willingness to serve if elected. If, at the time of the meeting, any Nominee is unable or unwilling to serve, shares represented by properly executed proxies will be voted at the discretion of the persons named therein for such other nominee as the Board (or Harbin pursuant to its existing designation rights) may designate, or the Board may elect to decrease the size of the Board.

Set forth below is information concerning each Nominee, and the key experience, qualifications and skills he or she brings to the Board.

Recommendation

THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE ELECTION OF THE NOMINEES AS DIRECTORS.

The Nominees

Kenneth A. Martindale, 59, became our Chief Executive Officer and a director on September 11, 2017. He was subsequently elected as Chairman of the Board in August, 2018. Mr. Martindale was previously CEO of Rite Aid Stores, a position held since August 3, 2015, and President of Rite Aid Corporation, a position held since June 2013. He previously served as Rite Aid’s Chief Operating Officer since June 2010. From December 2008 until June 2010, he served as Rite Aid’s Senior Executive Vice President and Chief Merchandising, Marketing and Logistics Officer. He served as co-President and Chief Merchandising and Marketing Officer for Pathmark Stores, Inc. from January 2006 until its acquisition by the Great Atlantic & Pacific Tea Company in December 2007. Mr. Martindale serves as a director of Fairway Group Holdings Corporation. Mr. Martindale’s years of executive leadership experience in retail operations led to the conclusion that he should serve as a director on the Board.

Robert F. Moran, 68, became one of our directors in June 2013 and served as our Interim Chief Executive Officer from July 2016 through September 10, 2017. He served as Non-Executive Chairman of the Board from September 2017 through August 2018, after which time he was elected as Lead Independent Director. Mr. Moran most recently served as Chairman and Chief Executive Officer of PetSmart, Inc., a leading specialty provider of pet products, services and solutions (“PetSmart”), from February 2009 to June 2013. Prior to being appointed Chairman, Mr. Moran was PetSmart’s President and Chief Executive Officer from June 2009 to January 2012

5

TABLE OF CONTENTS

and its President and Chief Operating Officer from December 2001 to June 2009. Before joining PetSmart in 1999, Mr. Moran was President of Toys “R” Us Canada. Mr. Moran served on the boards of directors of Collective Brands, Inc. from March 2005 to October 2012 and of PetSmart from September 2009 to June 2013. He currently serves on the boards of directors of Hanesbrands, Inc., for which he chairs the audit committee, and the USA Track & Field Foundation. Mr. Moran’s more than 40 years of executive leadership experience, both domestically and internationally, and extensive retail experience and expertise led to the conclusion that he should serve as a director on the Board.

Hsing Chow, 52, became one of our directors in January 2019, pursuant to the terms of the Stockholders Agreement with Harbin. Since 2015, Mr. Chow has served as Group Vice President of Harbin. Prior to his service at Harbin, Mr. Chow served as Regional General Manager at Flextronics Global OPS, a leading electronics manufacturing services provider focused on delivering complete design, engineering and manufacturing services to automotive, computing, consumer, industrial, infrastructure, medical and mobile OEMs. Mr. Chow holds both a Bachelor of Science and Master of Science degree from New Jersey Institute of Technology. Mr. Chow’s designation by Harbin pursuant to the terms of our Stockholders Agreement, along with his business and international experience, led to the conclusion that he should serve as a director on the Board.

Alan D. Feldman, 67, became one of our directors in June 2013. Mr. Feldman most recently served as Chairman, President and Chief Executive Officer of Midas, Inc., a provider of retail automotive services, from May 2006 until its merger with TBC Corporation in May 2012 and as its President and Chief Executive Officer from January 2003 until May 2006. From 1994 through 2002, Mr. Feldman held senior management posts at McDonald’s Corporation and, prior to that, with the Pizza Hut and Frito-Lay units of PepsiCo, Inc. Mr. Feldman also currently serves on the board of directors of Foot Locker, Inc., for which he chairs the compensation and management resources committee and serves as a member of the executive committee and the finance and strategic planning committee, and of John Bean Technologies Corporation, for which he chairs the audit committee and serves as a member of the nominating and governance committee. Mr. Feldman also serves as Chair of the University of Illinois Foundation. Mr. Feldman’s recognized leadership skills and years of broad-based experience in independent, franchised retail operations, brand management and customer relations led to the conclusion that he should serve as a director on the Board.

Michael F. Hines, 63, became one of our directors in November 2009. He served as Chairman of our Board from August 2014 to September 2017, and prior to that, served as our Lead Independent Director since July 2012. Mr. Hines was the Executive Vice President and Chief Financial Officer of Dick’s Sporting Goods, Inc., a sporting goods retailer, from 1995 to March 2007. From 1990 to 1995, he held management positions with Staples, Inc., most recently as Vice President, Finance. Earlier, he spent 12 years in public accounting, the last eight years with the accounting firm Deloitte & Touche, LLP in Boston. Mr. Hines serves on the board of directors of The TJX Companies, Inc., a retailer of apparel and home fashions (“TJX”), and is the chair of its audit committee and a member of its finance committee. He also serves on the board of directors of Dunkin Brands Group, Inc., the parent company of Dunkin’ Donuts and Baskin-Robbins, for which he chairs the audit committee and is a member of the nominating and corporate governance committee. Mr. Hines’s experience as a financial executive and certified public accountant, coupled with his extensive knowledge of financial reporting rules and regulations, evaluating financial results and generally overseeing the financial reporting process of large retailers, led to the conclusion that he should serve as a director on the Board.

Amy B. Lane, 66, became one of our directors in June 2011. Ms. Lane was a Managing Director and Group Leader of the Global Retailing Investment Banking Group at Merrill Lynch & Co., Inc., an investment bank, from 1997 until her retirement in 2002. Ms. Lane previously served as a Managing Director at Salomon Brothers, Inc., an investment bank, where she founded and led the retail industry investment banking unit. Ms. Lane serves on the board of directors of TJX, and is the chair of its finance committee and a member of its audit and executive committees. Additionally, she serves on the board of directors of Nextera Energy, Inc., an electric utility holding company, as the chair of its finance committee and a member of the compensation committee, and on the board of directors of Urban Edge Properties, a REIT spun off from Vornado Realty Trust. Ms. Lane’s experience as the leader of two investment banking practices covering the global retailing industry has given her substantial experience with financial services, capital markets, finance and accounting, capital structure, acquisitions and divestitures in the retail industry as well as management, leadership and strategy, which led to the conclusion that she should serve as a director on the Board.

6

TABLE OF CONTENTS

Philip E. Mallott, 61, became one of our directors in July 2012. Mr. Mallott retired as Vice President, Finance and Chief Financial Officer of Intimate Brands, an intimate apparel and personal care retailer and former subsidiary of Limited Brands, Inc. Mr. Mallott formerly served as a director of Big Lots, Inc., including non-executive chair for four years until May 2017, and as chair of the audit committee for fifteen years. In addition to his Board service at Big Lots, Mr. Mallott also serves on multiple board committees for Defiance College and United Church Homes, Inc. Mr. Mallott previously served as a director of Tween Brands, Inc. from 2000 to 2009. Mr. Mallott’s experience as a certified public accountant, his service on the boards of other public companies and charitable organizations, and his experience in leadership roles with other retailers led to the conclusion that he should serve as a director on the Board.

Michele S. Meyer, 54, became one of our directors in April 2019, pursuant to the terms of the Stockholders Agreement with Harbin. Ms. Meyer currently serves as President and Senior Vice President of the snacks operating unit, a $2 billion enterprise within General Mills, a Minneapolis, Minnesota based Fortune 500 global foods company. Ms. Meyer joined General Mills in 1988, and has held key leadership roles during her 30 years of service, including as President and Senior Vice President, and as Business Unit Director, Vice President, of other units within General Mills. In her current role, Ms. Meyer has driven sales growth, and has grown market share within her unit in key categories. Ms. Meyer possesses significant international experience, and is well versed in corporate restructuring and has acquisition integration experience, which combined with her business acumen and leadership skills, has led to the conclusion that she should serve as a director on the Board.

Yong Kai Wong, 42, became one of our directors in January 2019, pursuant to the terms of the Stockholders Agreement with Harbin.Mr. Wong has served as Managing Director of CITIC Capital Holdings Limited, an affiliate of Harbin, since 2012. Mr. Wong holds a CSREP degree from Harvard University, a Masters of Business Administration from University of Chicago Booth School of Business and a Master of Laws (LLM) from the University of Cambridge. Mr. Wong’s designation by Harbin pursuant to the terms of our Stockholders Agreement, along with his business and international experience, led to the conclusion that he should serve as a director on the Board.

The affirmative vote of the holders of a majority of the votes cast by our stockholders in person or represented by proxy and entitled to vote at the Annual Meeting is required to approve this Proposal 1. Any Director who receives less than a majority of affirmative votes cast by our stockholders for re-election must offer to resign from the Board if he or she is not re-elected at the Annual Meeting.

OTHER BOARD INFORMATION

Board Composition

The Board is currently composed of Kenneth A. Martindale, Jeffrey P. Berger, Hsing Chow, Alan D. Feldman, Michael F. Hines, Amy B. Lane, Philip E. Mallott, Michele S. Meyer, Robert F. Moran, Richard J. Wallace and Yong Kai Wong. The Board has adopted Corporate Governance Guidelines, which are available on the Corporate Governance page of the Investor Relations section of our website located at www.gnc.com and will be provided to any stockholder free of charge upon request. The Corporate Governance Guidelines provide that in the event the Chairperson of the Board is not an independent director, the Lead Independent Director of the Board is to serve as the chairperson of any meetings of the Board in executive session. Mr. Moran, an independent director, currently serves as Lead Independent Director of the Board.

In addition to the biographical information provided above for those Directors who are Nominees, set forth below is information concerning Messrs. Berger and Wallace, who currently serve on our Board, until their impending retirement at the Annual Meeting.

Jeffrey P. Berger, 69, became one of our directors in March 2011. Mr. Berger currently is a private investor. From 2008 until April 2013, Mr. Berger served as a consultant to H. J. Heinz Company, a leading producer and marketer of healthy and convenient foods (“Heinz”). From 2007 to 2008, Mr. Berger was the Chairman of Global Foodservice of Heinz. From 2005 to 2007, Mr. Berger was the Executive Vice President, President and Chief Executive Officer of Heinz Foodservice. From 1994 to 2005, Mr. Berger was President and Chief Executive Officer of Heinz North America Foodservice. Mr. Berger currently serves on the board of directors of Big Lots, Inc., a discount retailer.

7

TABLE OF CONTENTS

Richard J. Wallace, 67, became one of our directors in July 2010. Mr. Wallace served as a Senior Vice President for Research and Development at GlaxoSmithKline, a global pharmaceutical company (“GSK”), from 2004 until his retirement in 2008. Prior to that, he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace is also a director of ImmunoGen, Inc., for which he serves as a member of the audit and nominating and governance committees.

Board Meetings in 2018

The Board held fifteen (15) meetings during our fiscal year ended December 31, 2018.

Director Attendance

During our fiscal year ended December 31, 2018, each of our incumbent directors attended at least 75% of all meetings of the Board and committees of which he or she was then a member. We encourage, but do not require, our directors to attend our annual meetings of stockholders. All of our current directors who were serving on the Board at the time of our 2018 Annual Meeting attended the meeting.

Director Independence

Our Common Stock is listed for trading on the NYSE under the symbol “GNC”. The Board, upon the findings of the Nominating Committee, has determined as part of its annual review, that each of Ms. Lane, Ms. Meyer, and Messrs. Moran, Feldman, Hines and Mallott is “independent” within the meaning of Rule 303A.02 of the NYSE Listed Company Manual, and no family relationships exist among such Nominees and any of our executive officers. During this review, the Board considered transactions and relationships between each nominee for director with the Company (either directly or as a partner, stockholder or officer of any organization that has a relationship with the Company), including any potential related party transactions, as discussed below under “Certain Relationships and Related Transactions,” to determine whether any such relationships or transactions were inconsistent with a determination that the nominee for director is independent in accordance with independence requirements under our Corporate Governance Guidelines and as implemented by the NYSE.

Leadership Structure

The Board has adopted guidelines that provide the Board with the discretion and flexibility to decide if the roles of the Chief Executive Officer and Chairperson of the Board are to be separate or combined. Currently, the roles are combined, with Mr. Martindale serving as both Chief Executive Officer and Executive Chairman of the Board. The Board has determined that this is currently the appropriate leadership structure due to the fact that Mr. Martindale possesses detailed insight of the issues, opportunities and challenges facing the Company and its business and thus is best positioned to develop agendas that ensure the Board’s time and attention are focused on the most critical matters. His combined role enables decisive leadership, ensures clear accountability and enhances the Company’s ability to develop a long-term strategy that best serves the interest of its stakeholders. Each director, other than Messrs. Martindale, Chow and Wong, is independent, and the Board believes that the independent directors provide effective oversight of management. To further strengthen our governance structure, the Company also maintains a presiding non-employee director, which position is currently held by Mr. Moran.

Our Board’s Role in Risk Oversight

The Board and its Committees play an active role in overseeing the identification, assessment and mitigation of risks that are material to the Company. In fulfilling this responsibility, the Board and its Committees, regularly consult with management to evaluate and, when appropriate, modify our risk management strategies. While certain categories of risk are allocated to a particular Board committee for oversight based on the committee’s respective areas of expertise, the entire Board is regularly informed about such risks through committee reports.

The Board regularly reviews information regarding our primary areas of risk assessment- strategic, executional, competitive, economic, operational, financial (credit, liquidity, tax), legal, compliance, regulatory and reputational, as well as the risks associated with each. The Audit Committee has responsibilities related to the oversight and management of cybersecurity and financial risks, including compliance matters, tax strategies, information security measures and the internal audit function. The Compensation and Organizational Development Committee of the Board (the “Compensation Committee”) is responsible for overseeing the management of risks relating to our executive compensation policies, philosophies, practices and arrangements.

8

TABLE OF CONTENTS

The Finance Committee oversees risks related to financial planning and strategies, including capital structure, investments, liquidity and cash management, insurance programs, hedging policies, and our stock ownership profile. The Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”) is responsible for managing risks relating to our director compensation policies and arrangements, the independence of the Board, director candidates, board and committee composition, and other corporate governance matters. The risk oversight function does not impact the structure of the Board.

Company management is charged with adequately identifying material risks that the Company faces in a timely manner; implementing strategies that are responsive to the Company’s risk profile and specific material risk exposures; evaluating risk and risk management with respect to business decision-making throughout the Company; and efficiently and promptly transmitting relevant risk-related information to the Board or appropriate committee, so as to enable them to conduct appropriate risk management oversight. For example, the Audit Committee receives quarterly reports from the Internal Audit department on key risk indicators and the Compliance function on legal and regulatory compliance. The Legal Department provides a litigation report to the Board at least annually. The Chief Information Officer, with participation from the Chief Information Security Officer, reports quarterly to the Audit Committee on information security and compliance, including program maturity, data access control, security tests and training, key investments and security incident response.

Board Committees

Each of the below Committees is a standing committee of the Board. The Board has adopted written charters for each of these committees, each of which is available on the Corporate Governance page of the Investor Relations section of our website located at www.gnc.com and will be provided to any stockholder free of charge upon request. Further, each member of the Audit Committee, the Compensation Committee, the Finance Committee and the Nominating Committee has been determined by the Board to be independent under the NYSE’s current listed company standards.

Audit
Committee
Compensation and
Organizational
Development
Committee
Nominating and
Corporate
Governance
Committee
Finance
Committee
Jeffrey P. Berger*
X
X
Hsing Chow
Alan D. Feldman
Chair
X
Michael F. Hines*
Chair
X
Amy B. Lane
X
Chair
Philip E. Mallot*
X
Chair
Kenneth A. Martindale
Michele S. Meyer
Robert F. Moran
Richard J. Wallace
X
X
Yong Kai Wong
Number of Meetings
Nine (9)
Six (6)
Five (5)
Five (5)

X = Member

Chair = Chairperson

* = Financial Expert

Audit Committee

The Audit Committee, which is established in accordance with Section 3(a)(58)(A) of the Exchange Act, consists entirely of directors who meet the independence requirements of the listing standards of the NYSE and Rule 10A-3 under the Exchange Act. Further, the Board has determined that each of Messrs. Berger, Hines and Mallott qualifies as an “audit committee financial expert” as defined in Item 407(d)(5)(ii) of Regulation S-K and has the attributes set forth in such section, and they each have accounting and financial management expertise within the meaning of the listing standards of the NYSE.

9

TABLE OF CONTENTS

The principal duties and responsibilities of the Audit Committee are to:

approve, review, and monitor our financial reporting process and internal control system;
appoint and annually review performance of our independent registered public accounting firm, determine its compensation, its continued appointment and other terms of engagement and oversee its work;
oversee our audit and financial statements and related disclosures;
oversee the performance of our internal audit function; and
oversee our compliance with legal, ethical and regulatory matters.

The Audit Committee has the power to investigate any matter brought to its attention within the scope of its duties. It also has the authority to retain counsel and advisors to fulfill its responsibilities and duties.

Compensation Committee

The Board has determined that each of Amy B. Lane, Philip E. Mallott, and Richard J. Wallace qualify as independent under the current NYSE Corporate Governance Standards.

The principal duties and responsibilities of the Compensation Committee are to:

oversee the development and implementation of our executive compensation policies and objectives;
determine the structure of our executive compensation packages generally;
determine the annual compensation paid to each of our senior executives;
evaluate the performance of our Chief Executive Officer and other senior executives;
determine stock ownership guidelines for the Company’s directors and executives and monitor compliance with those guidelines;
review potential risk to the Company from its compensation policies and program, including incentive compensation plans;
review and recommend to the Board for approval the frequency with which the Company will conduct stockholder advisory votes on executive compensation, taking into account the results of the most recent stockholder advisory vote;
work with the Company’s Chief Executive Officer to develop succession plans for the Company and development initiatives for our senior executives; and
review and evaluate the implementation and effectiveness of such succession plans and development initiatives.

Compensation Committee Interlocks and Insider Participation. For our fiscal year ended December 31, 2018, (i) no member of the Compensation Committee (a) served as one of our officers or employees during or preceding their tenure on the Compensation Committee or (b) had any relationship requiring disclosure under Item 404 of Regulation S-K, and (ii) none of our executive officers served as a director or member of the compensation committee of another entity whose executive officers served on the Board or the Compensation Committee. During our fiscal year ended December 31, 2018, our Compensation Committee included Amy B. Lane, Philip E. Mallott, and Richard J. Wallace.

Finance Committee

The principal duties and responsibilities of the Finance Committee are to:

review and make recommendations to the Board with respect to the Company’s financial condition and long-range financial plans and strategies, including as they relate to the management of financial risk;
review and make recommendations to the Board with respect to the Company’s capital structure and the principal terms and conditions of significant proposed borrowings and issuances of debt or equity securities by the Company and its subsidiaries;

10

TABLE OF CONTENTS

review and make recommendations to the Board with regard to the Company’s proposed dividend policies and the repurchase or redemption of Company securities;
review and oversee the Company’s investment and cash management policies;
review and oversee the Company’s foreign currency exchange and other hedging policies;
review and make recommendations to the Board with respect to capital investment criteria, capital expenditures and annual lease commitments for the Company;
review and make recommendations to the Board with respect to the Company’s insurance and self-insurance programs (including directors’ and officers’ liability policies);
review and make recommendations to the Board with respect to the Company’s defense profile, strategies and plans for significant mergers, acquisitions, divestitures, joint ventures and other investments and strategic plans; and
review the Company’s stock ownership profile and the performance of the Company’s Common Stock.

Nominating and Corporate Governance Committee

The Board has determined that each of Jeffrey P. Berger, Richard J. Wallace and Alan D. Feldman qualify as independent under the current NYSE Corporate Governance Standards.

The principal duties and responsibilities of the Nominating and Corporate Governance Committee (the “Nominating Committee”) are as follows:

to establish criteria for board and committee membership and recommend to the Board proposed nominees for election to the Board and for membership on committees of the Board;
to oversee the evaluation of the Board and its committees;
to make recommendations to the Board regarding board governance matters and practices; and
to determine the structure and oversee the development and implementation of the Company’s compensation policies, objectives and administrative practices and all other matters relating to the compensation of the Company’s non-employee directors.

Director Qualifications; Nominating Committee Process. The Nominating Committee’s policy is to identify potential director nominees from any properly submitted nominations, including any properly submitted nominations from our stockholders, and subsequently evaluate each potential nominee. Stockholders may nominate director candidates for consideration by the Nominating Committee as set forth below.

In accordance with the Company’s amended and restated by-laws, to be timely for consideration by the Nominating Committee, notice of a proposed nomination must be delivered to or mailed and received at the Company’s principal executive offices not earlier than the opening of business on the 120th day nor later than the close of business on the 90th day prior to the one year anniversary of the date of the preceding year’s annual meeting of its stockholders; provided, however, that if the date of the annual meeting is more than 30 days prior to or delayed by more than 70 days after the anniversary of the preceding year’s annual meeting, the nomination must be received not earlier than the opening of business on the 120th day prior to the date of such annual meeting nor later than the later of the close of business on the (i) 90th day prior to the date of such annual meeting or (ii) 10th day following the day on which public announcement of such meeting date is first made.

In addition to information regarding the nominating stockholder as set forth in the Company’s amended and restated by-laws, in accordance with the Company’s corporate governance guidelines, such stockholder’s notice must set forth as to each individual whom the stockholder proposes to nominate for election or reelection as a director:

the name, age, business address and residence address of such individual;
the class, series and number of any shares of Company stock that are beneficially owned by such individual;
the date such shares were acquired and the investment intent of such acquisition;

11

TABLE OF CONTENTS

whether such stockholder believes any such individual is, or is not, “independent” as set forth in the requirements established by the NYSE or any other exchange or automated quotation service on which the Company’s securities are listed, and information regarding such individual that is sufficient, in the discretion of the Board or any committee thereof or any authorized officer of the Company, to make either such determination; and
all other information relating to such individual that is required to be disclosed in solicitations of proxies for election of directors in an election contest (even if an election contest is not involved), or is otherwise required, in each case pursuant to Regulation 14A (or any successor provision) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules and regulations promulgated thereunder.

Any such submission must be accompanied by the written consent of the individual whom the stockholder proposes to nominate to being named in the proxy statement as a nominee and to serving as a director if elected.

The Nominating Committee may, but is not required to, consider nominations not properly submitted in accordance with the Company’s Corporate Governance Guidelines, and the Committee may request further information and documentation from any proposed nominee or from any stockholder proposing a nominee. All nominees properly submitted to the Company (or which the Nominating Committee otherwise elects to consider) will be evaluated and considered by members of the Nominating Committee using the same criteria as nominees identified by the Nominating Committee itself.

In addition to the above, under the terms of the Company’s current Stockholders Agreement entered into with Harbin, and pursuant to the terms of the current Sixth Amended and Restated Bylaws of the Company, so long as Harbin continues to hold at least fifteen percent (15%) of the Company’s Common Stock (calculated on an as-converted basis), Harbin has the right, but not the obligation, to designate up to two additional directors (each an “Investor Designee”) to the Board, in addition to the initial Investor Designees Messrs. Chow and Wong, and the third Investor Designee, Ms. Meyer.

In evaluating the suitability of individual candidates (both new candidates and current Board members), in recommending candidates for election, and in approving (and, in the case of vacancies, appointing) such candidates, the Nominating Committee considers, in addition to such other factors as it shall deem relevant, the desirability of selecting directors who:

are of high character and possess fundamental qualities of intelligence, honesty, good judgment, integrity, fairness and responsibility;
have the ability to make independent analytical inquiries and possess a general understanding of marketing, finance, and other elements relevant to the success of a publicly traded company;
are accomplished in their respective fields, with superior credentials and recognition;
understand our business on a technical level and have relevant expertise and experience upon which to be able to offer advice and guidance to management;
have sufficient time available to devote to the affairs of our Company;
are able to work with the other members of the Board and contribute to our success;
can represent the long-term interests of our stockholders as a whole; and
are selected such that the Board represents a range of backgrounds and experience.

In addition to the considerations set forth above, the Nominating Committee considers a candidate’s background and accomplishments and candidates are reviewed in the context of the current composition of the Board and the evolving needs of our businesses. The Nominating Committee conducts the appropriate and necessary inquiries (as determined by the Nominating Committee) with respect to the backgrounds and qualifications of any potential nominees, without regard to whether a potential nominee has been recommended by our stockholders, and, upon consideration of all relevant factors and circumstances, recommends to the Board for its approval the slate of director nominees to be nominated for election at our annual meeting of stockholders. Although the

12

TABLE OF CONTENTS

Nominating Committee has not adopted a formal policy with respect to diversity, it does look for diversity of background (including, but not limited to, race, origin, age and gender) and experience in different substantive areas such as retail operations, marketing, technology, distribution and finance, as relevant factors in evaluating candidates.

2018 Director Compensation

The following table presents information regarding the compensation of our non-employee directors with respect to our fiscal year ended December 31, 2018 and should be read in conjunction with “Narrative to the Director Compensation Table” below. Employees of the Company do not receive any additional compensation for 2018 Board service. No information has been provided for Messrs. Chow or Wong or Ms. Meyer, as they did not join the Board of Directors until January and April 2019, respectively.

Name
Fees Earned or
Paid in Cash
($)
Stock
Awards
($)(1)(2)
All Other
Compensation
($)
Total
($)
Jeffrey Berger
 
102,500(3
) 
 
110,000
 
 
 
 
212,500
 
Alan Feldman
 
112,500(4
) 
 
110,000
 
 
 
 
222,500
 
Michael Hines
 
102,500(5
) 
 
110,000
 
 
 
 
212,500
 
Amy Lane
 
112,500(6
) 
 
110,000
 
 
 
 
222,500
 
Philip Mallott
 
120,000(7
) 
 
110,000
 
 
 
 
230,000
 
Robert Moran
 
175,000(8
) 
 
110,000
 
 
 
 
285,000
 
Richard Wallace
 
115,000(9
) 
 
110,000
 
 
 
 
225,000
 
(1)Reflects the approximate aggregate grant date fair value of the 2018 annual restricted stock awards granted to each of the directors computed in accordance with FASB ASC Topic 718. For the assumptions underlying the calculation of the aggregate grant date fair value, see Note 16, “Stock-Based Compensation,” to our audited consolidated financial statements included in the Annual Report. The 2018 annual awards were granted on May 21, 2018, had an approximate aggregate grant date fair value of $110,000 for each director and the restrictions with respect to the restricted stock is scheduled to lapse on the first anniversary of the grant date, provided the director has remained in service until the vesting date.
(2)The table below sets forth the number of stock awards and the exercisable and unexercisable stock options received for services as a director and held by the listed directors as of December 31, 2018. Ms. Lane elected to defer her 2018 annual restricted stock award of 31,609 shares, and as such will not be issued shares from the award until separation from service.
 
Stock Awards
Outstanding
Option Awards Outstanding
Name
Exercisable
Unexercisable
Jeffrey Berger
 
31,609
 
 
14,000
 
 
 
Alan Feldman
 
31,609
 
 
 
 
 
Michael Hines
 
31,609
 
 
11,920
 
 
 
Amy Lane
 
 
 
 
 
 
Philip Mallott
 
31,609
 
 
 
 
 
Robert Moran
 
31,609
 
 
 
 
 
Richard Wallace
 
31,609
 
 
35,000
 
 
 
(3)Reflects aggregate annual retainers paid to Mr. Berger, including $80,000 for his service as a director, $10,000 for his service as a member of the Nominating Committee and $12,500 for his service as a member of the Audit Committee.
(4)Reflects aggregate annual retainers paid to Mr. Feldman, including $80,000 for his service as a director, $10,000 for his service as a member of the Nominating Committee, $12,500 for his service as Chairperson of the Nominating Committee and $10,000 for his service as a member of the Finance Committee.
(5)Reflects aggregate annual retainers paid to Mr. Hines, including $80,000 for his service as a director, $12,500 for his service as a member of the Audit Committee, and $10,000 for his service as a member of the Finance Committee. Fees for his service as Chairperson of the Audit Committee, which began in December 2018, commenced with the first quarter 2019 payments.
(6)Reflects aggregate annual retainers paid to Ms. Lane, including $80,000 for her service as a director, $10,000 for her service as a member of the Compensation Committee, $12,500 for her service as Chairperson of the Finance Committee and $10,000 for her service as a member of the Finance Committee.
(7)Reflects aggregate annual retainers paid to Mr. Mallott, including $80,000 for his service as a director, $12,500 for his service as a member of the Audit Committee, $17,500 for his service as Chairperson of the Audit Committee, and $10,000 for his service as a member of the Compensation Committee. Fees for his service as Chairperson of the Compensation Committee, which began in December 2018, commenced with the first quarter of 2019.
(8)Reflects aggregate annual retainers earned by Mr. Moran, including $80,000 for his service as a director, $82,500 for his service as Chairman of the Board through June, 2018, and $12,500 for his service as Lead Independent Director beginning July, 2018.
(9)Reflects aggregate annual retainers paid to Mr. Wallace including $80,000 for his service as a director, $10,000 for his service as a member of the Nominating Committee, $15,000 for his service as Chairperson of the Compensation Committee, and $10,000 for his service as a member of the Compensation Committee. The change in fees related to his change in service as Chairperson of the Compensation Committee, which began in November 2018, commenced with the first quarter 2019 payments.

13

TABLE OF CONTENTS

Narrative to the Director Compensation Table. Our current director compensation policy (the “Director Compensation Policy”), adopted in 2013, provides that each non-employee director is entitled to receive an annual cash retainer for Board service, additional cash retainers service as a Committee member and/or Chairperson and an annual equity award. The Board believes that payments of retainer fees provide an appropriate balance of incentives for active participation and ease of administration, while the grant of annual equity awards aligns the long-term financial interests of our directors and our stockholders.

Specifically for 2018, our non-employee directors received (i) an $80,000 annual cash retainer for Board service, (ii) as applicable, an incremental annual cash retainer of $17,500, $15,000, $12,500 or $12,500 for service as Chairperson of the Audit Committee, Compensation Committee, Finance Committee or Nominating Committee, respectively, (iii) as applicable, an incremental annual cash retainer of $12,500 or $10,000 for service on the Audit Committee or another standing Committee, respectively, and (iv) annual equity award, in the form of restricted stock with one year cliff vesting, valued at $110,000 at the time of grant. For information regarding Compensation Committee Interlocks and Insider Participation, see “Other Board Information” above. In addition to the compensation noted above, the Chairman of the Board is entitled to receive an annual, incremental cash retainer, which in 2018 was $110,000. Additionally, in August, 2018 the annual cash retainer for the Lead Independent Director was established at $50,000. The annual cash retainers paid to our non-employee directors under the Director Compensation Policy are generally paid in four equal quarterly installments every March, June, September and December, and the annual equity award is typically granted in May.

We also maintain a deferred compensation plan under which our non-employee directors may elect to defer all or a portion of their compensation until the earliest of separation from the Board, death, a specified future date or a change in control of the Company. Annual equity retainers are deferred in the form of RSUs with identical vesting schedules to the shares of restricted stock. Ms. Lane elected to defer her 2018 annual restricted stock award and will not containbe issued shares from the award until separation from service.

Director Stock Ownership Guidelines. We believe that to align the interests of our non-employee directors with our stockholders, our directors should have a financial stake in the Company. The Board adopted a policy in December 2011 requiring each of our non-employee directors to own stock in the Company equal to a minimum of five times such director’s annual cash retainer for service on the Board (the “Director Stock Ownership Guidelines”). Any newly elected directors have five years from the date of their election to comply with the Director Stock Ownership Guidelines, and should retain at least 50% of all after-tax shares owned by or underlying equity awards granted to them (other than those granted on or prior to December 11, 2012) until the ownership thresholds are met. The Nominating Committee evaluates potential hardship exceptions for directors due to financial considerations or other appropriate reasons, including changes in value resulting from volatility in our share price. For the purposes of the Director Stock Ownership Guidelines, stock includes (i) directly held shares of our Common Stock, (ii) shares of unvested restricted stock and unvested RSUs (other than unvested shares of performance-vested restricted stock or unvested performance-vested restricted stock units) and (iii) vested shares of Common Stock allocated to the account of a non-employee director who was formerly an employee of the Company under any plan qualified under Section 401(a) of the Internal Revenue Code of 1986, as amended.

Code of Ethics

We have adopted a Code of Ethics applicable to our Chief Executive Officer and senior financial officers and a Code of Business Conduct and Ethics that is applicable to all employees. Each document is available on the Corporate Governance page of the Investor Relations section of our website located at www.gnc.com, and will be provided to any stockholder free of charge upon request. Any amendments to or waivers from our Code of Ethics with respect to our Chief Executive Officer and senior financial officers will also be disclosed on our website. Employees generally receive annual training with respect to the Code of Business Conduct and Ethics, and are required to acknowledge that they understand their responsibilities and will comply with all aspects of the Code of Business Conduct and Ethics.

Certain Relationships and Related Transactions

We recognize that transactions between the Company and related persons present a potential for actual or perceived conflicts of interest. Our general policies with respect to such transactions are included in our Code of Business Conduct and Ethics. All employees are required to follow the Code of Business Conduct and Ethics,

14

TABLE OF CONTENTS

and the Audit Committee of the Board, along with Corporate Compliance staff led by our Chief Legal Officer, oversee our Code of Business Conduct and Ethics, which provides that any actual or potential conflict of interest is to be disclosed.

Although we have not adopted formal written procedures for the review, approval or ratification of transactions with related persons, the Board reviews potential transactions with those parties we have identified as related parties prior to the consummation of the transaction, and we adhere to the general policy that such transactions should only be entered into if they are approved by the Board, in accordance with applicable law, and on terms that, on the whole, are no more or less favorable than those available from unaffiliated third parties. In 2018, we did not participate in any transactions involving an amount in excess of $120,000 in which any related person (as defined in Instruction 1 to Item 404(a) of Regulation S-K) has or will have a direct or indirect material interest.

Communications from Stockholders and Other Interested Parties

The Board welcomes communications from our stockholders and other interested parties. Stockholders and other interested parties wishing to communicate with the Board, our non-management directors or any particular director may send such communications to the following address: GNC Holdings, Inc., 300 Sixth Avenue, Pittsburgh, Pennsylvania, 15222, Attention: Secretary. Such communications should indicate clearly the director or directors to whom the communication is being sent so that each communication may be forwarded directly to the appropriate director(s).

Board Tenure and Evaluations

As noted in the Company’s Corporate Governance Guidelines, it is the general policy of the Company that no director may stand for election to the Board after his or her 72nd birthday and that no director may serve on the Board for more than fifteen years. However, it is not the intent of the Company that a director reaching retirement age or period of service limitations would prevent the director from continuing to serve the Company in a different capacity, such as Director Emeritus or as a consultant.

Both the full Board, as well as each Board Committee discussed within this proxy statement, completes an annual self-assessment, which is a structured, confidential questionnaire prepared by the legal department. The results of the questionnaires are reviewed and discussed, as applicable, within executive session, and further used to develop action plans in response to comments provided in said questionnaires.

Policy on Hedging and Pledging of Company Stock

The Company currently has a policy in place that is applicable to all employees and non-employee directors, which prohibits such persons from (i) within six months after purchasing any Company securities, selling any Company securities of the same class, (ii) selling the Company’s securities short, (iii) buying or selling puts or calls or other derivative securities on the Company’s securities, (iv) holding Company securities in a margin account or pledging Company securities as collateral for a loan or (v) entering into hedging or monetization transactions or similar arrangements with respect to Company securities.

15

TABLE OF CONTENTS

EXECUTIVE OFFICERS

Set forth below is information concerning our current executive officers.

Name
Age
Position
Kenneth A. Martindale
59
Chief Executive Officer
Tricia K. Tolivar
50
Executive Vice President, Chief Financial Officer
Guru Ramanathan
56
Senior Vice President, Chief Innovation Officer
Kevin G. Nowe
66
Senior Vice President, Chief Legal Officer and Secretary
Steven Piano
53
Senior Vice President, Chief Human Resources Officer
Susan M. Canning
49
Vice President, Deputy General Counsel and Corporate Secretary

The biography for Mr. Martindale is set forth above under “Election of Directors (Proposal 1).”

Tricia K. Tolivar became our Executive Vice President and Chief Financial Officer in March 2015. She served as our Interim Chief Marketing Officer in June 2017 through April 2018. In October 2018, Ms. Tolivar assumed responsibility and oversight of the Company’s real estate function. Previously, Ms. Tolivar served in leadership positions with Ernst & Young, LLP from October 2007 to February 2015, including most recently as Americas Director of Finance, Advisory, with responsibility for the leadership of finance, accounting and operations of a $3 billion client service organization in North and South America. Ms. Tolivar previously served as Chief Financial Officer of the Greater Memphis Arts Council from January 2006 to December 2008 and in a series of executive leadership positions with AutoZone, Inc. from 1996 to 2005. She is a graduate of Emory University.

Guru Ramanathan, Ph.D. joined our Company in 1998 and became our Senior Vice President and Chief Innovation Officer in December 2009 having previously served as Senior Vice President of Product and Package Innovation since February 2008 and Senior Vice President of Scientific Affairs since April 2007. He served as Vice President of Scientific Affairs from December 2003 to April 2007. Prior to joining the Company, Dr. Ramanathan worked as Medical Director and Secretary for the Efamol subsidiary of Scotia Pharmaceuticals in Boston and, in his capacity as a pediatric dentist and dental surgeon, held various industry consulting and management roles, as well as clinical, research and teaching appointments in Madras, India, and Tufts University and New England Medical Center in Boston, Massachusetts. Dr. Ramanathan earned his Ph.D. in Innovation Management from Tufts University and his MBA from Duke University’s Fuqua School of Business.

Kevin G. Nowe became our Senior Vice President, Chief Legal Officer and Secretary in March 2018. Previously he served as our Senior Vice President and Chief Legal Officer from April 2017 to October 2017 and as our Senior Vice President, Chief Legal Officer and Chief Compliance Officer from October 2017 to March 2018. Mr. Nowe previously served in leadership positions at Kennametal, Inc., most recently as Vice President, Secretary and General Counsel from 2009 to 2016, with responsibility for management of the company’s legal and general corporate governance matters, and as Assistant Secretary and Assistant General Counsel from 1992 to 2009. Mr. Nowe is a graduate of the University of Pittsburgh and the Case Western University School of Law.

Steven Piano became our Senior Vice President and Chief Human Resources Officer in January 2018. Mr. Piano previously served in leadership positions with MoneyGram International, Inc. from 2009 to 2017, most recently as Executive Vice President, Human Resources, Real Estate and Communications with responsibility for MoneyGram International’s global human resources and facilities management. Mr. Piano previously served in a variety of human resources leadership positions for National Grid USA, First Data Corporation and Lehman Brothers, Inc. Mr. Piano is a graduate of Hofstra University.

Susan M. Canning became our Vice President, Deputy General Counsel and Corporate Secretary in September 2018. Ms. Canning previously served as Senior Corporate Counsel and Assistant Secretary of Kellogg Company from 2017 to 2018, General Counsel - Europe of Kellogg Company from 2014 to 2017 and other legal roles since 2008. Ms. Canning previously served in a variety of legal positions for J.P. Morgan Chase & Co. from 1991 to 2008. She is a graduate of John Carroll University and the University of Detroit School of Law.

In addition to our current executive officers, below is biographical information for each of Joseph C. Gorman, age 48, and Gene Eddie Burt II, age 53, who served as executive officers until their resignations in March 2019, and are included as Named Executive Officers in this proxy statement for 2018.

16

TABLE OF CONTENTS

Joseph C. Gorman served as Executive Vice President, Operations, from March 2017 through March 2019. Prior to his appointment, Mr. Gorman served as Senior Vice President, Store Operations from January to March 2017 and Vice President, Western Division, from December 2015 to January 2017. Prior to joining the Company in 2015, Mr. Gorman was President of Anomaly Republic, a clothing retailer headquartered in Southern California from 2014 to 2015, with responsibility for the executive management and operational leadership of the company’s business. Prior to that, Mr. Gorman spent approximately six years at GameStop, an omni-channel video game and electronics retailer, where he held various field leadership positions from 2009 to 2014, and approximately sixteen years before that at The Home Depot, a home improvement retailer, where he held various operational roles in the field and headquarters.

Gene Eddie Burt II served as Executive Vice President, Chief Merchandising Officer and Chief Supply Chain Officer from January 2018 through March 2019. He previously served as our Senior Vice President and Chief Supply Chain Officer from January 2017 to January 2018. He previously served as Senior Vice President, Supply Chain for Tuesday Morning Corporation from February through September 2016, with responsibility for the oversight of the company’s product distribution network, and prior to that in a variety of executive roles with PetSmart, Inc. from 2007 to 2015, most recently as Senior Vice President, Real Estate and Development with responsibility for the company’s facilities and development initiatives. Mr. Burt is a graduate of Morehouse College.

ADVISORY VOTE ON EXECUTIVE COMPENSATION
(PROPOSAL 2)

In accordance with Section 14A of the Exchange Act, we are providing our stockholders the opportunity to cast a non-binding advisory vote to approve the 2018 compensation of our Named Executive Officers (defined below) as described in the Compensation Discussion and Analysis section of this proxy statement, the compensation tables that follow and narrative discussions set forth in these proxy materials. This proposal, commonly known as a “say-on-pay” proposal, gives our stockholders the opportunity to express their views on the compensation of our Named Executive Officers. Our Board recommended, and the stockholders approved at our 2017 annual meeting of stockholders, that such advisory vote would be conducted on an annual basis.

As described in the Compensation Discussion and Analysis section of this proxy statement, the primary objectives of our executive compensation program are to (i) align cash and stock-based rewards with Company performance that creates long-term stockholder value, (ii) attract and retain high performing, results oriented employees, (iii) build an ownership and long-term growth mentality and interest among our key employees and (iv) provide cost effective cash and stock-based rewards that are competitive with other organizations, reinforce our pay for performance culture, and equitable to our stockholders and employees. The foregoing objectives are applicable to the compensation of our Named Executive Officers.

We believe that our executive compensation program achieves these objectives by emphasizing long-term stock-based incentive awards and performance-based compensation, is appropriate in light of our overall compensation philosophy and objectives, and will play an essential role in our current business environment and future success.

Therefore, the Board recommends a vote in favor of the following resolution:

“RESOLVED, that the compensation paid to the Company’s Named Executive Officers for fiscal year ended December 31, 2018, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.”

As an advisory vote, this proposal is not binding upon us. Notwithstanding the advisory nature of this vote, the Compensation Committee values the opinions expressed by stockholders in their vote on this proposal, and will consider the outcome of the vote when making future compensation decisions for our Named Executive Officers. Currently, we expect to hold an advisory vote on the compensation paid to the Company’s Named Executive Officers each year and expect that the next such vote will occur at our 2020 Annual Meeting.

17

TABLE OF CONTENTS

The affirmative vote of the holders of a majority of the votes cast by our stockholders in person or represented by proxy and entitled to vote is required to approve this Proposal 2.

Recommendation

THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS FOR THE COMPANY’S FISCAL YEAR ENDED DECEMBER 31, 2018, AS DISCLOSED IN THESE PROXY MATERIALS.

18

TABLE OF CONTENTS

COMPENSATION DISCUSSION AND ANALYSIS

This section discusses the material elements of compensation awarded to, earned by or paid to our principal executive officer, our principal financial officer, and our three other most highly compensated executive officers who were serving as such on December 31, 2018. These individuals are referred to collectively as the “Named Executive Officers.”

For 2018, the Named Executive Officers were:

Name
Title
Kenneth A. Martindale
Chairman and Chief Executive Officer
Tricia K. Tolivar
Executive Vice President, Chief Financial Officer
Gene E. Burt
Former Executive Vice President, Chief Merchandising Officer and Chief Supply Chain Officer
Joseph C. Gorman
Former Executive Vice President, Operations
Steven Piano
Senior Vice President, Chief Human Resources Officer

The Company had a change in its Named Executive Officers from 2017 to 2018. Mr. Mantel, Executive Vice President and Chief Merchandising Officer, resigned from employment with the Company as of February 9, 2018. Mr. Piano joined the Company as Senior Vice President, Chief Human Resources Officer on January 22, 2018. Messrs. Gorman and Burt resigned from employment with the Company March 15, 2019.

Executive Summary

Our goal is to create a consistent and satisfying experience for all of our customers, whether they find us in a retail store, online, or on a mobile device, and we are investing in omni-channel capabilities to further enhance our in-store experience. Our store base is a competitive advantage over online-only competitors especially as we continue to develop our associates to deliver thoughtful assistance and advice.

In addition to addressing traffic trends in our retail stores, our management team is seeking other substantial opportunities to reposition the information that is importantCompany and drive profitable growth, including expansion of our business internationally, increased brand penetration, loyalty memberships, leveraging our strength in product innovation, and delivering a compelling omnichannel experience. As our key efforts take time to you, and is qualifiedproduce results, the Company’s operational results in its entirety2018 were challenged, impacting our year-over-year share price, down from approximately $3.50 per share at the beginning of 2018 to less than $3.00 per share by the relevant instruments and agreements themselves, which were included as an exhibit to our Current Report on Form8-K filed withend of the SEC on February 13, 2018, and are incorporated by reference herein. We encourage you to read the relevant instruments and agreements themselves in their entirety. Further, representations, warranties and covenants in the Securities Purchase Agreement are not intended to function or to be relied on as public disclosures.For more information about accessing the information that we file with the SEC, please see the section entitled “Where You Can Find More Information” below.

Overviewyear.

On February 13, 2018, the Company entered intoannounced it had reached an agreement regarding a strategic partnership and China joint venture agreement with Harbin Pharmaceutical Group (“Harbin”). Under the Securities Purchase Agreementterms of the agreement, Harbin invested approximately $300 million in GNC. In conjunction with the Investor, pursuantfinal investment, the formation of the Hong Kong-based China e-commerce joint venture with Harbin was completed in February 2019. The Hong Kong-based China e-commerce joint venture includes the operations of the existing profitable, growing cross border China e-commerce business. We anticipate completing the formation of the second, retail-focused joint venture located in China in the second or third quarter of 2019 following the completion of certain routine regulatory and legal requirements.

In February 2019, we announced the formation of a strategic partnership with International Vitamin Corporation (“IVC”). Under the joint venture agreement, GNC quality and R&D teams will continue to support product development and innovation, while IVC will manage manufacturing and integrate with GNC's supply chain. Under the terms of the agreement, GNC will receive $176 million over the next four years from IVC as their ownership of the joint venture increases to 100%. This partnership will allow GNC to further focus on innovation while IVC drives increased efficiencies in manufacturing.

In light of this transforming and challenging business environment, the Compensation Committee made the following pay determinations in 2018 for our Named Executive Officers:

Our Named Executive Officers received market competitive salary increases in 2018, in order to align with external benchmark peers and reflecting individual performance.
Partial cash incentive compensation payments were made to our Named Executive Officers for 2018 aligned with performance against established financial metrics under the 2018 plan.

19

TABLE OF CONTENTS

2016 performance share units for the performance period ending in 2018 did not meet the established goals and were forfeited based on the Company’s relative Total Shareholder Return (rTSR) over a three-year performance period when compared to S&P Specialty Retail Index.
The first tranche of the 2018 performance share units met partial performance against established financial goals. The earned shares will not vest until after the three year term, subject to continued employment. Unearned shares from the first tranche were forfeited.
Certain key leaders, including the Named Executive Officers, received a two-year retention agreement in connection with the Harbin deal in order to maintain leadership stability, focus, and execution in connection with the transition, which are more fully discussed below. The agreements also provided covenants regarding confidentiality, competition, solicitation, and recruitment.

Our executive compensation program has been structured to generate and reward superior company performance by establishing compensation packages under which variable, or incentive, compensation is weighted more heavily than base salary. We have established compensation programs to motivate our executives to focus on both our short-term and long-term performance by providing a mix of short-term and long-term incentive compensation in the form of annual cash incentive compensation and long-term equity-based incentive compensation. We believe that our approach appropriately allocates compensation toward non-cash equity compensation on average, and aligns the incentives of our executives with the interests of our stockholders.

Annual Cash Incentive Compensation. For 2018, we approved an annual cash incentive compensation program for our executives based 100% on achievement of pre-established adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) performance metric. We believed that this criteria would incentivize our Named Executive Officers to focus on stabilizing the Company’s EBITDA; driving growth to our top line, while creating operational efficiencies to benefit the bottom line.

Additionally, considering the challenging business environment and then-pending Harbin deal, the Company moved from an annual to quarterly Adjusted EBITDA goals (which aligned with the budget) in order to provide a responsive and viable plan for participants during the year. Any quarterly incentives earned based on achievement of quarterly Adjusted EBITDA goals are not paid until after the close of the fiscal year, so as to support our retention and stabilization efforts with leadership. The Company’s performance for 2018 resulted in partial payment of bonuses to the Named Executive Officers under the annual cash incentive compensation program or, in the case of Mr. Martindale, under his employment agreement. This is the first organization wide annual incentive payment since the 2015 plan year.

Long-term Incentive Compensation. We maintain a long-term incentive program that principally utilizes “full-value” awards, such as restricted stock awards (“RSAs”), Restricted Stock Units (“RSUs”) and Performance Share Units (“PSUs”), in combination with stock options. Our program aligns with the market trend in favor of grants of PSUs and RSUs and a reduced reliance on stock options. We believe that our long-term incentive program cultivates a long-term growth mentality among our executives that serves to focus management on achieving our strategic and financial objectives, thereby more closely aligning the interests of our executives with the long-term interests of our stockholders.

In February 2018, our executives, including all Named Executive Officers, received long-term incentive grants for 2018. The long-term incentive award grants in February 2018 to these Named Executive Officers were received in the form of PSUs and Restricted Cash. The awards granted were delivered 50% in PSUs, with a performance metric aligned with the stabilization of the Company’s EBITDA, and 50% in Restricted Cash, creating a long-term retention vehicle for the leadership team.

Other 2018 Compensation Highlights

Adoption of the GNC Holdings, Inc. 2018 Stock and Incentive Plan (the “2018 Stock Plan”) and approval by shareholders of an additional 8,720,000 shares to issue under the 2018 Stock Plan and approval of the non-binding, advisory “say on pay” proposal.
Partial cash incentive compensation payments were made to plan participants across the organization versus prior year when payments were not made, or made to select business segments based on performance against metrics.

20

TABLE OF CONTENTS

In February 2019, the Compensation Committee reviewed our executive compensation program with management from a risk perspective and determined that there are no risks created by our compensation policies and practices that are reasonably likely to have a material adverse effect on the Company. In reaching this conclusion, the Compensation Committee considered various factors, including the balance between annual and long-term compensation and between fixed and variable compensation, the use of multiple types of long-term incentive awards, the use of multiple performance criteria (including both short-term and long-term criteria) for payment of incentive compensation, the use of performance measures that are intended to increase stockholder value if goals are achieved, and various compensation policies and practices that mitigate excessive risk (including substantial stock ownership requirements for key executives, the clawback feature of the Company’s equity awards, the Compensation Committee’s negative discretion to reduce the amount of incentive awards, and the prohibition on hedging or pledging of Company stock by executives).

Compensation Policies and Objectives

The primary objectives of our executive compensation program, and the accordant Committee responsibilities, are to:

review and approve the Company’s compensation philosophy, policies and objectives;
align cash and stock-based awards with corporate performance that creates stockholder value;
build a long-term growth mentality among our key employees;
attract and retain high performing, results oriented employees;
review and determine the compensation for the Company’s executive officers, including the Named Executive Officers;
review and approve annually the corporate goals and objectives applicable to the compensation of the Company’s executive officers, including the Named Executive Officers;
review the potential risk to the Company from its compensation policies and program;
develop succession plans and implement development initiatives for the Company’s senior management; and
provide cost effective cash and stock-based rewards that are competitive with other organizations, reinforce our pay for performance culture, and are equitable to our stockholders and employees.

To facilitate the objectives, the Company provides base salary and related benefit plans, annual cash incentive compensation and long-term incentive compensation. The objectives apply to the compensation of the Named Executive Officers and to the elements of their respective executive compensation packages as follows:

Base Salary. The objective in determining base salaries for the Named Executive Officers is to set base salaries at levels that are (i) sufficient to attract and retain high performing, qualified employees and (ii) considered fair to our stockholders and employees. The Compensation Committee seeks to set base salaries at levels that are competitive with a peer group of companies and benchmarks salaries at the median of the peer group. In addition, base salaries are influenced by the complexity, scope and level of the applicable position, as well as, the background, skills, and experience of the incumbent.

Our Named Executive Officers received market competitive salary increases in 2018, in order to align with external benchmark peers and reflecting individual contributions.

Annual Cash Incentive Compensation. We use annual cash incentive compensation to incentivize the Named Executive Officers to contribute to our growth and financial performance and to provide rewards based on achievement of predetermined goals that are intended to drive increases in stockholder value. As additional cash compensation that is contingent on our financial performance, annual cash incentive compensation augments the base salary component while being tied to our financial performance.

The Company’s performance in 2018 resulted in partial payment of the annual cash incentive to the Named Executive Officers aligned with performance against established financial metrics.

21

TABLE OF CONTENTS

Long-term Incentive Compensation. We believe that long-term and stock-based awards are important in building a long-term growth mentality among our executives and aligning the long-term financial interests of our executives with those of our stockholders. Time- and performance-vested awards provide incentives to drive company performance, and have long-term horizons because value to our executives is dependent on continued employment, the achievement of pre-established performance goals (in the case of PSUs) and, ultimately, increases in the market value of our common stock.

Our 2018 equity awards consisted of PSUs and restricted cash, as noted above, which we believe focuses attention on building long-term stockholder value and creates stability in our executive leadership through retention.

Benefits and Perquisites. The Named Executive Officers are entitled to participate in, and to receive benefits under, the benefit plans, arrangements and policies available to our employees or executives generally. The Company does not have a practice of providing perquisites or make payment of perquisite allowances to any of its executives, other than certain run-out relocation benefits provided to Messrs. Burt and Gorman related to their 2017 relocations, and certain relocation benefits provided to Mr. Piano related to his 2018 relocation, and certain other minimal perquisite amounts each as identified in the Summary Compensation Table.

Executive Compensation Process

Role of the Compensation Committee

The Compensation Committee oversees the development and implementation of our executive compensation policies and objectives, determines the structure of our executive compensation packages generally, determines the actual compensation paid to each of our senior executives and evaluates the performance of our Chief Executive Officer. In addition, the Compensation Committee has the authority to (i) review our incentive compensation plans, recommend changes to such plans to the Board and exercise all the authority of the Board with respect to the administration of such plans, and (ii) retain, terminate and set the terms of our and the Compensation Committee’s relationship with any consultants and other outside advisors who assist the Compensation Committee in carrying out its duties.

Role of Management

The Compensation Committee considers the recommendations of management, principally our Chief Executive Officer when determining the structure of our executive compensation packages generally and the actual compensation paid to each of our senior executives. The Compensation Committee does not delegate any of its functions to others in setting compensation, no Named Executive Officer is a member of the Compensation Committee and our Chief Executive Officer does not provide recommendations with respect to his own compensation.

Role of Outside Advisors

The Compensation Committee has retained Korn Ferry Hay Group (US) (“Korn Ferry”) as an independent consultant to provide information, advice and recommendations regarding our executive compensation policies and design. In 2018, Korn Ferry was engaged to review and provide information, advice and recommendations regarding our executive compensation program generally, as well as the individual compensation packages of each of our senior executives, including the Named Executive Officers. Korn Ferry was directed to benchmark executive salaries and other short-term and long-term compensation, including the mix of performance-based compensation. As discussed below under “—Use of Peer Group Data,” at the direction of the Compensation Committee, Korn Ferry worked with our Chief Executive Officer and our Human Resources personnel to compare our executive compensation packages to those of a group of comparable companies.

Korn Ferry provides advice and recommendations to the Compensation Committee and reports to the Compensation Committee. Prior to its original engagement in 2011, Korn Ferry, except for executive search services performed by Korn Ferry prior to its acquisition of Hay Group and as set forth below, had not previously worked with the Company in any capacity, nor has it served us in any capacity, other than as a consultant to the Compensation Committee. The Compensation Committee has reviewed and considered information provided to it by Korn Ferry, the Compensation Committee members and our executive officers, and based on its review and the factors described in the NYSE listing standards and such other factors as it deemed

22

TABLE OF CONTENTS

relevant, the Compensation Committee has concluded that Korn Ferry is independent, that the advice it receives from Korn Ferry is objective and that Korn Ferry’s work has not raised any conflict of interest. In December 2015, Korn Ferry acquired Hay Group, which became a wholly owned subsidiary of Korn Ferry. The Company has engaged Korn Ferry to provide executive search services in the past and may do so from time to time in the future.

Use of Peer Group Data

The Compensation Committee seeks to determine how our compensation programs compare to other publicly traded companies similar to us. The Compensation Committee seeks to set compensation for the Named Executive Officers at levels that are competitive with similar companies in our industry but consistent with our growth strategy and with an emphasis on variable compensation, rather than fixed compensation.

With the assistance of Korn Ferry, the Compensation Committee reviewed its peer group in September 2018 in order to appropriately reflect companies with revenue sizes, sectors and business models similar to our own, as well as those with which we compete for talent. Other than the removal of certain companies due to delisting resulting from an acquisition or going private, there were no adjustments to the peer group. The peer group (the “2018 Peer Group”), which was used for comparative purposes in setting the levels of the 2018 long-term equity awards and cash compensation levels for our Named Executive Officers (other than Mr. Martindale, whose 2018 compensation levels were determined in connection with his appointments and employment agreement), was comprised of the following fourteen companies:

American Eagle Outfitters, Inc.
Nu Skin Enterprises, Inc.
Village Super Market
Big 5 Sporting Goods Corporation
Pier 1 Imports, Inc
Vitamin Shoppe, Inc.
Deckers Outdoor Corporation
Sally Beauty Holdings, Inc.
Weight Watchers International, Inc.
Hain Celestial Group, Inc.
Sprouts Farmers Markets, Inc.
Williams Sonoma, Inc.
Herbalife Ltd.
Ulta Beauty, Inc.

After consultation with Korn Ferry in July 2017, the Compensation Committee updated the peer group by removing Cabela’s, Inc., Dick’s Sporting Goods, Inc., Lululemon Athletica, Inc., and Panera Bread Co. from the 2017 Peer Group, and adding Big 5 Sporting Goods Corp. and Nu Skin Enterprises, Inc. (the updated peer group, the “2018 Peer Group”).

In February 2019, we used the 2018 Peer Group for comparative purposes in setting our most recent long-term equity awards and 2019 cash compensation levels for our executives, including the Named Executive Officers, other than Mr. Martindale, for whom 2019 compensation levels, including long-term equity awards, were determined under his employment agreement.

Elements of Compensation

Base Salary

With respect to 2018, the Compensation Committee established the annual base salaries of the Named Executive Officers as follows:

Name
2017 Base
Salary ($)
2018 Base
Salary ($)
Percentage
Increase (%)
Kenneth A Martindale(1)
 
975,000
 
 
975,000
 
 
N/A
 
Tricia K. Tolivar(2)
 
510,000
 
 
520,000
 
 
2.0
 
Gene E. Burt(3)
 
385,000
 
 
450,000
 
 
16.0
 
Joseph C. Gorman(4)
 
400,000
 
 
420,000
 
 
5.0
 
Steven Piano(5)
 
N/A
 
 
390,000
 
 
N/A
 
(1)Mr. Martindale was appointed as the Chief Executive Officer of the Company effective on September 11, 2017 and base salary was paid commencing on his appointment.
(2)Ms. Tolivar received a $10,000 (2.0%) increase in base salary on March 25, 2018 primarily as an adjustment to attain benchmark salary levels (“Benchmark Salary”). Additionally, Ms. Tolivar received a monthly stipend of $2,500 from January through April as compensation for her expanded role as the Interim Chief Marketing Officer.

23

TABLE OF CONTENTS

(3)Mr. Burt was appointed as the Executive Vice President, Chief Merchandising Officer and Chief Supply Chain Officer of the Company effective on January 28, 2018 and received a $65,000 (16%) increase in base salary to attain Benchmark Salary and in recognition of his expanded role. Additionally, Mr. Burt received a monthly stipend of $2,500 in January as compensation for his expanded role as the Interim Chief Human Resources Officer.
(4)Mr. Gorman was appointed Executive Vice President, Operations of the Company effective on March 3, 2017. He received a $20,000 (5.0%) increase in base salary on March 25, 2018 primarily as an adjustment to attain Benchmark Salary.
(5)Mr. Piano was appointed Senior Vice President, Chief Human Resources Officer of the Company effective January 22, 2018 and received a prorated salary based on his hire date.

Annual Cash Incentive Compensation

Annual cash incentive compensation is documented in an annual plan that is adopted by the Compensation Committee under the Company’s stock and incentive plan prior to or during the first quarter of the applicable year. The annual performance bonus for each Named Executive Officer has a threshold, target and maximum bonus amount expressed as a percentage of his or her annual base salary eligible earnings, which percentage is determined by the respective position and level of responsibility of such Named Executive Officer.

For 2018, the Company revised the design of the annual cash incentive plan to focus on strengthening the business foundation by providing a clear line of sight to financial performance metrics through individual and team efforts. The plan provided a flexible platform in goal setting to be responsive to actual financial and operational performance against plan during the year. Annual cash incentive payouts were measured and earned quarterly against Company Adjusted EBITDA goals, but payment was deferred until after the close of the fiscal year, ensuring the target remained a relevant and motivating metric throughout the year and providing a retentive element to the plan.

Quarterly Adjusted EBITDA threshold (90% of target), target, and maximum (110% of target) performance goals were reviewed and approved by the Committee prior to the beginning of each quarter. The Company’s quarterly Adjusted EBITDA incentive targets aligned with budget. Recipient’s annual cash incentive potential payout at target is split evenly over each quarter and earned payouts are determined based on achievement against quarterly metrics between threshold and maximum. Performance at threshold results in a payout of 33.3% of target, performance at target results in a payout of 100% of target, and performance at or above maximum results in a payout of 200% of target. Performance and related payments are interpolated between the various performance goals. Calculations prorate during each quarter based on changes in base salary eligible earnings, bonus target, and performance between threshold, target, and maximum performance goals. Quarterly earned payout amounts are deferred until Q1 of the following fiscal year and recipients must be actively employed on the date of payout to receive payment.

The annual cash incentive plan for 2018 performance (the “2018 Incentive Plan”) was adopted by the Compensation Committee in February 2018 and provided the following threshold, target and maximum bonus amounts for our Named Executive Officers, expressed as a percentage of annual base salary eligible earnings:

 
2018 Incentive Plan
Level
Threshold
Amount
Target
Amount
Maximum
Amount
Chief Executive Officer
 
50
%
 
150
%
 
300
%
Chief Financial Officer
 
25
%
 
75
%
 
150
%
Executive Vice President
 
20
%
 
60
%
 
120
%
Senior Vice President
 
15
%
 
45
%
 
90
%

Mr. Martindale’s annual cash incentive compensation was not established under the 2018 Incentive Plan, but in connection with his appointment and employment agreement, the threshold, target, and maximum payout amounts were set at 50%, 150% and 300%, respectively. Mr. Martindale was eligible to receive an annual bonus opportunity which could be earned based on the Compensation Committee’s evaluation of performance objectives established for the applicable year, which were the same incentives established under the 2018 Incentive Plan for all other Named Executive Officers.

24

TABLE OF CONTENTS

The following thresholds and related goals were established for all Named Executive Officers under the 2018 Incentive Plan:

Performance Measure(1)(2)
Threshold ($)
Target ($)
Maximum ($)
Relative Weight
Q1 Adjusted EBITDA
 
50,983,000
 
 
56,648,000
 
 
62,313,000
 
 
100
%
Q2 Adjusted EBITDA
 
62,034,000
 
 
68,927,000
 
 
75,820,000
 
 
100
%
Q3 Adjusted EBITDA
 
54,873,000
 
 
60,970,000
 
 
67,067,000
 
 
100
%
Q4 Adjusted EBITDA(3)
 
39,125,000
 
 
46,029,000
 
 
52,933,000
 
 
100
%
(1)As this performance measure is a non-GAAP financial metric, please see Annex A for a presentation of the reconciliation between Adjusted EBITDA and our GAAP financial metric based on the Company’s audited financial statements.
(2)The Company’s Adjusted EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization) excludes legal settlements beyond budget and one-time operational items approved by the Board.
(3)For Q4 Adjusted EBITDA, the Compensation Committee agreed to expand the performance leverage to threshold (85% of target) and maximum (115% of target) in order to maintain challenging but achievable targets in the final quarter of the fiscal year, versus the budget, which had known risks.

Results of the 2018 Incentive Plan. The Company’s performance for 2018 resulted in partial awards of bonuses during the fiscal year to the Named Executive Officers for whom threshold, target and maximum levels were established under the terms of the 2018 Incentive Plan or, in the case of Mr. Martindale, his appointment and employment agreement.Specifically, our results achieved for purposes of the 2018 Incentive Plan and the bonus eligibility under Mr. Martindale’s employment agreement were as follows:

Performance Measure
Results
Achieved
Results to
Target
Payout
Percentage
(to Target)
Q1 Adjusted EBITDA
$
59,300,000
 
 
104.8
%
 
147.8
%
Q2 Adjusted EBITDA
$
63,500,000
 
 
92.16
%
 
47.49
%
Q3 Adjusted EBITDA
$
50,100,000
 
 
82.18
%
 
0.0
%
Q4 Adjusted EBITDA
$
35,000,000
(1) 
 
81.52
%(1)
 
0.0
%
(1)The Q4 Adjusted EBITDA result of $37,500,000, resulting achieved performance percent, and payout percent were presented and certified by the Compensation Committee prior to the February 2019 closing adjustments subsequently determined by the Company.

Based on these results, under the terms of the 2018 Incentive Plan (or Mr. Martindale’s employment agreement, as applicable), our Named Executive Officers received partial cash incentive compensation payments for 2018 totaling roughly 48.82% of their annual target potential under the plan.

Name
Q1 Earned
Incentive ($)
147.8%
of Target
Q2 Earned
Incentive ($)
47.49%
of Target
Q3 Earned
Incentive ($)
0.00%
of Target
Q4 Earned
Incentive ($)
0.00%
of Target
Kenneth A. Martindale
 
540,233
 
 
173,632
 
 
0
 
 
0
 
Tricia K. Tolivar
 
152,585
 
 
47,192
 
 
0
 
 
0
 
Gene E. Burt
 
90,403
 
 
32,056
 
 
0
 
 
0
 
Joseph C. Gorman
 
88,995
 
 
29,918
 
 
0
 
 
0
 
Steven Piano
 
49,868
 
 
20,835
 
 
0
 
 
0
 

Long-term Incentive Compensation

Annual Long-Term Incentive Awards. In 2007, we adopted the GNC Acquisition Holdings Inc. 2007 Stock Incentive Plan (the “2007 Stock Plan”), in 2011, we adopted the GNC Holdings, Inc. 2011 Stock and Incentive Plan (the “2011 Stock Plan”), in 2015, we adopted the GNC Holdings, Inc. 2015 Stock and Incentive Plan (the “2015 Stock Plan”), and in 2018 we adopted the GNC Holdings, Inc. 2018 Stock and Incentive Plan (the “2018 Stock Plan”), under which plans awards are outstanding. Substantially all of our employees, and the employees of our direct and indirect subsidiaries and other affiliates, including the Named Executive Officers, are eligible for consideration of awards of stock options, restricted stock, RSUs (including PSUs) and other stock-based awards under the terms of the 2018 Stock Plan, which was adopted in 2018. The Compensation Committee is

25

TABLE OF CONTENTS

responsible for administering, selecting the individuals who are eligible to participate in and determining the types and amounts of stock-based awards granted under the 2018 Stock Plan and at the recommendation of management. Additionally, the Compensation Committee ultimately determines the size of stock-based awards for each Named Executive Officer in accordance with the Named Executive Officer’s position versus the market benchmark, performance and level of position. The Compensation Committee has discretion to delegate all or a portion of its authority under the 2018 Stock Plan, but has not done so. Following the adoption of the 2018 Stock Plan, we have not granted and will not grant any additional awards under the 2007 Stock Plan, the 2011 Stock Plan, nor the 2015 Stock Plan.

Stock options granted under the various plans generally are subject to vesting in annual installments and have terms of seven to ten years. Options and other stock-based awards under the 2011 Stock Plan, the 2015 Stock Plan, and 2018 Stock Plan are subject to clawback by the Company if the participant engages in any “detrimental activity” during the participant’s service or for one year after the participant’s service ends, which is generally defined to include disclosing confidential information about the Company, engaging in activities that result (or would result if known) in the termination of the participant’s service for cause, soliciting the Company’s employees on behalf of a competing employer, or materially breaching any agreement between the participant and the Company.

The Compensation Committee generally considers grants of long-term incentive compensation awards on an annual basis, except for certain new hires and promotions which are granted on an as-desired basis. We do not have any program, plan or practice to time annual or ad hoc grants of equity-based awards in coordination with the release of material non-public information or otherwise. For 2018, the Company revised the design of the long-term incentive plan to focus on strengthening the business foundation and long-term strategy by providing a clear line of sight to performance metrics through individual and team efforts, as well as, provide award vehicles that support retention efforts. The plan provided a suitable platform in goal setting to be responsive to actual financial and operational performance against plan during the performance period, allowing for consideration of the challenging environment during this period of transition. The Company did not make any adjustments to the annual long-term incentive performance target.

The plan utilized two vehicles to deliver the total long-term incentives: 50% in Performance Share Units (PSUs) and 50% in Restricted Cash (RC).

Performance Share Units (PSUs): Earned ratably over three years with distinct one-year performance periods and financial goals set at the beginning of each performance period. Shares can be earned annually based on performance against the established goals, but vesting will be deferred until after the third year. Once annual performance is determined, the earned shares are converted into time-based restricted shares for the balance of the three-year period. Unearned shares are forfeited. Final vesting will occur in Q1 following the close of the third year. Recipients must be actively employed at the time of vesting to receive the earned shares. The intent of the PSU award is to create a long-term performance based award that focuses the leadership team on the stabilization of EBITDA year over year.
Restricted Cash (RC): One third of the total award becomes unrestricted and is paid in cash each year after the award’s anniversary date. Recipients must be actively employed at the time the award becomes unrestricted to receive the payout. The intent of the RC award is to create a long-term retention award for our leadership team, providing stability within key roles.

In February 2018, the Company granted long-term incentive awards to certain Named Executive Officers, including Mr. Martindale, outlined below, under the 2015 Stock Plan (the 2018 Stock Plan was not adopted until March 2018) in the form of 50% PSUs and 50% RC. Base award values for these long-term incentive grants were determined based in part on the results of Korn Ferry’s analysis of the compensation packages of top executives at companies in the 2018 Peer Group, and were intended to be competitive compared to long-term incentive awards granted to executives with comparable titles and responsibilities within the 2018 Peer Group.

For the February 2018 awards, the 50% value attributable to the PSUs were determined by dividing the total grant value of the PSUs award by $4.20, which was the closing price per share of our common stock on February 21, 2018, the date of grant. The performance metric for the first tranche of the PSUs is based 100% on achievement of pre-determined Company Adjusted EBITDA. The portion of the first tranche of PSUs that will be earned by a grantee is based upon the Company’s achieved Adjusted EBITDA relative to the target Adjusted

26

TABLE OF CONTENTS

EBITDA which aligns with the budget. Annual Adjusted EBITDA threshold (85% of target), target, and maximum (115% of target) performance goals were reviewed and approved by the Committee during Q1 of 2018. Recipient’s annual long-term incentive potential vesting at target is split evenly over each performance year and earned shares are determined based on achievement against annual metrics between threshold and maximum. At the threshold level of performance, 50% of the PSUs are earned; at the target level, 100% of the PSUs are earned; and at or above the maximum level, 150% of the PSUs are earned, provided, in each case, that the executive has remained employed until the end of the three year period and vesting date. At the conclusion of the each performance year, the Compensation Committee will determine whether and the extent to which the Company agreed to issue and sell toperformance criteria have been achieved for the Investor, andpurpose of determining the Investor agreed to purchase frompercentage of the Company, 299,950 sharestarget amount of newly created Convertible Preferred StockPSUs that have earned for a purchase pricethe performance year. Any PSUs that have not been earned as of $1,000 per share, or an aggregate purchase pricethe end of approximately $300 million. The transaction is subject to customary closing conditions, including receipt of all necessary regulatory and governmental approvals, approval of our stockholders and entry into the Joint Venture. The Convertible Preferred Stockperformance year, based upon the Compensation Committee’s determination, will be convertible intoforfeited. The earned shares will be treated as time-based restricted stock fort the balance of the three year period. The Compensation Committee may, in its sole discretion, reduce the amount to less than the amount that is determined to be vested in accordance with the agreements providing for the PSUs.

Grant to Ms. Tolivar. Ms. Tolivar was granted a special recognition award of 29,762 PSUs, with a total award value of $125,000, and $125,000 in RC in February 2018. The PSUs and RC follow the same vesting schedule and terms as all other awards issued in February 2018. For more information, see “—Elements of Compensation —Long-Term Incentive Compensation” below. The additional award was issued in recognition of Ms. Tolivar’s efforts, oversight, and successful negotiation of the Company’s Common Stock atlong-term debt refinancing and as a retention vehicle.

Summary of 2018 Named Executive Officer Awards. The total award values for the Conversion Price,2018 awards for our Named Executive Officers, together with the corresponding number of (a) target PSUs and will accrue cumulative preferential dividends, payable quarterly in arrears, at an annual rate(b) RC awarded to each of 6.50%our Named Executive Officers, is set forth below:

Name
Total Award
Value ($)
Target
PSUs (#)
Restricted
Cash ($)
Kenneth A. Martindale
 
4,387,500
 
 
522,321
 
 
2,193,750
 
Tricia K. Tolivar(1)
 
1,000,000
 
 
119,048
 
 
500,000
 
Gene E. Burt
 
750,000
 
 
89,286
 
 
375,000
 
Joseph C. Gorman
 
750,000
 
 
89,286
 
 
375,000
 
Steven Piano
 
250,000
 
 
29,762
 
 
125,000
 
(1)Ms. Tolivar’s award values include her additional recognition award described earlier.

Results of the Stated Value.2018 Long-Term Incentive Plan: As described earlier, the performance metric for the first tranche of the PSU component of these long-term incentive awards is Adjusted EBITDA. The Compensation Committee established threshold, target and maximum levels of achievement with respect to Adjusted EBITDA. Performance is measured as of the end of the performance year on December 31, 2018. Performance and related payments are interpolated between the various performance goals.

The threshold, target and maximum levels of Adjusted EBITDA performance for the first tranche of the February 2018 PSU grants are as follows:

Metric
Threshold
($)
(50% payout)
Target
($)
(100% payout)
Maximum
($)
(150% payout)
Achieved
($)
Adjusted EBITDA(1)
 
198,050,000
 
 
233,000,000
 
 
267,950,000
 
 
207,900,000
(2) 
(1)The Company’s EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization) excludes legal settlements beyond budget and one-time operational items approved by the Board.
(2)The Adjusted EBITDA result of $210,500,000 (90.4% of target), resulting achieved performance percent, and earned PSU percent were presented and certified by the Compensation Committee prior to the February 2019 closing adjustments subsequently determined by the Company.

27

TABLE OF CONTENTS

Based on these results, under the terms of the Convertible Preferred Stock2018 Incentive Plan (or Mr. Martindale’s employment agreement, as applicable), our Named Executive Officers will be set forthearn partial PSUs for 2018 totaling 67.8% of their target potential for the first tranche under the plan.

Name
2018 Target
PSUs (#)
Earned PSU
Results
2018 Earned
PSUs (#)
Kenneth A. Martindale
 
174,107
 
 
67.8
%
 
118,045
 
Tricia K. Tolivar
 
39,683
 
 
67.8
%
 
26,905
 
Gene E. Burt
 
29,762
 
 
67.8
%
 
20,179
 
Joseph C. Gorman
 
29,762
 
 
67.8
%
 
20,179
 
Steven Piano
 
9,921
 
 
67.8
%
 
6,726
 

Additionally, as part of the 2018 long-term incentive plan, our Named Executive Officers received one-third of their 2018 RC award after the award’s anniversary date (February 21, 2019).

Benefits and Perquisites

The Company does not have a practice of providing perquisites or make payment of perquisite allowances to any of its executives, other than certain run-out relocation benefits provided to Messrs. Burt and Gorman related to their 2017 relocations, and certain relocation benefits provided to Mr. Piano related to his 2018 relocation, and certain other minimal perquisite amounts each as identified in the CertificateSummary Compensation Table.

Non-qualified Deferred Compensation Plan

We maintain the GNC Live Well® Later Non-Qualified Deferred Compensation Plan for the benefit of Designationsa select group of our highly compensated employees. Under this plan, certain eligible employees may elect to be fileddefer a portion of their future compensation under the deferred compensation plan by the Company with the Secretary of State of the State of Delawareelecting such deferral prior to the closingbeginning of the transaction. The Certificatecalendar year during which the deferral amount would be earned. Mr. Martindale and Mr. Gorman made contributions to the deferred compensation plan in 2018. For 2018, a dollar-for-dollar match with respect to the first three percent of Designations is described ina participant’s compensation deferred under the non-qualified deferred compensation plan was provided. For more detail ininformation regarding the section entitled “deferred compensation plan, please see “2018 Non-Qualified Deferred Compensation Table” below.

Description of the Convertible Preferred StockRetention Agreements” below.

In connection with the Securities Purchase Agreement, we will enterChina joint venture partnership, the Company entered into togetherretention agreements with certain key leaders and executives, including the Investor,Named Executive Officers. It is important for the Stockholders Agreement, which will provide for certain rightsCompany to maintain leadership stability, focus, and responsibilities of the partiesexecution at all times, but specifically in connection with the Investor’s investmentefforts required over the foreseeable future related to the transition and the governancesuccessful implementation of the Company, and the Registration Rights Agreement, which willpartnership. The agreements provide for four ratable payments to the obligationparticipants over the course of two years from the Company, atannouncement date (February, 2018), for which the request ofrecipients have to remain actively employed to receive the Investor, to register the resale of the Common Stock underlying the Convertible Preferred Stock with the SEC. In addition, the Securities Purchase Agreement providespayment. The agreements also include confidentiality, non-competition, non-recruitment and non-solicitation provisions in exchange for the parties to use reasonable best efforts to negotiate definitive documentation with respect toconsideration provided. For more information regarding the Joint Venture, pursuant to which, among other things, the Joint Venture would be granted an exclusive right to use the Company’s trademarks and manufacture and distribute the Company’s products in China (excluding Hong Kong, Taiwan and Macau). retention payments, please see “Summary Compensation” table below.

Executive Severance Pay Policy

The Company would receive royalties on all products sold bymaintains an Executive Severance Pay Policy (the “Executive Severance Policy”) for executive officers who are involuntarily terminated from employment and otherwise meet the Joint Venture. The Joint Venture would be owned 65% by the Investor and 35% by the Company. The Stockholders Agreement, the Registration Rights Agreement and the Joint Venture are described in more detail in the section entitled “Description of the Transaction Documents” below.

Additionally, on February 28, 2018, the Company completed the refinancing of the Company’s Existing Credit Agreement, which providesrequirements for (i) the amendment and restatement of the Company’s Existing Credit Agreement to extend the maturity date of certain term loans of the Company, (ii) the repayment in full andbenefits. Upon an involuntary termination of the Company’s revolving credit facility, (iii) the repayment of a portion of the Company’s existing term loans and (iv) the entrance into a new asset-based term loan facility. These financing-related transactions satisfy the condition to completion of the issuance, purchase and sale of the Convertible Preferred Stock with respect to the Credit Agreement Refinancing (as defined in the Securities Purchase Agreement). Additional information regarding these amendments to the Company’s Existing Credit Agreement can be found in the section entitled “—The Credit Agreement Refinancing” below.

Use of Proceeds

Pursuant to the Securities Purchase Agreement, the Company will use the proceeds of the Share Issuanceother than for (i) the repayment, in whole or in part, of the Company’s outstanding indebtedness under its credit agreement,

dated as of November 26, 2013, with JPMorgan Chase Bank, N.A. as administrative agent, as amended (the “Existing Credit Agreement”), (ii) repayment of fees and expenses in connection with the transaction and (iii) other general corporate purposes as may be mutually agreed by the Company and the Investor.

The Credit Agreement Refinancing

On February 28, 2018, the Company entered into certain amendments to its Existing Credit Agreement and a new ABL credit agreement (collectively, the “Credit Agreement Refinancing”), pursuant to which the Company has agreed to:

the amendment and restatement of the Existing Credit Agreement in order to, among other things, extend the Tranche B Term Loan maturity date with respect to the term loans of consenting term loan lenders to the earlier to occur of (1) March 4, 2021 and (2) May 16, 2020, which is the date that is 91 days prior to the stated maturity of the 1.50% Convertible Senior Notes due August 15, 2020 (the “Convertible Senior Notes”) under that certain indenture dated as of August 10, 2015 among GNC Holdings, Inc., GNC Corporation, General Nutrition Centers, Inc., certain other subsidiaries party thereto, and Bank of New York Mellon Trust Company, N.A., as trustee (or, if between such dates, the date that is 91 days prior to the stated maturity of any debt that refinances the Convertible Senior Notes), unless (in the case of this clause (2)), all amounts exceeding $50,000,000 of the Convertible Senior Notes have been repaid or converted prior to such date (any such repayment or conversion, the “Existing Indenture Discharge”);

the termination of the “Revolving Credit Commitment” and repayment in full of the outstanding “Revolving Credit Loans” (eachCause, as defined in the Existing Credit Agreement);

Executive Severance Policy, eligible executives are entitled to receive:

Cash severance benefits of six months of base salary, in the repaymentcase of Vice Presidents, or
One year base salary, in the case of positions senior to Vice President.
The severance is increased to one year and two years for such positions, respectively, in the case of a portiontermination of employment without Cause, or resignation for Good Reason, as defined in the Executive Severance Policy, occurring within 24 months following a Change in Control of Company, also as defined in the Executive Severance Policy.

28

TABLE OF CONTENTS

Payments and benefits under the Executive Severance Policy are contingent upon the executive’s execution and non-revocation of a release of claims against the Company and compliance with covenants set forth in the Executive Severance Policy, which include confidentiality, non-competition and non-solicitation of the existing term loansCompany’s employees. In addition, if such executive obtains subsequent employment that are extendedis considered comparable to his or her previous employment with the Company, then the amount remaining to be paid to such executive, under the Executive Severance Policy, is offset by the annual gross base salary payable to such executive pursuant to such subsequent employment.

Mr. Martindale Employment Agreement

In connection with his appointment as described above;Chief Executive Officer, we entered into a three-year employment agreement with Mr. Martindale in September 2017. Under the terms of the employment agreement, we agreed to provide Mr. Martindale with an annual salary of $975,000, an annual bonus opportunity of at least 150% of base salary and

certain cash and equity payments as relocation/make-whole awards, which were detailed in our 2018 proxy statement. Under the entry into (a) a new asset-based term loan facility advanced on a“first-in,last-out” basisEmployment Agreement, Mr. Martindale will also receive cash severance in an aggregate principal amountthe event his employment is terminated by the Company without Cause (as defined therein) or by Mr. Martindale resigning voluntarily for Good Reason. The employment agreement also provides that any incentive compensation payable to Mr. Martindale will be subject to the clawback policies adopted or implemented by us, including in respect of $275,000,000the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and any rules promulgated thereunder. Please see “Potential Payments Upon Termination or Change in Control” below for more information regarding such employment agreement and termination and payments made in connection with a maturity datechange in control.

Mr. Martindale also agreed to the Company’s standard senior executive restrictive covenants including confidentiality of indefinite duration; nonsolicitation of customers; and noncompetition and nonsolicitation/no-hire of employees during his employment and for 24 months following his termination of employment for any reason. No other Named Executive Officer has or had employment agreements with the Company.

Impact of Accounting and Tax Considerations

As a general matter, the Compensation Committee reviews and considers the various tax and accounting implications of the earliercompensation vehicles we utilize.

Prior to occurthe enactment of (1)the Tax Cuts and Jobs Act, Section 162(m) of the Internal Revenue Code generally disallowed public companies a tax deduction for compensation in excess of $1,000,000 paid to their chief executive officer and their three other most highly compensated executive officers (excluding the chief financial officer) unless certain performance and other requirements are met. As part of the Tax Cuts and Jobs Act, the exemption from the deduction limitation for performance-based compensation provided by Section 162(m) has been repealed. This change will be effective for taxable years beginning after December 202231, 2017. As a result, compensation paid to certain executive officers which exceeds $1,000,000 will not be deductible unless it qualifies for transition relief applicable to certain arrangements in place as of November 2, 2017.

For 2018, the Compensation Committee factored in the potential loss of deductibility during the pay setting approval process. Our intent generally is to design and (2) May 16, 2020 (or, if between such dates, the dateadminister executive compensation programs in a manner that is 91 dayswill preserve deductibility of compensation paid to our executives, and, prior to the stated maturityenactment of any debtthe Tax Cuts and Jobs Act, we believed that refinances the Convertible Senior Notes), unless (in the case of this clause (2)) the Existing Indenture Discharge has occurred which will consist of (x) cash funded loans the proceeds of which will be used to prepay a substantial portion of our current executive compensation program (including the term loans of certain extending lendersannual incentive program and the long-term incentive awards that may be granted under the Existing Credit Agreement and (y) loans that will be issued2015 Stock Plan) would satisfy the requirements for exemption from the $1,000,000 deduction limitation. However, certain awards, such as the inducement awards granted to our Chief Executive Officer in exchangeconnection with his appointment were not granted under a stockholder-approved plan as required for a portiondeduction under Section 162(m). Also, because of ambiguities and uncertainties as to the application and interpretation of Section 162(m) and the regulations issued thereunder, including the uncertain scope of the term loans of other extending lenderstransition relief for the exemption from the deduction limitation for performance based compensation provided by Section 162(m), there can be no assurance that any amounts paid under the Existing Credit Agreement and (b) a new asset-based revolving credit facility in an aggregate principal amount of up to $100,000,000 with a maturity date of the earlier to occur of (1) the date that is four andone-half years after February 28, 2018 and (2) May 16, 2020 (or, if between such dates, the date that is 91 dayscompensation programs, even prior to the stated maturityeffectiveness of any debtthe legislative changes, will be deductible under Section 162(m), including, without limitation, in special circumstances related to other hirings and separations.

29

TABLE OF CONTENTS

Additionally, we reserve the right to design programs and to structure other compensation arrangements that refinancesrecognize a full range of performance criteria important to our success or that contain different terms, even where the Convertible Senior Notes) unless (incompensation paid under such programs may not be deductible. The Compensation Committee will, in the caseexercise of this clause (2))its business judgment, continue to monitor our executive compensation program as part of its primary objective of ensuring that compensation paid to our executives is reasonable, performance-based and consistent with our goals and the Existing Indenture Discharge has occurred.

goals of our stockholders.

PartiesExecutive Stock Ownership Guidelines

We believe that, to align the Transactions

GNC Holdings, Inc.

GNC Holdings, Inc. (NYSE: GNC) is headquarteredlong-term financial interests of our executive officers with those of our stockholders, our executives should hold a financial stake in Pittsburgh, PA and isthe Company. The Board adopted a leading global specialty health, wellness and performance retailer.

The Company connects customers to their best selves by offering a premium assortment of health, wellness and performance products, including protein, performance supplements, weight management supplements, vitamins, herbs and greens, wellness supplements, health and beauty, food and drinkpolicy in December 2011 (revised most recently in February 2015) requiring our Chief Executive Officer and other general merchandise. This assortment features proprietary “GNC” and nationally recognized third-party brands.

The Company’s diversified, multi-channel business model generates revenue from product sales through company-owned retail stores, domestic and international franchise activities, third-party contract manufacturing,

e-commerce and corporate partnerships. As of December 31, 2017,executive officers to own stock in the Company had approximately 9,000 locations,(our “Executive Stock Ownership Guidelines”). Specifically, our Executive Stock Ownership Guidelines are outlined below:

Chief Executive Officer
Aggregate value of 6x his or her annual base salary
Executive Vice Presidents
Aggregate value of 2x his or her annual base salary
Senior Executive Officers
Aggregate value of 1x his or her annual base salary

The Executive Stock Ownership Guidelines provide that our newly appointed executive officers have five years from the date of which approximately 6,700 retail locationstheir appointment to comply with the Executive Stock Ownership Guidelines, and should retain at least 50% of all after-tax shares owned by or underlying equity awards granted to them after December 11, 2012 until the ownership thresholds are met. The Compensation Committee will evaluate whether exceptions should be made for any executive officer on whom this requirement would impose a financial hardship or for other appropriate reasons as determined by the Compensation Committee, and will work actively with officers or directors who are not in compliance as a result of stock price volatility. For the United States (including approximately 2,400 Rite Aid franchisestore-within-a-store locations) and franchise operations in approximately 50 countries.

Harbin Pharmaceutical Group Holding Co., Ltd. and Harbin Pharmaceutical Group Co., Ltd.

Harbin Pharmaceutical Group Holding Co., Ltd., referred to as “Hayao”, is headquartered in Harbin City Heilongjiang Province, China and is onepurposes of the leading pharmaceuticalExecutive Stock Ownership Guidelines, Company stock includes (i) directly held shares of our common stock, (ii) shares of unvested restricted stock or RSUs (other than unvested shares of performance-vested restricted stock or unvested PSUs) and VMS (vitamins, minerals(iii) vested shares of our common stock held in any plan qualified under Section 401(a) of the Internal Revenue Code of 1986, as amended.

Policy on Hedging and supplements) companies in China.Pledging of Company Stock

The Investor hasWe have a broad portfoliopolicy applicable to our directors and all of OTC(Over-The-Counter), Rx (prescription) and VMS products, and is also engaged in pharma distribution and retail pharmacy businesses. The Investor has many national renowned brands in Chinaour employees, including our Named Executive Officers, that have very high consumer awareness including “San Jing,” and command leading market share inprohibits such persons from (i) within six months after purchasing any Company securities, selling any Company securities of the mineral supplements category.

The Investor owns controlling interests in two subsidiaries listedsame class, (ii) selling the Company’s securities short, (iii) buying or selling puts or calls or other derivative securities on the Shanghai Stock Exchange: Harbin Pharmaceutical Group Co., Ltd. (SHSE: 600664), which focuses on the OTC, RxCompany’s securities, (iv) holding Company securities in a margin account or pledging Company securities as collateral for a loan or (v) entering into hedging or monetization transactions or similar arrangements with respect to Company securities.

30

TABLE OF CONTENTS

COMPENSATION COMMITTEE REPORT

The following Compensation Committee Report does not constitute soliciting material and VMS business, and HPGC Renmintongtai Pharmaceutical Corporation (SHSE: 600829), which focuses on the distribution and retail pharmacy business.

The Investor has access to an extensive distribution and retailing networkshould not be deemed filed or incorporated by directly operating more than 300 chain retail pharmacies and collaboration with approximately 800 drug and VMS distributors to build nationwide coverage in China.

Background of the Share Issuance

The Board and management periodically review and assess the Company’s operations and financial performance, business strategy, the various trends and conditions affecting the nutritional supplement industry and a variety of strategic alternatives reasonably available to the Company. In this regard, the Board and management periodically explore potential commercial partnership opportunities for thereference into any other Company in China, aiming to enhance the Company’s position in China and capitalize on the substantial market opportunities for the Company’s products. In addition, as early as May 2016, the Board began to discuss the approaching maturity of the Company’s credit facilities and potential debt refinancing alternatives, as well as potential equity investment alternatives to reduce the Company’s leverage and position the Company for future growth.

In February 2017, the Company began initial discussions with Goldman Sachs & Co. LLC (“Goldman Sachs”) regarding potential commercial partnership opportunities for the Company in China. In May 2017, Goldman Sachs was engaged as financial advisor to the Company in connection with its exploration of potential commercial partnerships in China. In connection with this process, Goldman Sachs contacted twenty potential partners, including seventeen potential strategic partners and three potential private equity sponsors. The Company subsequently entered into confidentiality agreements with twenty-four entities representing seventeen potential partners interested in exploring a potential Chinese partnership and furnished due diligence information and engaged in discussions with such parties. Seven parties, including the Investor, submitted initial proposals for potential Chinese partnerships and the Company and Goldman Sachs engaged in discussions with such parties.

In the spring of 2017, at the instruction of the Board, the Company approached existing lenders under the Existing Credit Agreement, seeking to amend and extend the credit facilities thereunder. However, the Company could not reach an agreement on favorable terms for such a transaction at that time. Then, in the late summer and fall of 2017, in light of the approaching maturity of the Existing Credit Agreement, the Board and management accelerated their efforts to explore and execute potential debt refinancing alternatives. In November 2017, the Company sought to complete a private placement offering of senior secured notes under Rule 144Afiling under the Securities Act of 1933 as amended,or the Exchange Act, except to the extent the Company specifically incorporates this Report by reference therein.

The Compensation Committee has reviewed and discussed with management the Compensation Discussion and Analysis contained in these proxy materials. Based on the Compensation Committee’s review of and the rulesdiscussions with management with respect to the Compensation Discussion and regulations promulgated thereunder (the “Securities Act”)

Analysis, the Compensation Committee recommended to the Board that the Compensation Discussion and to enter into a new credit facility,Analysis be included in these proxy materials and incorporated by reference in the Annual Report for filing with the goalSEC.

The foregoing report is provided by the following directors, who constitute the Compensation Committee:

COMPENSATION AND ORGANIZATIONAL DEVELOPMENT COMMITTEE
Philip E. Mallott (Chairperson)
Amy B. Lane
Richard J. Wallace

31

TABLE OF CONTENTS

NAMED EXECUTIVE OFFICER COMPENSATION

Summary Compensation Table – 2018, 2017 and 2016

The following table sets forth information concerning the compensation we paid to the Named Executive Officers for services rendered in all capacities as employees to us during our last three fiscal years. In accordance with SEC rules, the compensation described in this table does not include the value of usingmedical or group life insurance received by the proceedsNamed Executive Officers that is available generally to all of each to refinanceour salaried employees. Only 2017 and 2018 compensation is presented for Mr. Martindale, because 2017 was his first year as an employee of the loans outstandingCompany. Only 2018 compensation is presented for Mr. Piano, because 2018 was his first year as an employee of the Company. A “Change in Pension Value and Nonqualified Deferred Compensation Earnings” column is not presented because none of our Named Executive Officers participate in a pension plan or receive above-market or preferential earnings on nonqualified deferred compensation.

Name and Principal Position
Year
Salary
($)
Bonus
($)(1)
Stock
Awards
($)(2)
Option
Awards
($)(3)
Non-Equity
Incentive Plan
Compensation
($)(4)
All Other
Compensation
($)(5)
Total ($)
Kenneth A. Martindale
Chief Executive Officer
2018
 
975,000
 
 
487,500
 
 
2,193,750
 
 
 
 
2,907,615
 
 
30,282
 
 
6,594,147
 
2017
 
262,500
 
 
 
 
4,650,026
 
 
1,900,001
 
 
 
 
105,625
 
 
6,918,152
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tricia K. Tolivar
Executive Vice President,
Chief Financial Officer
2018
 
517,691
 
 
191,250
 
 
500,000
 
 
 
 
699,777
 
 
1,113
 
 
1,909,831
 
2017
 
514,033
 
 
 
 
1,633,288
 
 
327,000
 
 
 
 
15,446
 
 
2,489,767
 
2016
 
450,571
 
 
 
 
802,271
 
 
300,000
 
 
 
 
16,436
 
 
1,569,278
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene E. Burt
Former Executive
Vice President,
Chief Merchandising Officer
and Chief Supply Chain
Officer(6)
2018
 
445,008
 
 
112,500
 
 
375,000
 
 
 
 
497,459
 
 
2,736
 
 
1,432,703
 
2017
 
354,616
 
 
75,000
 
 
204,561
 
 
114,450
 
 
 
 
31,595
 
 
780,222
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joseph C. Gorman
Former Executive
Vice President,
Operations(6)
2018
 
415,381
 
 
100,000
 
 
375,000
 
 
 
 
493,914
 
 
50,041
 
 
1,434,336
 
2017
 
378,850
 
 
 
 
179,039
 
 
114,450
 
 
 
 
52,267
 
 
724,606
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Steven Piano
Senior Vice President, Chief
Human Resources Officer
2018
 
367,500
 
 
147,500
 
 
125,000
 
 
 
 
195,703
 
 
28,569
 
 
864,272
 
(1)For 2018, reflects retention bonuses paid in connection with the Harbin deal, as discussed under the heading “Retention Agreements” in this proxy statement, and a $50,000 sign-on incentive bonus paid to Mr. Piano in January 2018. For 2017, reflects a $75,000 sign-on incentive bonus paid to Mr. Burt in February 2017.
(2)The 2018 values set forth in this column represents the aggregate grant date fair value of performance share unit (PSU) awards granted, which have been computed in accordance with FASB ASC Topic 718 (excluding the effect of estimated forfeiture). For 2017, values set forth in this column represent the aggregate grant date fair value of the restricted stock unit (RSU) and PSU awards granted, which have been computed in accordance with FASB ASC Topic 718 (excluding the effect of estimated forfeiture). For 2016, values set forth in this column represent the aggregate grant date fair value of PSU and RSU awards granted, which have been computed in accordance with FASB ASC Topic 718 (excluding the effect of estimated forfeitures). The grant date fair values for the PSU awards have been determined assuming 100% of target performance is achieved. If maximum share payouts were achieved for the 2018 PSU awards, the aggregate grant date fair value for these units would be 150% of the amount disclosed. If we assume the maximum 150% of target performance would be achieved, the grant date values of the PSUs granted to Mr. Martindale, Ms. Tolivar, and Messrs. Burt, Gorman, and Piano in 2018 would be $3,290,625, $750,000, $562,500, $562,500, and $187,500, respectively. If maximum share payouts were achieved for the 2016 and 2017 PSUs, the aggregate grant date fair value for these units would be twice the amount disclosed in each year in the table related to the PSUs. If we assume the maximum 200% of target performance would be achieved, the grant date values of (a) the PSUs granted to Ms. Tolivar and Messrs. Burt and Gorman in 2017 would be $702,400, $234,283 and $205,054, respectively, (b) the PSUs granted to Ms. Tolivar in 2016 would be $1,004,541. For the assumptions underlying the calculation of the aggregate grant date fair value, see Note 14, “Stock-Based Compensation,” to our audited consolidated financial statements included in the Annual Report filed with the Securities and Exchange Commission on March 13, 2019 (the “2019 Annual Report”). The amounts shown in the table may not correspond to the actual value that may be realized by such persons with respect to these awards.
(3)The values set forth in this column reflect the aggregate grant date fair value of stock option awards granted during each fiscal year, computed in accordance with FASB ASC Topic 718. For the assumptions underlying the calculation of the aggregate grant date fair value, see Note 16, “Stock-Based Compensation,” to our audited consolidated financial statements included in the 2019 Annual Report. The amounts may not correspond to the actual value that may be realized by such persons with respect to these awards.

32

TABLE OF CONTENTS

(4)Reflects the non-discretionary component of cash incentive compensation. For 2018, also includes the RC award value to Mr. Martindale, Ms. Tolivar, and Messrs. Burt, Gorman, and Piano of $2,193,750, $500,000, $375,000, $375,000, and $125,000, respectively.
(5)The components of “All Other Compensation” for our fiscal year ended December 31, 2018 are set forth in the following table:
Named Executive Officer
Perquisites ($)(a)
Imputed Value for
Life Insurance
Premiums ($)
Company Contributions
to Deferred
Compensation Plan ($)(b)
Total ($)
Kenneth A. Martindale
 
 
 
 
1,032
 
 
29,250
 
 
30,282
 
Tricia K. Tolivar
 
540
 
 
573
 
 
 
 
1,113
 
Gene E. Burt
 
2,184
 
 
552
 
 
 
 
2,736
 
Joseph C. Gorman
 
37,243
 
 
360
 
 
12,438
 
 
50,041
 
Steven Piano
 
28,187
 
 
382
 
 
 
 
28,569
 
(a)For Messrs. Burt, Gorman, and Piano, this column includes $1,643, $34,221, and $27,587, respectively, of relocation expenses, which reflects the actual cost incurred by each in relocating. For Mr. Gorman, amounts also reflect $3,000 for tuition reimbursement. For Ms. Tolivar, the column only includes taxable parking benefits. For Messrs. Burt, Gorman, and Piano, this column also includes $540, $22, and $600 in taxable parking benefits, respectively. During 2018, Mr. Martindale was provided with access to a parking space to use at our corporate headquarters in Pittsburgh, which was provided as a perquisite at no incremental cost to the Company.
(b)Reflects matching contributions by the Company with respect to compensation deferred by each executive pursuant to the Company’s Non-Qualified Deferred Compensation Plan. For more information, see the “2018 Non-Qualified Deferred Compensation Table” below.
(6)Resigned from the Company effective March 15, 2019.

2018 Grants of Plan Based Awards Table

The following table sets forth information concerning awards under the Existing Credit Agreement. However,2015 Stock Plan and the Company could not reach an agreement on favorable terms, so2018 Incentive Plan granted to each of the Board continued to explore potential debt refinancing alternatives. Subsequently, the Board engaged Goldman Sachs as its strategic financial advisor to help the Board evaluate alternatives to optimize the Company’s capital structure and enhance stockholder value. The Company issued a press release to announce the engagement of Goldman Sachs in such capacity onNamed Executive Officers during our fiscal year ended December 4, 2017.

Also31, 2018. Assumptions used in the fallcalculation of certain dollar amounts are included in Note 16 “Stock-Based Compensation,” to our audited consolidated financial statements included in the 2019 Annual Report.

 
 
Estimated Future Payouts
Under Non-Equity Incentive
Plan Awards(1)
Estimated Future Payouts
Under Equity Incentive Plan
Awards(2)
All
Other
Stock
Awards:
Number
of
Shares
(#)
All
Other
Option
Awards:
Number of
Shares
(#)
Exercise
Price of
Options
($)
Grant
Date Fair
Value of
Stock
and
Option
Awards
($)(3)
Name
Grant
Date
Threshold
($)
Target
($)
Maximum
($)
Threshold
(#)
Target
(#)
Maximum
(#)
Kenneth A. Martindale
2/21/18
 
487,500
 
 
1,462,500
 
 
2,925,000
 
 
261,161
 
 
522,321
 
 
783,482
 
 
 
 
 
 
 
 
 
 
 
2,193,750
 
 
2/21/18
 
 
 
 
2,193,750
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tricia K. Tolivar
2/21/18
 
130,000
 
 
390,000
 
 
780,000
 
 
59,524
 
 
119,048
 
 
178,572
 
 
 
 
 
 
 
 
 
 
 
500,000
 
 
2/21/18
 
 
 
 
500,000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene E. Burt(4)
2/21/18
 
90,000
 
 
270,000
 
 
540,000
 
 
44,643
 
 
89,286
 
 
133,929
 
 
 
 
 
 
 
 
 
 
 
375,000
 
 
2/21/18
 
 
 
 
375,000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joseph C. Gorman(4)
2/21/18
 
84,000
 
 
252,000
 
 
504,000
 
 
44,643
 
 
89,286
 
 
133,929
 
 
 
 
 
 
 
 
 
 
 
375,000
 
 
2/21/18
 
 
 
 
375,000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Steven Piano
2/21/18
 
58,500
 
 
175,500
 
 
351,000
 
 
14,881
 
 
29,762
 
 
44,643
 
 
 
 
 
 
 
 
 
 
 
125,000
 
 
2/21/18
 
 
 
 
125,000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1)The amounts for Mr. Martindale represent threshold, target and maximum payout amounts under the terms of his employment agreement for the 2018 Incentive Plan. The amounts for the other Named Executive Officers represent the threshold, target and maximum payout amounts under the 2018 Incentive Plan. See “Compensation Discussion and Analysis – Elements of Compensation – Annual Cash Incentive Compensation” above for more information regarding the 2018 Incentive Plan. The additional amounts included for all Named Executive Officers represent the value of the Restricted Stock Cash Award granted in 2018.
(2)The amounts represent the threshold, target and maximum number of shares of our common stock that may be earned under the 2018 PSU awards. The PSUs are scheduled to vest on December 31, 2020 subject to company performance and each officer’s continued employment. See “Compensation Discussion and Analysis – Elements of Compensation – Long Term Incentive Compensation” above for more information regarding the PSUs.

33

TABLE OF CONTENTS

(3)For our Named Executive Officers, reflects the aggregate grant date fair value of the stock options, the RSUs and the target PSUs granted to them in February 2018, computed in accordance with FASB ASC Topic 718. For the assumptions underlying the calculation of the aggregate grant date fair value, see Note 14, “Stock-Based Compensation,” to our audited consolidated financial statements included in the 2019 Annual Report. The amounts shown in the table may not correspond to the actual value that may be realized by such persons with respect to these awards.
(4)Resigned from the Company effective March 15, 2019. As a result of Messrs. Burt’s and Gorman’s resignations in March 2019, all unvested equity and any unpaid balance of restricted cash awards were forfeited.

Outstanding Equity Awards as of December 31, 2018

The following table sets forth information regarding outstanding equity awards held by the Named Executive Officers under the 2007 Stock Plan, the 2011 Stock Plan and the 2015 Stock Plan as of December 31, 2018 and, for Mr. Martindale, equity awards granted in September 2017 as make-whole and inducement awards in connection with pending discussionsthe commencement of his employment which were not issued under any stockholder approved plan.

 
Option Awards(1)
Stock Awards
Name
Date of
Grant
Exercisable
Unexercisable
Option
Exercise
Price($)
Option
Expiration
Date
Number
of
Restricted
Shares
and RSUs
That Have
Not Yet
Vested
(#)(2)
Market
Value of
Restricted
Shares
and RSUs
That Have
Not Yet
Vested
($)(3)
Equity
Incentive
Plan
Awards:
Number of
Unearned
PSUs
(#)(4)
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
PSUs
($)(3)
Kenneth A. Martindale
9/11/2017
 
173,042
 
 
346,084
 
 
8.95
 
 
9/11/2027
 
 
187,876
 
 
445,266
 
 
 
 
 
 
 
 
2/21/2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
261,161
 
 
618,950
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tricia K. Tolivar
2/16/2016
 
24,875
 
 
24,876
 
 
27.30
 
 
2/16/2026
 
 
3,663
 
 
8,681
 
 
 
 
 
 
 
 
2/22/2017
 
25,000
 
 
75,000
 
 
7.99
 
 
2/22/2027
 
 
21,868
 
 
51,827
 
 
15,308
 
 
36,279
 
 
5/11/2017
 
 
 
 
 
 
 
 
 
 
 
 
 
150,000
 
 
355,500
 
 
 
 
 
 
 
 
2/21/2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44,643
 
 
105,804
 
 
2/21/2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14,881
 
 
35,268
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene E. Burt
2/22/2017
 
8,750
 
 
26,250
 
 
7.99
 
 
2/22/2027
 
 
7,294
 
 
17,287
 
 
5,106
 
 
12,101
 
 
2/21/2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44,643
 
 
105,804
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joseph C. Gorman
12/7/2015
 
6,001
 
 
2,001
 
 
30.91
 
 
12/7/2025
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2/22/2017
 
8,750
 
 
26,250
 
 
7.99
 
 
2/22/2027
 
 
6,384
 
 
15,130
 
 
4,469
 
 
10,591
 
 
2/21/2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44,643
 
 
105,804
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Steven Piano
2/21/2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14,881
 
 
35,268
 
(1)Time-vested stock option awards made under the 2015 Stock Plan vest in four equal annual installments commencing on the first anniversary of the date of grant, subject to continuing employment. Time-vested stock options granted to Mr. Martindale pursuant to his inducement awards vest in three equal installments commencing on the first anniversary of the date of grant, subject to continuing employment.
(2)Includes time-vested restricted stock and RSUs awarded under the 2015 Stock Plan, which generally vest in three equal annual installments commencing on the first anniversary of the date of grant, subject to continuing employment. Ms. Tolivar’s May 2017 award vests over four year from the grant date; 20% in May 2019, 30% in May 2020, and the remaining 50% in May 2021. Also includes RSAs awarded to Mr. Martindale as make-whole and inducement awards, not under any stockholder approved plan, a portion of which were fully vested on grant, a portion of which vested on the last trading day in 2017 and a portion of which vest in three equal annual installments commencing on the first anniversary of the date of grant.
(3)Market value is based on the closing price of our Common Stock of $2.37 per share on December 31, 2018.
(4)Represents the threshold number of the total PSUs granted in 2017 and 2018 under the 2015 Stock Plan. The PSUs granted in 2016, under the 2011 Stock Plan, were scheduled to vest on December 31, 2018 (threshold performance was not achieved and no portion of this award vested). The PSUs granted in 2017 are scheduled to vest on December 31, 2019 and the PSUs granted in 2018 are scheduled to vest on December 31, 2020, in each case subject to Company performance and the Named Executive Officer’s continued employment. The threshold award shown above represents 35% of the target award for the 2017 awards and 50% of the target award for the total 2018 awards; the actual number of PSUs that may be earned may range from 0% to 200% (for 2017 awards) and 0% to 150% (for 2018 awards) of the target number, as described under “Compensation Discussion and Analysis – Long-Term Incentive Compensation” above.

34

TABLE OF CONTENTS

2018 Option Exercises and Stock Vested Table

The following table sets forth information regarding a Chinese joint venture, the Company began consideringvesting of RSUs and restricted stock and exercise of options by the possibilityNamed Executive Officers during our fiscal year ended December 31, 2018.

 
Option Awards
Stock Awards
Name
Number of
Shares
Acquired on
Exercise (#)
Value
Realized
on Exercise ($)
Number of
Shares
Acquired
Upon
Vesting (#)(1)
Value
Realized
Upon
Vesting ($)(2)
Kenneth A. Martindale
 
 
 
 
 
93,939
 
 
272,423
 
Tricia K. Tolivar
 
 
 
 
 
17,168
 
 
71,823
 
Gene E. Burt
 
 
 
 
 
3,647
 
 
14,770
 
Joseph C. Gorman
 
 
 
 
 
3,866
 
 
14,720
 
Steven Piano
 
 
 
 
 
 
 
 
(1)For Mr. Martindale, reflects the gross number of shares acquired upon vesting of the first tranche of his September 2017 restricted stock awards. For Ms. Tolivar, reflects the gross number of shares acquired upon vesting of (i) the third tranche of her March 2015 restricted stock award and (ii) the second tranche of her February 2016 RSU award, and (iii) the first tranche of her February 2017 RSU award. For Mr. Burt, reflects the gross number of shares acquired upon vesting of the first tranche of his February 2017 RSU award. For Mr. Gorman, reflects the gross number of shares acquired upon the vesting of (i) the third tranche of his December 2015 RSU award and (ii) the first tranche of his February 2017 RSU award.
(2)Market value is based on the average of the high and low trading prices for our Common Stock on the NYSE on the date of vesting.

35

TABLE OF CONTENTS

2018 Non-Qualified Deferred Compensation Table

We maintain the GNC Live Well® Later Non-Qualified Deferred Compensation Plan for the benefit of a private placement equity investment in the Company by the potential Chinese joint venture partners. At the Board’s request, the Company and Goldman Sachs held discussions with the Investor and the other potential Chinese joint venture partners regarding an equity or other junior capital investment in the Company (the “Potential Equity Investment”).

In December 2017, the Board directed Goldman Sachsselect group of our highly compensated executives. Under this plan, certain eligible employees may elect to approach certain holders of its Convertible Senior Notes to explore the possibility of exchanging, in privately negotiated transactions,defer a portion of their holdingsfuture salary and bonus compensation up to a maximum of 80% of salary and 100% of bonus, or such other specified limit established by the Company, until a specified future year, or until retirement. We may in our discretion elect to make a matching contribution to the plan for a calendar year, based on amounts deferred by participants for that year. Participants may select the investment fund or funds in which such deferred amounts are deemed to be invested for the purpose of crediting deferrals with earnings, and investment gains and losses. The Company’s contributions to the Non-Qualified Deferred Compensation Plan become fully vested after three years from the start of the Convertible Senior Notesyear of deferral. Participants receive vested distributions on elected scheduled withdrawal dates or upon separation from service.

Mr. Martindale, and Mr. Gorman each elected to make contributions to the deferred compensation plan in 2018. The following table identifies, for Common Stock.each Named Executive Officer, his or her contributions, our contributions, the aggregate earnings and withdrawals in 2018 and the aggregate balance as of December 31, 2018:

Name
Executive
Contributions
in Last Fiscal
Year(1)
Registrant
Contributions
in Last Fiscal
Year (2)
Aggregate
Earnings in
Last Fiscal
Year (3)
Aggregate
Withdrawals/
Distributions
Aggregate
Balance at
Last Fiscal
Year End(4)
Kenneth Martindale
$
29,250
 
$
29,250
 
$
(6,574
)
$
0
 
$
69,012
 
Tricia Tolivar
$
0
 
$
0
 
$
(6,883
)
$
0
 
$
120,689
 
Gene E. Burt
$
0
 
$
0
 
$
366
 
$
0
 
$
25,749
 
Joseph C. Gorman
$
12,438
 
$
12,438
 
$
(46
)
$
0
 
$
42,830
 
Steve Piano
$
0
 
$
0
 
$
0
 
$
0
 
$
0
 
(1)Amounts reflected are included in the “Salary” column of the Summary Compensation Table above.
(2)Amounts reflected are included in the “All Other Compensation” column of the Summary Compensation Table above.
(3)Amounts reflected are not included as compensation for the relevant Named Executive Officers in the Summary Compensation Table above.
(4)For Mr. Martindale, Ms. Tolivar, and Mr. Burt, the amount reported includes $16,875, $44,688, and $25,322, respectively, previously earned, but deferred, salary and matching contributions reported in our Summary Compensation Table for 2017. Ms. Tolivar’s amount also includes $40,551 for 2016 and $26,154 for 2015.

Potential Payments Upon Termination or a Change in Control

The termination and change in control arrangements for the Named Executive Officers are generally governed by Company policy, other than Mr. Martindale whose terms are governed by his employment agreement with the Company. As a result ofsuch, these discussions, on December 20, 2017,arrangements generally are uniform and not highly negotiated. The Compensation Committee does not generally consider the Company executed exchange agreementsamounts payable in connection with certain holderstermination and change in control events when establishing compensation of the Convertible Senior NotesNamed Executive Officers. The Compensation Committee, together with the Board, established the termination and change of control arrangements described herein to exchange $98,935,000address the following considerations:

conforming to our overall compensation objectives in aggregate principal amountattracting and retaining the caliber of executives that are integral to our growth and maintaining market competitiveness;
maintaining management continuity, particularly through periods of uncertainty related to change in control events;
providing our key personnel with the assurance of equitable treatment following a change in control and other events; and
ensuring that our management is held to high standards of integrity and performance.

Such policies and arrangements are evidenced by the Company’s Executive Severance Policy, as described in the Compensation Discussion and Analysis section of this proxy statement. Under the Executive Severance Policy, a “Change in Control” occurs when: (i) any person or entity becomes the beneficial owner of securities representing thirty percent (30%) or more of the Convertible Senior Notes for an aggregate of 14,626,473 newly issued shares of Common Stock, together with approximately $0.5 million in cash.

At the Board’s request in January 2018, the Company and Goldman Sachs contacted certain lenders holding, in the aggregate, a significant portioncombined voting power of the Company’s then outstanding principal amount ofsecurities; (ii) the term loans under the Existing Credit Agreement (the “Ad Hoc Group”) to discuss a potential amendment of the Existing Credit Agreement to, among other things, (i) extend the maturity date, in whole or in part, of the outstanding term loan indebtedness thereunder and (ii) permit the entering into and incurrence of indebtedness under a new asset-based term loan facility and a new asset-based revolving credit facility (collectively, the “Potential Credit Agreement Refinancing”). The Company subsequently entered into confidentiality agreements with each of the members of the Ad Hoc Group, which provided for the right of either party to publicly disclose communications between the Company and the Ad Hoc Group related to the Potential Credit Agreement Refinancing if no agreement was reached with respect to the Potential Credit Agreement Refinancing prior to February 12, 2018.

By late January 2018, the Company had received three indications of interest from potential Chinese partners, including the Investor, and seven indications of interest from potential US domestic investors, regarding Potential Equity Investments in the Company. The indications of interest from each potential Chinese partner were conditioned upon the concurrent negotiation of a Chinese joint venture with such Chinese partner. The indication of interest from the Investor contemplated an investment in convertible preferred stock with a conversion price at a premium to current trading values and that would result in the Investor holding a majority of the outstanding voting power following the proposed investment. The indicationsBoard is no longer made up of interest from the other potential Chinese partners contemplated an investment in Common Stock priced at current trading values. The indications of interest from the potential US domestic investors contemplated second lien “mezzanine” debt accompanied with warrants, convertible debt, and preferred convertible-debt, at interest rates significantly above the dividend yield proposed by the Investor.

On January 23, 2018, the Company and its advisors provided a Potential Equity Investment term sheet for a Common Stock investment, at a premium to current trading values, to the three potential Chinese partners, including the Investor and the two additional Chinese parties (respectively, “Party A” and “Party B”), together with term sheets for potential Chinese joint ventures with such parties.

On January 25, 2018, after reviewing initial proposals for the Potential Equity Investment from the potential Chinese and US investors and initial feedback on the Company’s term sheets from the potential Chinese investors, the Board, after consulting with management, Goldman Sachs and Latham, decided to focus on the potential Chinese investors, given the relative attractiveness of those potential transactions compared to the

indications of interest from potential US investors. The Board authorized management and the advisors to continue to exchange term sheets for a Potential Equity Investment and a potential Chinese joint venture with either Investor, Party A or Party B. The Board explored these Potential Equity Investments, working to develop one or more definitive transaction proposals prior to the beginning of the Chinese New Year holiday during the week of February 12, 2018, to facilitate the negotiations around the Potential Credit Agreement Refinancing and to avoid possible delays in a transaction with the Chinese parties during the holiday season. This timeline also aligned with the February 12, 2018 deadline by which the members of the Ad Hoc Group could require the Company to disclose all materialnon-public information regarding discussions of the Potential Credit Agreement Refinancing.

Also on January 25, 2018, the Board formed a transaction committee of independentcontinuing directors to oversee the day to day negotiations of the Potential Equity Investment and Potential Credit Agreement Refinancing. The Board also directed management to engage Valuation Research Corporation (“VRC”) as an independent financial advisor to review and analyze the price to be paid for any Common Stock and the conversion price of any convertible preferred stock proposed to be issued by the Company in connection with the Potential Equity Investment and to deliver a written opinion to the Board as to the fairness, from a financial point of view, of the price to be paid for any Common Stock and the conversion price of any convertible preferred stock issued in connection with the Potential Equity Investment.

The Investor and Party B submitted revised drafts of the proposed Potential Equity Investment term sheet on or about January 29, 2018 and February 2, 2018, respectively. The Investor proposed to purchase convertible perpetual preferred stockdescribed in the Company with a conversion priceExecutive Severance Policy;

36

TABLE OF CONTENTS

(iii) the consummation of $4.60 and a dividend yield of 8.0%, whereas Party B proposed to purchase Common Stock at a price based on the30-day volume weighted average price of Common Stock as of the day immediately preceding the Company’s announcement of completion of the Potential Credit Agreement Refinancing. Both parties requested majority ownership in an exclusive Chinese joint venture with the Company as a condition to the Potential Equity Investment and continued to negotiate a separate term sheet with the Company for such a joint venture. Although the Company and its advisors continued to engage in discussions with Party A, Party A did not submit an updated proposal and indicated it would need additional time to move forward with the Potential Equity Investment. At the direction of the Board, the Company continued to negotiate with the Investor and Party B, exchanging revised term sheets for the Potential Equity Investment and China joint venture with each party. With respect to the Investor, the Company proposed to issue convertible perpetual preferred stock in the Company with a conversion price of $6.00 and a dividend yield of 5.0%.

On February 4, 2018, to afford the Company the opportunity to meet the timeline contemplated by the Board, the Company and its advisors furnished draft definitive documentation for the Potential Equity Investment to the Investor and Party B, based on the latest Potential Equity Investment term sheets with the respective parties. Party B continued to express an interest in a transaction with the Company, but did not provide further counterproposals to the terms and definitive documents offered by the Company. The Investor engaged with the Company, Goldman Sachs and Latham to negotiate the definitive terms and documents of the Potential Equity Investment. Between February 4, 2018 and February 11, 2018, the Company, the Investor and their respective financial and legal advisors engaged in extensive negotiations regarding the Potential Equity Investment and exchanged numerous drafts of the Securities Purchase Agreement, the Stockholders Agreement, the Registration Rights Agreement, the Certificate of Designations and the other related transaction documents, including the key terms of the Joint Venture, which would be a condition to completion of the Potential Equity Investment. During this time, Goldman Sachs continued to engage in discussions with Party B around a potential transaction, but Party B did not submit a formal counterproposal to the terms and definitive documents offered by the Company. The Company, Goldman Sachs and Latham also engaged in extensive negotiations with the Ad Hoc Group regarding the Potential Credit Agreement Refinancing.

On February 10, 2018, the Board met with management, and representatives of Goldman Sachs and Latham. The Board received an update on the status of the discussions regarding the Potential Equity Investment and the

Potential Credit Agreement Refinancing and determined to meet again on February 11,2018 for an additional update and to determine the path forward for each transaction.

On February 11, 2018, the Board reconvened with management and its advisors to discuss the then-current terms of (i) the Securities Purchase Agreement and the other related transaction documents and (ii) the Potential Credit Agreement Refinancing. Goldman Sachs and Latham discussed the financial and legal terms, respectively, of the agreements and the proposals for each key term that had been exchanged between the Company and the Investor. After evaluation and discussion of factors raised by management and the financial and legal advisors, as well as other factors related thereto, the Board instructed management and the advisors to continue to negotiate the few remaining open items and seek to finalize the necessary documents. On February 12, 2018, after further negotiations with the Investor to finalize the remaining open points in the Potential Equity Investment, the Board met with management and representatives of Goldman Sachs, Latham and VRC in order for the Board to consider formally approving the Securities Purchase Agreement and the other related transaction documents for the Potential Equity Investment. Goldman Sachs and Latham provided the Board with an update on the final terms of the transaction and VRC delivered its written opinion to the Board to the effect that, subject to the assumptions, limitations, qualifications and conditions set forth therein, the Conversion Price of the Convertible Preferred Stock was fair, from a financial point of view, to the Company. After a discussion of the Securities Purchase Agreement, the transactions contemplated thereby and factors raised by management and the advisors, the Board: (i) unanimously approved the Share Issuance and the other transactions with the Investor; (ii) determined that the terms of the Securities Purchase Agreement and the other transaction documents and the transactions contemplated thereby, including the Share Issuance, were advisable, substantively and procedurally fair to, and in the best interests of, the Company and its stockholders; (iii) directed that the Share Issuance be submitted to the stockholders of the Company for approval; and (iv) recommended approval of the Share Issuance by the Company’s stockholders. On February 13, 2018, the Company and the Investor executed the Securities Purchase Agreement and announced that the Ad Hoc Group had indicated its support with respect to the Potential Credit Agreement Refinancing, subject to definitive documentation on terms and conditions consistent in all material respects with the two term sheets related thereto filed by the Company with the SEC as Exhibit 99.2 to its Current Report on Form8-K on February 13, 2018.

Thereafter, Goldman Sachs and Latham continued to negotiate with the Ad Hoc Group and other lenders to move the Potential Credit Agreement Refinancing towards execution of the definitive documentation. On February 28, 2018, the Company entered into definitive agreements with respect to the Potential Credit Agreement Refinancing, which extended the maturity date of the term loans held by approximately 87% of the term lenders to March 2021, entered into a new $100 million ABL revolving credit facility, exchanged a portion of the extended term loans for ABL FILO term loans and entered into new ABL FILO term loans in an aggregate principal amount, when taken together with the extended term loans exchanged for ABL FILO term loans, of $275 million. The Company and the Investor agree that such definitive documentation satisfies the closing condition in the Securities Purchase Agreement related to the Credit Agreement Refinancing. Additional information regarding these financing-related transactions can be found in the section entitled “—The Credit Agreement Refinancing” above.

Opinion of the Financial Advisor to the Company

At the request of the Board, VRC rendered its written opinion to the Board that, as of February 12, 2018, and based upon and subject to the factors, qualifications and assumptions set forth therein, the Conversion Price of the Convertible Preferred Stock to be issued and sold by the Company in the Transaction (defined below) was fair from a financial point of view to the Company.

The full text of the written opinion of VRC, dated February 12, 2018, which sets forth assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken in connection with the opinion, is attached as Annex I to this proxy statement. VRC provided its opinion for the information and assistance of the Board in connection with the Board’s consideration of the transactions contemplated by the issuance and sale of the Convertible Preferred Stock (the “Transaction”). The VRC

opinion is not a recommendation as to the issuancecertain mergers or sale of the Convertible Preferred Stock or any other matter.

In connection with rendering the opinion described above and performing its related financial analyses, VRC reviewed, among other things:

the form of the Securities Purchase Agreement, together with the forms of other documents related to the Transaction and referred to therein;

annual reports to stockholders and Annual Reports on Form10-K of the Company for the five fiscal years in between and including those ended December 31, 2011 and December 31, 2016, respectively;

certain interim reports to stockholders and Quarterly Reports on Form10-Qconsolidations of the Company; or (iv) stockholder approval of certain other communications fromplans of complete liquidation or dissolution or the Company to its stockholders;

certain publicly available research analyst reportsconsummation of agreements for the Company;

certain internal financial analyses and forecasts for the Company for the four full years ended 2021, prepared by the Company’s management and approved for VRC’s use by the Company and the Board in connection with the Transaction (collectively, the “Forecasts”);

the reported price and trading activity for the Common Stock; and

the financial termssale or disposition of certain recent business combinations in the same industry as the Company and in other industries.

VRC also held discussions with members of the senior management of the Company regarding senior management’s assessment of the past and current business operations, financial condition and future prospects of the Company and the strategic rationale for, and the potential benefits to the Company of, the Transaction. VRC also compared certain financial and stock market information for the Company with similar information for certain other companies the securities of which are publicly traded, including a review of the current and historical market prices and trading volume for the Company’s publicly traded securities, and the historical market prices and certain financial data of publicly traded securities of certain other companies that VRC deemed to be relevant. Finally, VRC performed such other financial studies, inquiries and analyses, and considered such other factors and information, as VRC deemed appropriate.

For purposes of rendering the written opinion described above, VRC, with the Company’s consent, relied upon and assumed the accuracy and completeness ofall or substantially all of the financial, legal, regulatory, tax, accounting and other information provided to, or discussed with or reviewed by, VRC, without assuming any responsibility for independent verification or update thereof. In that regard, VRC assumed that the Forecasts were reasonably prepared in good faith and were based upon assumptions that were reasonable and reflected the best then currently available estimates and judgments of the Company’s management as to the matters covered thereby, and that the Company approved the Forecasts for VRC’s use in connection with VRC’s opinion.

Further, with the Company’s consent, VRC assumed without independent verification that (i) all procedures required by law to be taken in connection with the Transaction had been, or would be, duly, validly and timely taken and that the Transaction would be consummated in a manner that complied with all applicable laws and regulations and that conformed in all material respects to the description thereof set forth in its written opinion; (ii) the Transaction would be consummated in a timely manner in accordance with the terms and conditions set forth in the forms of the related definitive agreements and other documents provided to VRC; and (iii) each of the Board and the Company was in compliance in all material respects (and would remain in compliance in all material respects) with any and all applicable laws, rules or regulations of any and all relevant legal or regulatory authorities.

VRC’s opinion did not address the underlying business decision of the Company to issue the Convertible Preferred Stock or the purchase price thereof; nor did the VRC opinion address any legal, regulatory, tax or accounting matters. VRC’s opinion addressed only the fairness from a financial point of view to the Company, as of February 12, 2018, of the Conversion Price. VRC’s opinion did not express any view on, and did not address,

(i) any other term or aspect of the Transaction, (ii) any term or aspect of any other agreement or instrument contemplated by the Transaction, or entered into, or amended in connection with, the Transaction, or (iii) the impact of the Transaction on the holders of any class of securities of the Company, any creditors of the Company, or any other constituency of the Company.

VRC’s opinion was necessarily based on economic, monetary, market and other conditions as in effect on, and the information made available to VRC as of, the date of the opinion (and in each case to the extent that such information could be evaluated by VRC as of such date), and VRC assumed no responsibility for updating, revising or reaffirming its opinion based on circumstances, developments or events occurring after the date of its opinion. In addition, VRC did not express any opinion as to the impact of the Transaction and the conversion of the Convertible Preferred Stock to Common Stock on the solvency or viability of the Company or the ability of the Company to pay its obligations when and as they come due. VRC’s opinion was approved by a fairness opinion committee of VRC.

VRC did not make any independent evaluation of the Company’s (or any other party’s) solvency or creditworthiness nor did it make any physical inspection or independent appraisal or evaluation of any of the assets, properties or liabilities (contingent or otherwise) of the Company or any other party. VRC’s fairness opinion did not express any opinion regarding the liquidation value of any entity or business. In addition, VRC did not undertake any independent analysis of any potential or actual litigation, regulatory action, possible unasserted claims or other contingent liabilities to which the Company is or may be a party or of which it may be the subject, or of any governmental investigation of any possible unasserted claims or other contingent liabilities to which the Company is or may be a party or otherwise may be subject.

VRC’s opinion was not intended to constitute a recommendation to the Board, the Company or any other party as to how they should vote or otherwise act with respect to any matters relating to the Transaction. The opinion does not represent an assurance, warranty, or guarantee that the Conversion Price is the highest or best amount that can be obtained in connection with the Transaction or any other transaction.

In rendering its opinion, VRC did not initiate any discussions with, or solicit any indications of interest from, any third parties with respect to the Company or the Transaction. VRC’s opinion was rendered only as of the date thereof and addressed only the Transaction, and did not speak to or address any period thereafter or any subsequent business transaction, acquisition, dividend, share repurchase, debt or equity financing, recapitalization, restructuring or other actions, transactions or events not specifically referred to in the opinion. Furthermore, VRC’s opinion did not represent an assurance, guarantee, or warranty that the Company will not breach, or default on or under, any of its debt covenants or other obligations or liabilities, nor did VRC make any assurance, guarantee, or warranty that any covenants, financial or otherwise, associated with any financing or existing indebtedness would not be breached in the future.assets.

The following is a summary of the material financial analyses delivered by VRCtermination and change of control provisions in the employment agreements for Mr. Martindale and the policies and arrangements otherwise applicable to the Board in connection with renderingNamed Executive Officers as of December 31, 2018.

Mr. Martindale

Mr. Martindale’s employment agreement provides for certain benefits upon termination of employment. Upon Mr. Martindale’s death or disability, he (or his estate) is entitled to:

any unpaid salary, accrued but unpaid vacation, accrued and vested welfare and retirement benefits and all reimbursable business expenses through the opinion described above. The following summary, however, does not purportdate of termination (“accrued obligations”),
any unpaid annual bonus for the year prior to be the year of termination, and
a complete descriptionprorated annual bonus for the year of termination, based on the actual period of employment and actual level of achievement of the financial analyses performed by VRC, nor doesperformance objectives for the orderyear of analyses described representtermination.

Also, in such cases, Mr. Martindale’s time-vesting equity awards would immediately vest; and any performance-vesting awards would become vested at a prorated actual amount, based on the relative importance or weight given to those analyses by VRC. Someactual period of employment and assuming “target’ level of achievement of the summariesperformance objectives.

Upon termination of employment by us without cause, including a non-renewal of the financial analyses include information presentedemployment term, or voluntarily by Mr. Martindale for good reason, subject to the execution of a written release, he is also entitled to:

two times the sum of:
base salary; and
either (i) the average of the actual annual bonus paid in the two years immediately preceding the date of termination (or, for any of the first two years where an annual bonus had not yet been determined the target bonus) where termination occurs prior to or more than 24 months following a change in control (as defined in the employment agreement), or (ii) target bonus (if termination occurs on or within 24 months following a change in control), which amounts are payable in installments over a 24-month period or in a lump sum cash payment, depending on whether the termination occurred under the timeframe provided in (i) or (ii) above;
any unpaid annual bonus for the year prior to the year of termination, and a prorated annual bonus for the year of termination, based on the actual period of employment and actual level of achievement of the performance objectives for the year of termination; and
reimbursement for any portion of the monthly cost of COBRA coverage that exceeds the amount of monthly health insurance premium (with respect to Mr. Martindale’s coverage and any eligible dependent coverage) payable by Mr. Martindale immediately prior to such termination, such reimbursements to continue for up to 18 months.

Also, in tabular format. The tables must be read together withsuch cases, Mr. Martindale’s “sign-on” equity awards would immediately vest (to the full text of each summary and are alone not a complete description of VRC’s financial analyses. Except as otherwise noted, the following quantitative information,extent any remained unvested); any time-vesting equity awards (other than sign-on awards) to the extent that it is based on market data, is based on market data as it existed on or before February 12, 2018,that would have become vested within 24 months following the date of termination shall immediately vest (with respect to said amount); and is not necessarily indicative of current market conditions.

VRC reviewed Wall Street analyst research and analyst targeted prices for the Common Stock. The analysts’ target prices for the Common Stock ranged from $2.50 per share to $7.00 per share.

VRC analyzed the Conversion Price in relation to the closing price of the Common Stock as of the undisturbed date (February 12, 2018). This analysis indicated that the Conversion Price representedany performance-vesting awards shall become vested at a premium of 27.7%prorated actual amount, based on the Common Stock priceactual period of $4.19 as of market close on February 12, 2018.

VRC alsoemployment and calculated the Company’s enterprise value using three separate methodologies: (i) the Company’s market stock price as of February 12, 2018, plus the face value of outstanding debt, minus cash on hand, (ii) the Company’s market stock price as of February 12, 2018, plus the market value of outstanding debt, and (iii) the Company’s equity assuming all primary shares had a price equivalent to the Conversion Price, plus the book value of outstanding debt, which resulted in implied enterprise values of $1,584.5 million, $1,398.7 million, and $1,755.4 million, respectively.

Illustrative Discounted Cash Flow Analysis

VRC performed an illustrative discounted cash flow analysis of the Company based on forecasted estimates of unlevered free cash flows of the Company to derive an illustrative range of implied enterprise values and present values per share for the Company. VRC noted that the illustrative discounted cash flow analysis assumed the Company continued as a going concern and did not consider the risk of breach or default on or under any of the Company’s debt covenants or other obligations or liabilities. VRC performed the illustrative discounted cash flow analysis using discount rates ranging from 12.0% to 13.0%, reflecting estimates of the Company’s weighted average cost of capital. VRC discounted to present value, as of February 12, 2018, (i) estimates of unlevered free cash flow for the Company from February 12, 2018 through December 31, 2018, and then annually through December 31, 2021 as reflected in the Forecasts and (ii) a range of illustrative terminal values for the Company, which were calculated by applying perpetuity growth rates ranging from 1.5% to 2.5%, to a terminal year estimate of the free cash flow to be generated by the Company, as reflected in the Forecasts. VRC derived such discount rates by application of the capital asset pricing model, which requires certain company-specific inputs, including the industry’s target capital structure weightings, cost of debt, future applicable marginal tax rate and a beta for the company, as well as certain financial metrics for the United States financial markets generally. VRC estimated the range of perpetuity growth rates utilizing its professional judgment and experience, taking into account the Forecasts and market expectations regarding long-term real growth of gross domestic product and inflation. VRC’s derived ranges of illustrative enterprise values for the Company by adding the ranges of present values it derived as described above. The derived illustrative enterprise values ranged from $1,843.0 million to $2,143.1 million. VRC then subtracted from the range of illustrative enterprise values it derived for the Company the net debt of the Company as of February 12, 2018, to derive a range of illustrative equity values for the Company. VRC then divided each illustrative equity value it derived by the number of primary outstanding shares of the Company, as provided by the management of the Company, to derive a range of illustrative present values per share of Common Stock ranging from $7.28 to $10.87.

Selected Companies Analysis

VRC reviewed and compared certain financial information for the Company to corresponding financial information, ratios and public market multiples for the following publicly traded corporations in the specialty retail industry (collectively referred to as the selected companies):

Bed Bath & Beyond Inc.

Dick’s Sporting Goods, Inc.

The Michaels Companies, Inc.

Party City Holdco Inc.

Sally Beauty Holdings, Inc.

Vitamin Shoppe, Inc.

William-Sonoma, Inc.

Although none of the selected companies is directly comparable to the Company, VRC chose the aforementioned companies because they are publicly traded companies with business operations that, for purposes of analysis, may be considered similar to the Company’s in market size or in certain results of operations of the Company.

With respect to each of the selected companies, VRC calculated and compared various financial multiples and such company’s EV. As used herein, “EV” means the market capitalization of a company that VRC derived based on the closing priceactual level of achievement of the shares ofperformance objectives, such company’s common stock andthat payment would be received following the number of shares of common stock outstanding on a fully diluted basis, plus the book value of debt, less the book value of liquid cash and cash equivalents, as a multiple of estimated EBITDA for the last twelve months (“LTM”) and calendar years 2018 and 2019, as provided by Capital IQ. As used herein, “EBITDA” means, with respect to a company, earnings before interest, taxes, depreciation and amortization (as adjusted for certainnon-recurring charges). Unless otherwise noted, all EV calculations were determined based on publicly available information as of February 12, 2018.

       EV/EBITDA 
Company Name  BEV   LTM   2018E   2019E 

Bed Bath & Beyond Inc.

  $4,112.7    3.5x    3.9x    4.5x 

Dick’s Sporting Goods, Inc.

  $3,919.7    5.4x    5.2x    6.0x 

The Michaels Companies, Inc.

  $7,417.6    8.9x    8.6x    8.6x 

Party City Holdco Inc.

  $3,552.7    9.7x    8.4x    8.0x 

Sally Beauty Holdings, Inc.

  $4,155.6    6.8x    6.9x    7.0x 

Vitamin Shoppe, Inc.

  $225.7    2.9x    4.3x    4.0x 

Williams-Sonoma, Inc.

  $4,645.6    7.0x    7.0x    6.8x 

High

     9.7x    8.6x    8.6x 

Upper Quartile

     7.9x    7.7x    7.5x 

Mean

     6.3x    6.3x    6.4x 

Median

     6.8x    6.9x    6.8x 

Lower Quartile

     4.4x    4.8x    5.2x 

Low

     2.9x    3.9x    4.0x 

VRC then applied an illustrative range of 2018 estimated EBITDA multiples of 6.5x to 7.5x to the Company’s 2018 estimated EBITDA and an illustrative range of 2019 estimated EBITDA multiple of 6.0x to 7.0x to the Company’s 2019 estimated EBITDA to derive a range of implied enterprise values of $1,515.8 million to $1,855.6 million. VRC then subtracted from the range of illustrative enterprise values it derived for the Company the net debt of the Company as of February 12, 2018, to derive a range of illustrative equity values for the Company. VRC then divided the range of illustrative equity values it derived by the number of primary outstanding shares of the Company, as provided by the management of the Company, to derive a range of illustrative values per share of Common Stock ranging from $3.37 to $7.43.

Selected Transactions Analysis

VRC analyzed certain information relating to certain selected control transactions in the retail industry since 2012. For each of the selected transactions, VRC calculated and compared various financial multiples, financial ratios and other financial information. Although none of the operations of companies in the selected transactions are directly comparable to the Company, such transactions were chosen because the related companies have operations that, for purposes of analysis, may be considered similar to the Company’s operations in certain results of operations and product profiles. VRC noted that the selected transactions represent acquisitions of controlend of the relevant companies, whereasperformance period. The total amount payable may be subject to reduction to the Transaction is not a control transaction.

extent Mr. Martindale would be subject to an excise tax as an excess parachute amount.

For purposes of Mr. Martindale’s employment agreement, “cause” generally means his:

The applicable information for the selected transactions is summarized below.

material failure to comply with any material obligation imposed by his employment agreement;
DateAcquirerTargetEBITDA
10/18/2017Hin Sang Group Holding Co. Ltd.Fullshare Holdings Limited  7.7x
9/12/2017Sycamore PartnersStaples, Inc.  5.3x
8/28/2017Amazon.com, Inc.Whole Foods Market, Inc.10.3x
6/1/2017LetterOne RetailHolland and Barrett Retail Limited11.8x
5/18/20171111267 B.C. Ltd.Immunotec Inc.  4.1x
4/21/2016Apollo Global Management, LLCThe Fresh Market, Inc.  7.0x
2/18/20163K Limited PartnershipCalloway’s Nursery, Inc.  5.2x
2/5/2016Steinhoff InternationalMattress Firm Holding Corp.11.0x
2/5/2016Mattress Firm, Inc.Sleepy’s11.1x
1/31/2016CVC Capital Partners LimitedPETCO Animal Supplies, Inc.10.0x
12/18/2015The Kroger Co.Roundy’s, Inc.  7.0x
12/10/2015Sycamore PartnersBelk, Inc.  6.9x
12/2/2015BPS Direct, L.L.C.Cabela’s Incorporated10.6x
8/21/2015Ascena Retail Group, Inc.ANN INC.  9.2x
8/2/2015NABarnes & Noble, Inc.  6.5x
7/13/2015Bluestem Brands, Inc.Orchard Brands Corporation  5.8x
6/29/2015BootBarn Inc.Shelpers, Inc.  9.9x
3/11/2015BC PartnersPetSmart, Inc.  9.0x
10/20/2014Mattress Firm, Inc.The Sleep Train16.7x
5/29/2014

Signet Jewelers Limited

Zale Corporation

7.4x
4/1/2014

Ares Management

Guitar Center

9.2x
10/3/2013

Jarden Corp.

Yankee Candle Group LLC

8.9x
6/12/2013

Sycamore Partners

Hot Topic, Inc.

8.7x
3/28/2013

Leon’s Furniture Limited

The Brick Ltd.

7.4x
3/18/2013

Tempur-Pedic International Inc.

Sealy Corporation

7.6x
12/31/2012

Starbucks Corporation

Teavana

17.9x
11/27/2012

Berkshire Hathaway Inc.

OTC Direct, Inc.

7.1x
8/1/2012

Advent International

Serta/Simmons

10.0x
7/27/2012

Thomas H. Lee

Party City Holdings Inc.

10.2x
6/28/2012

Bed Bath & Beyond Inc.

Cost Plus, Inc.

12.7x
6/12/2012

Ascena Retail Group, Inc.

Charming Shoppes Inc.

10.2x
Min4.1x

Lower Quartile

7.1x
Median9.0x
Average9.1x

Upper Quartile

10.3x
Max17.9xbeing convicted (including a plea of nolo contendere) of a misdemeanor that causes substantial economic harm to us, or a felony;

VRC then applied an illustrative range

37

TABLE OF CONTENTS

intentional theft or embezzlement or fraud in connection with the performance of 2017 EBITDA multipleshis duties;
engaging in any activity that gives rise to a material conflict of 6.5xinterest with us;
intentional misappropriation of any of our material business opportunities;
willful or reckless material failure to 7.5xcomply with, observe or carry out our rules, regulations, policies or codes of ethics or conduct;
substance abuse or illegal use of drugs that impairs his performance or causes or is likely to cause substantial harm to us; or
intentional or reckless engagement in conduct that he knows or should know is materially injurious to us.

For purposes of Mr. Martindale’s employment agreement, “good reason” generally means, without Mr. Martindale’s prior written consent and unless we timely cure the Company’s 2017 EBITDAgood reason:

our material failure to derive implied enterprise valuescomply with material obligations under his employment agreement;
a reduction by us of $1,739.4 millionhis titles, positions, status or authority or a material reduction by us of his responsibilities and duties other than due to $2,007.0 million. VRC then subtracteda temporary period of incapacity;
our removal of him from the rangeposition of illustrative enterprise values it derivedChief Executive Officer, or failure to elect (or nominate) him to, or removal other than for the Company the net debt of the Company as of February 12, 2018, to derive a range of illustrative equity values for the Company. VRC then divided the range of illustrative equity values it derived by the number of primary outstanding shares of the Company, as provided by the management of the Company, to derive a range of illustrative values per share of Common Stock rangingcause, from $6.04 to $9.25.

General

The preparation of a fairness opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. Selecting portions of the analyses or of the summary set forth above, without considering the analyses as a whole, could create an incomplete view of the processes underlying VRC’s opinion. In arriving at its fairness determination, VRC considered the results of all of its analyses and did not attribute any particular weight to any factor or analysis considered by it. Rather, VRC made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of its analyses. No selected company or transaction used in the above analyses as a comparison is directly comparable to the Company or the Transaction, as the case may be.

VRC prepared these analyses for purposesGeneral Nutrition Centers, Inc. boards of delivering its opinion to the Board as to the fairness, as of February 12, 2018, from directors; or

a financial point of the Conversion Price. These analyses do not purport to be appraisals nor do they necessarily reflect the prices at which businessesmaterial reduction in his base salary or securities actually may be sold. Analyses based upon forecasts of future results are not necessarily indicative of actual future results, which may be significantly more or less favorable than suggested by these analyses. Because these analyses are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties or their respective advisors, none of the Company, the Investor or VRC or any other person assumes responsibility if future results are materially different from those forecast.

The Conversion Price was determined througharm’s-length negotiations between the Company and the Investor and was approved by the Board. VRC did not provide advice to the Company during these negotiations. Furthermore, VRC did not recommend any specific conversion price to the Company or the Board, nor did VRC recommend or represent that any specific conversion price constituted the only appropriate conversion price for the Convertible Preferred Stock in the transactions contemplated by the Transaction.

VRC’s opinion to the Board was one of many factors taken into consideration by the Board in making the determination to approve the Transaction. The foregoing summary does not purport to be a complete description of the analyses performed by VRC in connection with its fairness opinion and the foregoing summary is qualified in its entirety by reference to the written opinion of VRC attached as Annex I to this proxy statement.

VRC is actively engaged in performing valuation advisory services with respect to businesses and their securities in connection with mergers and acquisitions and other transactions for corporate and other purposes. Except for VRC’s engagement to deliver its fairness opinion in connection with the Transaction, VRC has not acted as financial advisor to the Company in connection with the Company’s consideration of the Transaction and has not participated in the negotiations leading to the Transaction.VRC will receive a fee in connection with the delivery of its opinion, and the Company has agreed to reimburse certain of VRC’s expenses and indemnify VRC against certain liabilities arising out of its engagement. No portion of VRC’s fee is contingent upon either the conclusion expressed in its opinion or whether the Transaction is successfully consummated. VRC may provide valuation advisory services to the Company in the future, in connection with which VRC may receive compensation. From time to time, VRC and its affiliates have in the past provided valuation services to the Company unrelated to the proposed Transaction, including valuation services for the Company for financial reporting purposes.

The Board selected VRC as the fairness opinion provider because VRC is a recognized financial advisory firm that has substantial experience with transactions similar to the Transaction. Pursuant to a letter agreement dated

target bonus.

February 12, 2018, the Board engaged VRC to provide a fairness opinion in connection with the contemplated Transaction. The engagement letter between the Company and VRC provides for the Company to pay VRC a fee of $380,000, to reimburse VRC for certain of its expenses, including attorneys’ fees and disbursements, and to indemnify VRC and related persons against various liabilities, including certain liabilities under the federal securities laws.

Regulatory Approvals Required

General

The Company and the Investor have agreed to use reasonable best efforts to comply with all regulatory notification requirements and obtain all regulatory approvals required to consummate the Share Issuance. These approvals include the completion of the process of review of the Share Issuance by the Committee on Foreign Investment in the United States (“CFIUS”) and the PRC Approvals (as described below). Although we expect that all required regulatory clearances and approvals will be obtained, we cannot assure you that these regulatory clearances and approvals will be timely obtained, obtained at all or that the granting of these regulatory clearances and approvals will not involve the imposition of additional conditions on the completion of the Share Issuance, including the requirement to divest assets or require changes to the terms of the Securities Purchase Agreement or the other transaction documents.

HSR Act and Other Competition Laws

The Company and the Investor have determined that no filings are required with respect to the Share Issuance under the HSR Act. Accordingly, the Company and the Investor have agreed that the condition to closing of the Share Issuance under the Securities Purchase Agreement related to the HSR Act is deemed to be satisfied. The Company and the Investor have similarly determined that no filings are required under the competition laws of any other jurisdiction.

CFIUS Clearance

In the Securities Purchase Agreement, the parties agreed to file a joint voluntary notice with CFIUS, pursuant to Section 721 of the Defense Production Act of 1950, as amended, 50 U.S.C. Section 4565 (“Section 721”), and the applicable CFIUS regulations thereunder. Section 721 provides for national security reviews and, where appropriate, national security investigations by CFIUS, of transactions in which a foreign person or entity could acquire control of a U.S. business. CFIUS review of a covered transaction takes place during a30-day review period that begins upon the CFIUS staff’s determination that the joint voluntary notice satisfies all applicable requirements and has been accepted for review. The30-day review period may be followed by an additional45-day investigation period. Both the review period and the investigation period may be suspended or restarted if the parties to the transaction fail to respond promptly to additional questions or requests received from CFIUS. With regard to covered transactions submitted to CFIUS, the CFIUS process may be resolved in a number of ways. At the conclusion of its work, CFIUS may, without requiring further action, issue a letter to the parties indicating that there are no unresolved national security issues, thereby “clearing” the transaction. In other cases, CFIUS may seek to negotiate for mitigation terms or conditions in order to resolve any national security concerns. In such cases, CFIUS will issue a letter to the parties indicating that there are no unresolved national security issues only upon agreement of the parties and CFIUS on such mitigation terms and conditions. If CFIUS concludes that a transaction presents national security concerns for which there are no adequate mitigation terms and conditions, or CFIUS and the parties cannot reach agreement on such mitigation, CFIUS may send a report to the President of the United States. That report can unanimously recommend that the transaction be suspended or prohibited or indicate that CFIUS cannot agree on a recommendation with respect to the disposition of the covered transaction. If the matter is referred to the President of the United States, he has fifteen days to decide whether to block the transaction or to take other action.

Under the terms of the Securities Purchase Agreement, completion of the Share Issuance is subject to the condition that one of the following shall have occurred:

The parties shall have received written notice from CFIUS that CFIUS has determined that the Share Issuance is not a “covered transaction” and not subject to review under Section 721;

The parties shall have received written notice from CFIUS that review and, if necessary, investigation under Section 721 with respect to the Share Issuance has been concluded and that there are no unresolved national security concerns with respect to the Share Issuance; or

CFIUS shall have sent a report to the President of the United States requesting the President’s decision with respect to the Share Issuance and either (i) the period under which the President may announce his decision to take action to suspend, prohibit or place any limitations on the transaction shall have expired without any such action being taken or (ii) the President shall have announced a decision not to take any action to suspend, prohibit or place any limitations on the transaction.

We refer to any to the foregoing actions that result in clearance of the Share Issuance by CFIUS as the “CFIUS Clearance”.

The Company and the Investor have agreed to use reasonable best efforts to obtain the CFIUS Clearance as promptly as practicable. Such efforts include, as required, entering into mitigation agreements necessary to obtain the CFIUS Clearance, so long as such agreements do not materially interfere with the Investor’s right to exercise its rights under the Securities Purchase Agreement and do not have an adverse material effect on the Investor, the Company or its subsidiaries. The Company and the Investor have further agreed that the Investor will not be required to sell Convertible Preferred Stock in order to obtain the CFIUS Clearance. The Company has agreed to take certain actions with respect to the Company’s stores on United States military facilities, and data the Company may have collected with respect to customers who have participated in any Company “loyalty program”, in each case as may be required by CFIUS in order to receive the CFIUS Clearance (the “Required Actions”). Except as may be required by the Required Actions, the Company will not be required to sell or divest any material assets as a condition to receiving the CFIUS Clearance.

In the event the CFIUS Clearance is not obtained and the agreement is terminated by the Investor or the Company, in certain circumstances the Investor will be required to pay the investor termination fee, as described below in the section entitled “Description of the Transaction Documents – Termination Fee; Effect of Termination”.

PRC Approvals

The Share Issuance cannot be completed until the Investor makes the following filings and receives the related regulatory approvals with governmental authorities in the People’s Republic of China (“PRC”):

approval of the State-owned Assets Supervision and Administration Commission of the State Council of the PRC or its competent local counterparts;

filing with and/or confirmation from the National Development and Reform Commission of the PRC or its competent local counterparts with respect to the consummation of the transactions contemplated by the Securities Purchase Agreement;

the filing with and/or the issuance of the certificate of outbound investment by enterprises by the Ministry of Commerce of the PRC or its competent local counterparts with respect to the consummation of the transactions contemplated by the Securities Purchase Agreement; and

the foreign exchange registration conducted by authorized banks under the supervision of the State Administration of Foreign Exchange of the PRC or its competent local counterparts in connection with the transactions contemplated by the Securities Purchase Agreement.

We refer to the foregoing collectively as the “PRC Approvals.”

The Investor has agreed to make all appropriate filings required in connection with the PRC Approvals as promptly as practicable within the applicable period required by applicable law, and supply as promptly as practicable any additional information and documentary material that may be requested pursuant to applicable law in connection with the PRC Approvals. To the extent permitted by applicable law, the Investor has also agreed to inform the Company of any communication with any governmental entity regarding the PRC Approvals and share with the Company any related documents, analyses, presentations, opinions and proposals.

The Company has agreed to reasonably cooperate with the Investor to provide the information and documents required for obtaining the PRC Approvals and to assist the Investor in promptly responding to any requests for information or documents.

In the event the PRC Approvals are not obtained and the agreement is terminated by the Investor or the Company, in certain circumstances the Investor will be required to pay the investor termination fee, as described below in the section entitled “Description of the Transaction Documents – Termination Fee; Effect of Termination”.

Investor’s Assignment

The Investor has agreed to assign its rights and obligations under the Securities Purchase Agreement to its subsidiary, Harbin Pharmaceutical Group Co., Ltd (SHA: 600664), which is publicly traded on the Shanghai Stock Exchange, prior to the closing of the Share Issuance. The Investor has agreed to take all appropriate action to cause Harbin Pharmaceutical Group Co., Ltd (SHA: 600664) to accept and assume the Securities Purchase Agreement, subject to any regulatory approvals and stockholder approvals that may be required. The parties have agreed that such assignment will not impede or delay the closing of the Share Issuance.

DESCRIPTION OF THE TRANSACTION DOCUMENTS

While we believe that the summary below of the agreements entered into in connection with the Share Issuance describes the material terms of such agreements, it may not contain all of the information that is important to you, and is qualified in its entirety by the relevant instruments and agreements themselves, which were included as an exhibit to our Current Report on Form8-K filed with the SEC on February 13, 2018, and are incorporated by reference herein. We encourage you to read the relevant instruments and agreements themselves in their entirety. Further, representations, warranties and covenants in the Securities Purchase Agreement are not intended to function or to be relied on as public disclosures. For more information about accessing the information that we file with the SEC, please see the section entitled “Where You Can Find More Information” below.

Securities Purchase Agreement

The Securities Purchase Agreement provides that, subject to the terms and conditions set forth in the Securities Purchase Agreement, the Company will issue and sell to the Investor, and the Investor will purchase and acquire from the Company, 299,950 shares of Convertible Preferred Stock at a purchase price of $1,000.00 per share, for an aggregate purchase price of $299,950,000 (the “Purchase Price”). The Convertible Preferred Stock will be convertible into shares of Common Stock of the Company at an initial conversion price of $5.35 per share, subject to customary antidilution adjustments (such Common Stock following conversion, the “Underlying Shares”). The terms of the Convertible Preferred Stock will be set forth in the Certificate of Designations to be filed by the Company with the Secretary of State of the State of Delaware prior to the Closing (as defined below) of the transaction and described elsewhere in greater detail in the section entitled “Description of the Convertible Preferred Stock” below.

Completion of the Securities Purchase Agreement

The closing of the issuance, purchase and sale of the Convertible Preferred Stock will take place at 10:00 a.m., New York City time, on the third business day after the satisfaction or waiver of all conditions to the completion of the issuance, purchase and sale of the Convertible Preferred Stock (other than those conditions that can only be satisfied at such closing, but subject to the fulfillment or waiver of such conditions at such closing), at the offices of Latham & Watkins LLP, 885 Third Avenue, New York, NY 10022, or at such other place, time or date as may be mutually agreed upon in writing by the Company and the Investor (the “Closing”).

Representations and Warranties

The Securities Purchase Agreement contains customary representations and warranties made by the Company to the Investor and customary representations and warranties made by the Investor to the Company.

The Company’s representations and warranties under the Securities Purchase Agreement relate to, among other things:

the due organization, valid existence, good standing and corporate power of the Company and each of its subsidiaries;

the capitalization of the Company, including the number of shares of Common Stock and preferred stock, options and other equity interests outstanding and the ownership of the capital stock of its subsidiaries;

the absence of restrictions or encumbrances with respect to the capital stock of the Company and its subsidiaries;

the authority of the Company to enter into the Securities Purchase Agreement and complete the issuance and sale of the Convertible Preferred Stock and the other transactions contemplated by the Securities Purchase Agreement and the enforceability of the Securities Purchase Agreement against the Company;

the absence of any voting requirement in connection with the issuance, purchase and sale of the Convertible Preferred Stock, other than the vote of the stockholders of the Company to be taken at the Special Meeting on the Share Issuance proposal;

the absence of (1) any conflict with or violation of the organizational documents of the Company, (2) any conflict with or violation of the organization documents of any Company subsidiary, (3) any conflict with or violation of applicable laws, or (4) any required consents or approval, breach, loss of benefit, change of control or default under any contract of the Company or its subsidiaries, in each case, as a result of the execution and delivery by the Company of the Securities Purchase Agreement and the completion by the Company of the issuance, purchase and sale of the Convertible Preferred Stock;

the consents, filings and approvals required by governmental entities in connection with the transactions contemplated by the Securities Purchase Agreement;

the absence of a general solicitation or general advertising with respect to offers or sales of the Convertible Preferred Stock or the Underlying Shares, and the exemption of the Convertible Preferred Stock and the Underlying Shares from registration and prospectus delivery requirements of the Securities Act;

the authority of the Company to issue and sell the Convertible Preferred Stock and the Underlying Shares free and clear of all liens and transfer restrictions (other than restrictions under applicable securities laws or the transactions contemplated by the Securities Purchase Agreement) and preemptive or other similar rights;

compliance with SEC filing requirements for the Company’s SEC filings since January 1, 2016, including the accuracy of information contained in such documents and compliance with U.S. GAAP and the rules and regulations of the SEC with respect to the consolidated financial statements contained therein;

the absence of certain undisclosed liabilities;

adequacy of disclosure controls and internal controls over financial reporting;

the absence of certain changes and events since September 30, 2017;

the absence of action by the Company to terminate the registration of the Common Stock under the Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”);

the accuracy of information contained in this proxy statement, as it may be amended or supplemented from time to time;

litigation matters;

compliance with applicable laws and governmental orders;

required franchises, grants, licenses, permits and other similar governmental approvals necessary for the conduct of the Company’s business;

employee benefit plans;

labor and other employment matters;

environmental matters;

ownership of real property free and clear of all liens, valid and binding leasehold interests in real property and ownership or leasehold interests in certain tangible personal property;

tax matters;

material contracts and the absence of breach or default thereunder;

intellectual property and privacy law matters;

brokers’ and financial advisors’ fees related to the issuance and sale of the Convertible Preferred Stock;

receipt by the Board of an opinion of VRC as to the fairness, from a financial point of view, of the Conversion Price for the Convertible Preferred Stock;

neither the Company nor any of its subsidiaries being an investment company within the meaning of the Investment Company Act of 1940;

the absence of restrictions under any anti-takeover statute or regulation;

insurance policies and claims;

compliance with the Foreign Corrupt Practices Act of 1977, which we refer to as the “FCPA” in this proxy statement, or other applicable domestic or foreign anti-bribery or anti-corruption laws during the past three years;

compliance with applicable import and export control laws, including economic sanctions laws administered by the Office of Foreign Assets Control;

the absence of contracts involving the Company or its subsidiaries or any other person of the type required to be disclosed pursuant to Item 404 of RegulationS-K prescribed under the Securities Act; and

the absence of any additional representations and warranties except for the representations and warranties expressly set forth in the Securities Purchase Agreement.

The Investor’s representations and warranties under the Securities Purchase Agreement, relate to, among other things:

the Investor’s due organization, valid existence, good standing and corporate power;

the authority of the Investor to enter into the Securities Purchase Agreement and complete the purchase of the Convertible Preferred Stock and the other transactions contemplated by the Securities Purchase Agreement and the enforceability of the Securities Purchase Agreement against the Investor;

the absence of (1) any conflict with or violation of the organizational documents of the Investor, (2) any conflict with or violation of applicable laws or (3) any required consent or approval, breach, loss of benefit or default under any contract of the Investor, in each case, as a result of the execution and delivery by the Investor of the Securities Purchase Agreement and completion by the Investor of the issuance, purchase and sale of the Convertible Preferred Stock;

the consents, filings and approvals required by governmental entities in connection with the transactions contemplated by the Securities Purchase Agreement;

litigation matters;

the sufficiency of the funds that the Investor has, or will have access to, to fund the Purchase Price;

the accuracy of information supplied to the Company in writing by the Investor for use in this proxy statement, as it may be amended or supplemented from time to time;

the absence of beneficial ownership of the Company’s Common Stock;

the absence of any agreement or understanding with any person that is not an affiliate of the Investor, and is not a member of a “group” pursuant to Section 13(d)(3) of the Exchange Act, with respect to the Company or its equity interests;

the Investor, its affiliates and its beneficial owners are (i) not included on a government list or is owned or controlled by a person on a government list and (ii) not acting directly or indirectly on behalf of terrorists, terrorist organizations or narcotics traffickers;

none of the funds used to purchase the Convertible Preferred Stock has been knowingly derived from activities that contravene applicable laws concerning money laundering, terrorism, narcotics trafficking or bribery, or from a person on a government list;

brokers’ and financial advisors’ fees related to the purchase of the Convertible Preferred Stock;

the authority of Infinite Benefits Limited (the “Guarantor”) to enter into and to be bound by the Limited Guarantee, by and between the Company and the Guarantor (the “Guarantee”) with respect to the investor termination fee and the absence of a default under the Guarantee; and

the absence of any additional representations and warranties except for the representations and warranties expressly set forth in the Securities Purchase Agreement.

The representations and warranties in the Securities Purchase Agreement will survive for a period of twelve months following the Closing.

Many of the representations and warranties in the Securities Purchase Agreement are qualified by a materiality or a Company material adverse effect standard (that is, they will not be deemed to be untrue or incorrect unless a materiality threshold is satisfied or their failure to be true or correct would, or would reasonably be expected to, result in a Company material adverse effect) and by a Company disclosure schedule and certain portions of the Company’s filings with the SEC.

For purposes of the Securities Purchase Agreement, a “Company material adverse effect” means, with respect to the Company, any change, event, occurrence or development that has, or would reasonably be expected to have a material adverse effect on the business, financial condition or results of the operations of the Company or its subsidiaries, takenMr. Martindale’s employment agreement, “change in control” is as a whole, except that adverse effects arising out of, resulting from or attributable to the following will not constitute or be deemed to contribute to or be taken into accountdefined in determining if a material adverse effect with respect to the Company has occurred or would be reasonably expected to occur:

any change or proposed change in applicable law or GAAP or changes in interpretations or enforcement of applicable law or GAAP;

any change in general economic, business, labor or regulatory conditions, or changes in securities, credit or other financial markets, including interest rates or exchange rates, in the United States or globally, or changes generally affecting the industries (including seasonal fluctuations) in which the Company or its subsidiaries operate in the United States or globally (except to the extent such effect disproportionately impacts the Company relative to other companies operating in the same industry);

any change in global or national political conditions (including the outbreak or escalation of war (whether or not declared), military action, sabotage or acts of terrorism), changes due to natural disasters or changes in the weather or changes due to the outbreak or worsening of an epidemic, pandemic or other health crisis (except to the extent such effect disproportionately impacts the Company relative to other companies operating in the same industry);

any action or omission taken or not taken at the request of, or with the consent of, the Investor or any of its affiliates;

the negotiation, announcement, pendency or consummation of the Securities Purchase Agreement and the transactions contemplated thereby, including the identity of, the Investor or any of its affiliates or

any communication by the Investor or any of its affiliates regarding plans, proposals or projections with respect to the Company, its subsidiaries or their employees (including any impact on the relationship of the Company or any its subsidiaries, contractual or otherwise, with its customers, suppliers, distributors, vendors, lenders, employees or partners);

any actions, suits, claims, mediations, arbitrations or proceedings, in each case, by or before any governmental entity arising from allegations of breach of fiduciary duty or violation of law relating to the Securities Purchase Agreement or the transactions contemplated thereby;

any decrease in the trading price or trading volume of, or suspension of trading in, the Convertible Preferred Stock, or any changes in the trading prices of, or defaults under, the Existing Credit Agreement, any asset based indebtedness permitted to be incurred pursuant to the Existing Credit Agreement or the Indenture, dated as of August 10, 2015, by and among the Company, the subsidiary guarantors party thereto and Bank of New York Mellon Trust Company, N.A., as Trustee (the “Convertible Notes Indenture”), provided that the underlying cause of such failure (unless such underlying cause would otherwise be excluded from this definition) will be taken into account in determining whether a Company material adverse effect has occurred; or

any failure by the Company or any of its subsidiaries to meet any revenue, earnings or other financial projections or forecasts, provided that the underlying cause of such failure (unless such underlying cause would otherwise be excluded from this definition) will be taken into account in determining whether a Company material adverse effect has occurred.

Covenants Regarding Conduct of Business by the Company Pending the Closing

The Company has agreed to certain covenants in the Securities Purchase Agreement restricting the conduct of its business between the date of the Securities Purchase Agreement and the earlier of the Closing and the termination of the Securities Purchase Agreement.

In general, the Company has agreed that, except (i) as set forth in the Company’s confidential disclosure schedule delivered to the Investor concurrently with the execution of the Securities Purchase Agreement, (ii) as contemplated by the Securities Purchase Agreement or (iii) with the prior written consent of the Investor (not to be unreasonably withheld, conditioned or delayed), from the date of the Securities Purchase Agreement until the earlier of the Closing or termination of the Securities Purchase Agreement, it will and will cause each of its subsidiaries to, use commercially reasonable efforts to (a) conduct its operations in the ordinary course of business and (b) preserve the goodwill and current relationships with customers, suppliers and other persons with which the Company or any of its subsidiaries have business relations.

Additionally, from the date of the Securities Purchase Agreement until the earlier of the Closing or termination of the Securities Purchase Agreement, the Company will not, and will not permit any of its subsidiaries to, take any of the following actions without the prior written consent of the Investor (not to be unreasonably withheld, conditioned or delayed):

change or amend the certificate of incorporation, Bylaws (as defined below, in the section entitled “Stockholder Proposals for2019 Annual Meeting”) or other organizational documents of the Company or any of its subsidiaries, except as otherwise required by law;

authorize for issuance, issue, grant, sell, deliver, dispose of, pledge or otherwise encumber any equity interests of the Company or any of its subsidiaries, except for issuances of shares of Common Stock upon the exercise of existing Company options or the issuance of incentive equity awards under Company Incentive Plans (as defined below) as in effect on the date of signing in the ordinary course of business, consistent with past practice;

except as required by the terms of the Company’s 2015 Stock and Incentive Plan, as amended and restated (formerly knownwhich is generally the same as the Company 2011 Stock and Incentive Plan), the GNC Acquisition

Holdings Inc. 2007 Stock Incentive Plan, as amended, and all other plans, programs, agreements or arrangements (including inducement award agreements) (“Company Incentive Plans”) pursuant to which equity and/or equity-based incentive awards have been or may be issued, as in effect on the date of signing, purchase, repurchase or redeem any equity interest of the Company;

appoint or remove any member of the Board, otherwise than in accordance with the Company’s organizational documents;

increase or decrease the size of the Board;

make or declare any dividend or distribution to the stockholders of the Company;

sell, assign, transfer, convey, lease or otherwise dispose of any material assets or properties, except pursuant to existing contracts or for sales of productsdefinition provided in the ordinaryExecutive Severance Policy.

Tabular Presentation. The following table quantifies the estimated payments and benefits that the Named Executive Officers would have received if their employment had terminated on December 31, 2018 under the circumstances shown or if we had undergone a change in control on such date. The tables exclude (i) compensation amounts accrued through December 31, 2018 that would be paid in the normal course of business consistent with past practice;

make any material loans or material advances of money to any person (other than the Companycontinued employment, such as accrued but unpaid salary and its subsidiaries), except for (i) loans made pursuant to Company employee benefit plans, (ii) advances to employees or officers of the Company or any of its subsidiaries for expenses incurred in the ordinary course of business consistent with past practice or (iii) trade credit extended to customers, franchisees and other business counterparties in the ordinary course of business consistent with past practice;

except as required by the terms of any Company employee benefit plan as in effect on the date of the Securities Purchase Agreement, pay or enter into any agreement to pay any transaction-related, retention, or severance compensation or benefits to any director, officer or key employee of the Company or any of its subsidiaries;

merge or consolidate the Company or any of its subsidiaries with any person or adopt a plan of complete or partial liquidation or resolutions providing for a complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization of the Company or any of its subsidiaries, except with respect to any wholly-owned subsidiary of the Company;

commence any bankruptcy or receivership proceeding;

acquire (including by merger, consolidation, or acquisition of stock or assets) any person or assets, other than (i) acquisitions of inventory, raw materials and other property in the ordinary course of business consistent with past practicebonus, and (ii) any other acquisitions with a purchase price of less than $25 million, including the assumption of indebtedness and liabilities outside of the ordinary course of business;

incur any indebtedness or assume, guarantee or endorse, or otherwise as an accommodation become responsible for (whether directly, contingently or otherwise), the indebtedness of any person, except (i) for indebtednessvested account balances under the documentation related to (x) the amendment of the Credit Agreement, (y) the refinancing or repayment, in whole or in part, of the indebtedness outstanding as of the date of the Securities Purchase Agreement under the Credit Agreement, and/or (z) the entering into and incurrence of indebtedness under any asset-based indebtedness permitted to be incurred pursuant to the Credit Agreement (such transactionsour 401(k) plan that are generally referredavailable to asall of our salaried employees.

Where applicable, the Credit Agreement Refinancing in this proxy statement and the related documentation is referred to as the “Credit Agreement Refinancing Documentation”), (ii) for borrowings and/or letters of credit issued under the Credit Agreement in the ordinary course of business, (iii) issuances of commercial paper for working capital and general corporate purposes in the ordinary course of business or consistent with past practice or industry standards, and (iv) indebtedness not to exceed $25 million in any single transaction or series of related transactions; or

authorize or enter into any contract or otherwise make any commitment to do any of the foregoing.

No Solicitation of Acquisition Proposals; Changes in Board Recommendation

The Company has agreed to cease discussions or negotiations that may have been conducted prior to the date of the Securities Purchase Agreement with any parties with respect to an acquisition proposal (as defined below) and to request to have returned to it or have destroyed any information that had been provided to any such party.

From the date of the Securities Purchase Agreement until the earlier of the Closing and termination of the Securities Purchase Agreement, the Company has agreed not to, and to cause its subsidiaries not to and instruct its representatives not to:

initiate, solicit or intentionally encourage the submission of any acquisition proposal or engage in any discussions or negotiations with respect thereto or in connection with any acquisition proposal or proposal reasonably likely to lead to an acquisition proposal; or

disclose or furnishnon-public information or afford access to its properties, books or records to any third party (other than informing any third party of the existence of the Company’snon-solicitation obligations);

except that

prior to the receipt of stockholder approval of the Share Issuance, the Company may ascertain facts from any person making an acquisition proposal for the purpose of the Board informing itself about such acquisition proposal and the third party making it.

However, if at any time after the date of the Securities Purchase Agreement and prior to obtaining stockholder approval of the Share Issuance, the Company has received a bona fide, unsolicited written acquisition proposal from a third party, the Company and its Board and representatives may engage in negotiations or substantive discussions regarding the acquisition proposal with, or furnish any information to, any third party making such acquisition proposal and its representatives or potential sources of financing, if the Board (or a duly authorized committee thereof) determines in good faith, after consultation with its financial advisor and outside counsel, based on information then available, that such unsolicited acquisition proposal constitutes or would reasonably be expected to lead to a superior proposal (as defined below). However, any materialnon-public information concerning the Company or its subsidiaries provided to any third party will, to the extent not already provided, be provided to the Investor as promptly as reasonably practicable (and in any event, within 24 hours of delivery to any such third party), except to the extent providing the Investor with such information would violate any applicable law.

In addition, the Company has agreed that the Board (and committees thereof) will not (i) approve or recommend, or publicly propose to approve or recommend, any acquisition proposal, (ii) withdraw, change or qualify, in a manner adverse to the Investor, the recommendation of the Board to approve the Share Issuance, (iii) approve or cause the Company to enter into any stock purchase agreement, merger agreement, letter of intent or other similar agreement relating to any acquisition proposal, or (iv) resolve or agree to do any of the foregoing (each action set forth in the foregoing clauses (i)-(iv) of this sentence, a “Change of Board Recommendation”).

However, prior to obtaining stockholder approval of the Share Issuance, if the Company receives a written acquisition proposal that did not result from a breach by the Company of its covenants relating to solicitation of acquisition proposals, the Board may make a Change of Board Recommendation (subject to the Investor’s right to terminate the Securities Purchase Agreement following such Change of Board Recommendation) if:

the Company promptly (and in any event within 24 hours) notified the Investor in writing of the receipt of an acquisition proposal or any request fornon-public information relating to the Company or any of its subsidiaries other than requests for information in the ordinary course of business, including the identity of the third party andtable uses a copy of, or description of the material terms of, the acquisition proposal;

the Company promptly (and in any event within 24 hours) notified the Investor in writing of its decision to enter into discussions or negotiations with third parties concerning an acquisition proposal;

the Board has determined, after consultation with its financial and outside legal advisors, that the acquisition proposal constitutes a superior proposal;

the Board has determined that failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of the Company’s directors;

the Company has provided the Investor at least five business days’ prior written notice of the Company’s intention to effect a Change of Board Recommendation, which notice will include material terms and conditions of the acquisition proposal, and provided the Investor a copy of the available proposed transaction agreement to be entered into in respect of such acquisition proposal;

the Company and its legal and financial advisors have engaged in good faith negotiations with the Investor regarding amendments to the Securities Purchase Agreement proposed in writing by the Investor during such five business day notice period; and

the Board has considered any adjustments and/or proposed amendments to the Securities Purchase Agreement and have determined in good faith that a superior proposal would continue to constitute a superior proposal if such proposals were to be given effect.

In addition, the Board may terminate the Securities Purchase Agreement to enter into a definitive agreement solely with respect to a superior majority proposal (as defined below), provided that the Company pays a termination fee in advance of or concurrently with its entry into a definitive agreement with respect to such superior majority proposal (as more fully described in the section entitled “ —Termination Fee; Effect of Termination”).

A material revision or amendment to the superior proposal will require the Company to deliver a new written notice to the Investor and to again comply with the above requirements, except that the five business day notice period described above is reduced to three business days with respect to such revised superior proposal.

The Board may also make a Change of Board Recommendation (but may not terminate the Securities Purchase Agreement) in circumstances other than in response to an acquisition proposal if, prior to obtaining stockholder approval of the Share Issuance:

(a) the Board (or a duly authorized committee thereof) determines that an intervening event (as defined below) has occurred and is continuing; and (b) the Board (or a duly authorized committee thereof) determines, after consultation with its legal advisor, that the failure to effect a Change of Board Recommendation in response to such intervening event would reasonably be expected to be inconsistent with its fiduciary duties to the stockholders of the Company;

the Company has provided the Investor with five business days’ prior written notice advising the Investor of the Company’s intention to take such action and specifying all available material information with respect to such intervening event;

the Company and its legal and financial advisors have, if requested by the Investor, engaged in good faith negotiations with the Investor regarding amendments to the Securities Purchase Agreement proposed in writing by the Investor during such five business day notice period; and

the Board has considered any adjustments and/or proposed amendments to the Securities Purchase Agreement and have determined in good faith that an intervening event would continue to constitute an intervening event if such proposals were to be given effect.

For the purposes of the Securities Purchase Agreement, the term “acquisition proposal” means any offer or proposal from a third party concerning (i) a merger, consolidation or other business combination transaction

involving the Company, (ii) a sale, lease or other disposition by merger, consolidation, business combination, share exchange, joint venture or otherwise, of assets of the Company (including equity interests of any subsidiary of the Company) or its subsidiaries for consideration, representing 25% or more of the consolidated assets of the Company and its subsidiaries, based on their fair market value as determined in good faith by the Board (or any duly authorized committee thereof), (iii) an issuance (including by wayper share of merger, consolidation, business combination or share exchange) of equity interests representing 25% or more of the voting power of the Company, or (iv) any combination of the foregoing (in each case, other than the transactions contemplated by the Securities Purchase Agreement).

For the purposes of the Securities Purchase Agreement, the term “superior majority proposal” means a bona fide written acquisition proposal (except the references to “25%” in parts (ii) and (iii) of the definition thereof will be replaced by “50.01%”) that the Board (or a duly authorized committee thereof) determines in good faith, after consultation with its financial advisor and outside counsel, taking into account such factors as the Board (or any duly authorized committee thereof) considers in good faith to be appropriate (including the conditionality, timing and likelihood of consummation of such proposal), is more favorable from a financial point of view to the Company and its stockholders than the transactions contemplated by the Securities Purchase Agreement.

For the purposes of the Securities Purchase Agreement, the term “superior minority proposal” means a bona fide written acquisition proposal (except the references to “25% or more” in parts (ii) and (iii) of the definition thereof will be replaced by “between 40% and 50.01%”) that the Board (or a duly authorized committee thereof) determines in good faith, after consultation with its financial advisor and outside counsel, taking into account such factors as the Board (or any duly authorized committee thereof) considers in good faith to be appropriate (including the conditionality, timing and likelihood of consummation of such proposal), is more favorable from a financial point of view to the Company and its stockholders than the transactions contemplated by the Securities Purchase Agreement.

For the purposes of the Securities Purchase Agreement, the term “superior proposal” means a superior majority proposal or a superior minority proposal, as applicable.

For the purposes of the Securities Purchase Agreement, the term “intervening event” means any event, circumstance, change, effect, development, state of facts, condition or occurrence (including any acceleration or deceleration of existing changes or developments) that is material to the Company and its subsidiaries that (i) was not known or reasonably foreseeable (or, if known, the consequences of which were not known or reasonably foreseeable) to the Board as of or prior to the date of the Securities Purchase Agreement, and (ii) does not involve an acquisition proposal.

Moreover, from the date of the Securities Purchase Agreement until the earlier of December 31, 2018 and the termination of the Securities Purchase Agreement (other than as a result of a superior minority proposal that is not accompanied by a Competing China JV Proposal (as defined below)), the Company has agreed not, and to cause its subsidiaries not, and instructed its representatives not, on behalf of the Company, to:

initiate, solicit or intentionally encourage the submission of any proposal$2.37 for or engage in any discussions or negotiations with respect to or in connection with any joint venture involving, or acquisition of, the Company’s business in the PRC (a “Competing China JV Proposal”);

disclose or furnishnon-public information or afford access to its properties, books or records to any third party in connection with a Competing China JV Proposal (other than informing any third party of the Company’snon-solicitation obligations); or

enter into any definitive agreement, letter of intent or similar agreement related to a Competing China JV Proposal;

except that the Company may enter into discussions or negotiations with or provide disclosures ofnon-public information to, a third party in the event that (i) the Company receives an acquisition proposal from the third

party that contains or is conditioned upon a Competing China JV Proposal and (ii) the Board (or a duly authorized committee thereof) determines to enter into discussions or negotiations with such third party or to disclosenon-public information to such third party in response to such acquisition proposal.

The Company agreed to promptly cease discussions or negotiations that may have been conducted prior to the date of the Securities Purchase Agreement with any parties with respect to a Competing China JV Proposal and to request to have returned to it or have destroyed any information that had been provided to any such party.

Required Stockholder Vote

As promptly as practicable, and in any event within fifteen business days following the date on which the SEC confirms it has no further comment to this proxy statement, the Company is obligated to use commercially reasonable efforts to mail this proxy statement to holders of the Company’sour Common Stock, as of the record date (not to be more than thirty days after the mailing of this proxy statement). Subject to the provisions of the Securities Purchase Agreement, the Company will take all action necessary in accordance with the Delaware General Corporation Law, the NYSE and the Company’s organizational documents to duly call, give notice of, convene and hold a meeting of the stockholders promptly following the mailing of this proxy statement, for the purpose of obtaining the approval of the Share Issuance.

Subject to a Change of Board Recommendation, the Company will use its commercially reasonable efforts to solicit proxies in favor of the adoption of the Securities Purchase Agreement, including by postponing or adjourning the stockholder meeting from time to time by up to a total of ten business days to allow additional solicitation of votes if necessary to obtain stockholder approval. Subject to limits specified in the Securities Purchase Agreement in certain cases, such stockholder meeting may also be postponed or adjourned (i) with the consent of the Investor, (ii) if a quorum has not been established, (iii) to allow reasonable additional time for the filing and mailing of supplemental or amended disclosure which the Board has determined in good faith after consultation with outside legal and financial advisors and the Investor is necessary under applicable law and for such supplemental or amended disclosure to be disseminated and reviewed by the Company’s stockholders prior to the meeting, or (iv) if required by law. Subject to the Company’s right to effect a Change of Board Recommendation (in certain circumstances, as described above), the Company is obligated to include in this proxy statement the recommendation of the Board that the Company’s stockholders vote in favor of the proposal to approve the Share Issuance.

Consents, Approvals and Filings

The Company and the Investor have each agreed, subject to the terms of the Securities Purchase Agreement, to use their reasonable best efforts to:

prepare and file as promptly as practicable with any governmental entity or other third party all documentation to effect all necessary filings, notices, petitions, statements, registrations, submissions of information, applications and other documents; and

obtain and maintain all approvals, consents, registrations, permits, authorizations and other confirmations required to be obtained from any governmental entity or other third party that are necessary to consummate the transactions contemplated by the Securities Purchase Agreement, including the CFIUS Clearance and the PRC Approvals.

HSR Act

Each of the Company and the Investor have determined that a filing of a Notification and Report Form pursuant to the HSR Act is not required, and, accordingly, have agreed that the condition to closing of the Share Issuance under the Securities Purchase Agreement related to the HSR Act is deemed to be satisfied.

CFIUS

Each of the Investor and the Company will use its reasonable best efforts to obtain CFIUS Clearance as promptly as practicable. As promptly as practicable after the execution of the Securities Purchase Agreement, the Investor and the Company will prepare,pre-file a draft joint voluntary notice, and then as soon as reasonably practicable thereafter, file with CFIUS a joint voluntary notice pursuant to Section 721 with respect to the transactions contemplated by the Securities Purchase Agreement. The Company and the Investor will, as promptly as practicable, provide CFIUS with any additional or supplemental information requested by CFIUS or its constituent agencies during the review process.

The Company and the Investor will also take, or cause to be taken, all actions that are customarily undertaken or reasonably achieved to obtain CFIUS Clearance so as to enable the Closing to occur as promptly as practicable, including promptly making anypre-notification and notification filings required in connection with CFIUS Clearance, and providing any information requested by CFIUS or any other agency or branch of the United States government in connection with their review of the transactions contemplated by the Securities Purchase Agreement.

Such efforts will include, to the extent necessary to obtain CFIUS Clearance, the execution of mitigation agreements containing terms customarily included in such mitigation agreements, provided however that no party will be required to enter into any agreement that materially interferes with the Investor’s ability to exercise any and all rights accorded to it pursuant to the terms of the Securities Purchase Agreement in any material respect. With respect to any mitigation, the Investor and the Company will be entitled to a reasonable period of time to engage in discussions and negotiations with CFIUS and between themselves on the nature and scope of such measures, to ensure that any agreed upon measures are reasonable without any adverse material effect on the Investor, the Company or its subsidiaries.

The Investor will not be required to enter into any agreement, consent decree or other commitment to sell the Convertible Preferred Stock as a condition to receiving CFIUS Clearance.

Each of the Investor and the Company will promptly furnish to the other copies of any notices or written communications received by such party or any of its affiliates from CFIUS or any of its constituent agencies with respect to the transactions contemplated by the Securities Purchase Agreement, unless otherwise prohibited by CFIUS or applicable laws. Each of the Investor and the Company will permit the other’s counsel to have an opportunity to review in advance, and such party will consider in good faith the views of such counsel in connection with, any proposed communications by such party or its affiliates to CFIUS concerning the transactions contemplated by the Securities Purchase Agreement. Each of the Investor and the Company may, as either party deems advisable and necessary, reasonably designate any competitively sensitive materials or information provided to the other party as “outside counsel only.” Such materials and the information contained therein will be given only to the outside legal counsel of the other party, and such party will cause such outside counsel not to disclose such materials or information to any employees, officers, directors or other representatives of the Company, unless express written permission is obtained in advance from the party providing such materials and information.

PRC Approvals

Following the date of the Securities Purchase Agreement, the Investor will:

make all appropriate filings required in connection with the PRC Approvals as promptly as practicable within the applicable period required by applicable law, and supply as promptly as practicable any additional information and documentary material that may be requested pursuant to applicable law in connection with the PRC Approvals; and

to the extent permitted by applicable law, promptly inform the Company of any oral communication with, and provide copies of written communications with, any governmental entity regarding the PRC Approvals and share with the Company any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of the Investor relating to the PRC Approvals; provided, that in each case above, the Company will reasonably cooperate with the Investor to provide the information and documents required for obtaining the PRC Approvals and will assist the Investor in promptly responding to any requests for information and/or documents from any governmental entity in connection with making such applications and/or filings to obtain the PRC Approvals.

From and after the date of the Securities Purchase Agreement until the earlier of the Closing and the termination of the Securities Purchase Agreement, unless prohibited by applicable law, each party will give prompt notice to the other party if any of the following occur:

receipt of any notice or other communication in writing from any person alleging that the consent or approval of such person is or may be required in connection with the transactions contemplated by the Securities Purchase Agreement;

receipt of any notice or other communication from any governmental entity in connection with the transactions contemplated by the Securities Purchase Agreement; or

such party becoming aware of the occurrence of an event that would reasonably be expected to prevent or delay, beyond November 13, 2018 (as may be extended, the “Outside Date”), the consummation of the transactions contemplated by the Securities Purchase Agreement or that would reasonably be expected to result in any of the conditions to the Closing not being satisfied.

Other Covenants and Agreements

The Securities Purchase Agreement contains certain other covenants and agreements, including covenants relating to:

cooperation between the Company and the Investor in the preparation and filing of this proxy statement;

reasonable access to information about the Company and any of its subsidiaries to be given to the Investor;

confidentiality obligations of and access by the Investor to certain information about the Company pursuant to the confidentiality agreement between the Company and the Investor;

the Investor’s obligation to provide (within ten business days of the date of the Securities Purchase Agreement) the Company with a complete and accurate schedule of all individuals and entities that hold, own or control equity in the Investor of 5% or greater, all individuals and entities that are affiliated with any foreign government or may be “foreign government controlled” under Section 721 of the Defense Production Act, and any foreign government or person controlled by a foreign government that holds interest in the Investor;

obtaining the prior written consent of the other party prior to public announcements with respect to the Securities Purchase Agreement or the transactions contemplated thereby;

the Company’s use of reasonable best efforts to obtain debt refinancing and to keep the Investor reasonably informed of any material developments with respect thereto;

the Company and the Investor using their commercially reasonable best efforts to identify alternative financing arrangements for the Company’s indebtedness;

the Company and the Investor using their respective reasonable best efforts to negotiate in good faith definitive documentation with respect to the Joint Venture;

the Company and the Board taking all action reasonably available to it to render takeover statutes inapplicable;

the Company’s commitment to cause the authorized capital stock of the Company to include a sufficient number of authorized but unissued shares of Common Stock to satisfy the Investor’s right to convert Convertible Preferred Stock into Underlying Shares;

the Company’s obligation not to sell, offer for sale or solicit offers to buy or otherwise negotiate any security that would be integrated with the offer or sale of the Convertible Preferred Stock or the Underlying Shares in a manner that would require registration under the Securities Act of the Convertible Preferred Stock or Underlying Shares to the Investor;

the Company’s obligation to submit an application to the NYSE for the listing of the Underlying Shares or the securities laws of any state, as applicable;

the Company’s obligation to take all necessary action to increase the size of the Board to eleven directors (each a “Director”);

the Company and the Investor will cooperate to identify their designees to the Board as promptly as practicable, and in any event no later than thirty business days prior to the Closing;

the Board’s duty to take all necessary actions to cause the Certificate of Designations to be adopted and filed with the Secretary of State of the State of Delaware and to cause the Bylaws to be amended and restated;

cooperation of the Company and the Investor to use reasonable best efforts to promptly, but in no event later than fifteen business days after the signing of the Securities Purchase Agreement, negotiate and execute an escrow agreement with JPMorgan Chase Bank, N.A., Hong Kong Branch (or another internationally recognized bank with a branch in Hong Kong) in accordance with the terms of the Securities Purchase Agreement;

the Investor’s obligation, prior to Closing, to assign the Securities Purchase Agreement to Harbin Pharmaceutical Group Co., Ltd.; and

the Investor’s obligation to, as promptly as practicable following the signing of the Securities Purchase Agreement, cause a letter of credit from a reputable bank, in an amount equal to the Purchase Price,closing price of our Common Stock on December 31, 2018.

Named Executive Officer
Resignation
for Good
Reason(1)
Retirement(1)
By Company
Without Cause
Termination
Without Cause /
Good Reason
Following a
Change of Control
Death or
Disability
Kenneth A. Martindale(2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash Severance(3)
$
1,950,000
 
$
1,950,000
 
$
1,950,000
 
$
1,950,000
 
 
 
Pro-rated Bonus(3)
$
1,088,183
 
$
1,088,183
 
$
1,088,183
 
$
1,088,183
 
$
713,865
 
Health and Welfare Benefits(4)
$
20,520
 
 
 
$
20,520
 
$
20,520
 
$
250,000
 
Additional Stock Award Vesting(5)
$
813,611
 
$
813,611
 
$
813,611
 
$
857,900
 
$
857,900
 
Retention Award(6)
$
1,462,500
 
$
1,462,500
 
$
1,462,500
 
$
1,462,500
 
$
1,462,500
 
Total
$
5,334,814
 
$
4,939,975
 
$
5,334,814
 
$
5,379,103
 
$
3,284,265
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tricia Tolivar
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash Severance(3)
 
 
 
 
$
520,000
 
$
1,040,000
 
 
 
Pro-rated Bonus(3)
 
 
 
 
$
199,777
 
$
199,777
 
 
 
Health and Welfare Benefits(4)
 
 
 
 
 
 
 
 
$
250,000
 
Additional Stock Award Vesting(5)
 
 
 
 
 
 
$
702,420
 
 
 
Retention Award(6)
$
573,750
 
 
 
$
573,750
 
$
573,750
 
$
573,750
 
Total
$
573,750
 
 
 
$
1,293,527
 
$
2,515,947
 
$
823,750
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

38

TABLE OF CONTENTS

Named Executive Officer
Resignation
for Good
Reason(1)
Retirement(1)
By Company
Without Cause
Termination
Without Cause /
Good Reason
Following a
Change of Control
Death or
Disability
Gene E. Burt
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash Severance(3)
 
 
 
 
$
450,000
 
$
900,000
 
 
 
Pro-rated Bonus(3)
 
 
 
 
$
122,459
 
$
122,459
 
 
 
Health and Welfare Benefits(4)
 
 
 
 
 
 
 
 
$
250,000
 
Additional Stock Award Vesting(5)
 
 
 
 
 
 
$
217,707
 
 
 
Retention Award(6)
$
337,500
 
 
 
$
337,500
 
$
337,500
 
$
337,500
 
Total
$
337,500
 
 
 
$
909,959
 
$
1,577,666
 
$
587,500
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joseph C. Gorman
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash Severance(3)
 
 
 
 
$
420,000
 
$
840,000
 
 
 
Pro-rated Bonus(3)
 
 
 
 
$
118,914
 
$
118,914
 
 
 
Health and Welfare Benefits(4)
 
 
 
 
 
 
 
 
$
250,000
 
Additional Stock Award Vesting(5)
 
 
 
 
 
 
$
214,113
 
 
 
Retention Award(6)
$
300,000
 
 
 
$
300,000
 
$
300,000
 
$
300,000
 
Total
$
300,000
 
 
 
$
838,914
 
$
1,473,027
 
$
550,000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Steven Piano
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash Severance(3)
 
 
 
 
$
390,000
 
$
780,000
 
 
 
Pro-rated Bonus(3)
 
 
 
 
$
70,703
 
$
70,703
 
 
 
Health and Welfare Benefits(4)
 
 
 
 
 
 
 
 
$
250,000
 
Additional Stock Award Vesting(5)
 
 
 
 
 
 
$
62,964
 
 
 
Retention Award(6)
$
292,500
 
 
 
$
292,500
 
$
292,500
 
$
292,500
 
Total
$
292,500
 
 
 
$
753,203
 
$
1,206,167
 
$
542,500
 
(1)No amount is payable to any Named Executive Officer upon any termination for cause or voluntary resignation from service to the Company other than in the case of a resignation for good reason. Mr. Martindale’s employment contract is silent on payments at retirement. Further, the Company does not maintain a stand-alone retirement policy. As such, for purposes of this table, amounts included reflect assumed payments coinciding with a termination without cause, excluding health and welfare benefits.
(2)For Mr. Martindale, termination by the Company without cause includes termination by nonrenewal of his employment agreement.
(3)Amounts have been calculated in accordance with the terms of the applicable agreements or plan. For terminations by the Company without cause, amounts will be paid in installments over a period not exceeding two years following termination. For terminations in connection with a change of control, amounts will be paid in a lump sum upon termination. We have assumed that none of the payments or benefits provided to any Named Executive Officer would have been subject to or resulted in the imposition of the excise tax imposed by Internal Revenue Code Section 4999. Accordingly, no reductions in such payments and benefits have been applied in the table above.
(4)Amounts reflect value of basic life insurance payable upon separation due to Death; these amounts are not payable in the event of separation due to Disability. For Mr. Martindale, payment includes an eighteen month COBRA payment in the following circumstances: Resignation for Good Reason, Termination by Company Without Cause, and Termination Without Cause or for Good Reason Following a Change of Control.
(5)The value of Additional Stock Award Vesting represents the value at December 31, 2018 of all shares of restricted stock, restricted stock units (along with any dividend equivalents accrued on the restricted stock units), and earned PSUs (along with dividend equivalents on the PSUs) that on that date were subject to service-based restrictions, which restrictions lapse on or after certain terminations of employment, including following a change in control, to the extent such restrictions would not lapse on retirement alone.
(6)The value of the outstanding balance of the Retention Awards issued to our Named Executive Officers in connection with the Harbin transaction. Per the agreement, outstanding balances are accelerated in the case involuntary separation without cause, due to good reason, death, or disability. The balance of the Retention Awards would also be paid in the event of a Change in Control.

The change in favor of the Company.

Conditions to Completion of the Issuance, Purchase and Sale of the Convertible Preferred Stock

The obligations of the Company and the Investor to complete the issuance, purchase and sale of the Convertible Preferred Stock are subject to the satisfaction or waiver (to the extent permitted by applicable law) by the Company and the Investor at or prior to the Closing ofcontrol definitions used in each of the following conditions:

the approval of the Share Issuance by the Company’s stockholders;

the absence of an order, decree of judgment of any government entity having competent jurisdiction that prohibits or makes illegal the transactions contemplated by the Securities Purchase Agreement or the Credit Agreement Refinancing;

the receipt of the PRC Approvals2015 and CFIUS Clearance; and

the entrance into the Joint Venture.

The obligations of the Company to complete the issuance, purchase and sale of the Convertible Preferred2018 Stock are subject to the satisfaction or waiver by the Company at or prior to the Closing of each of the following conditions:

each representation and warranty of the Investor contained in the Securities Purchase Agreement, without giving effect to any qualifications as to materiality or Company material adverse effect or other

similar qualifications contained therein, being true and correct at and as of the date of the Securities Purchase Agreement and as of the Closing as though made on the Closing, except for representations and warranties that relate to a specific date or time (which need only be true and correct as of such date or time), and except as has not had and would not reasonably be expected to have, individually or in the aggregate with all other failures to be true or correct, a Company material adverse effect on the ability of the Investor or its affiliates to perform its obligations under the Securities Purchase Agreement or under any of the documents contemplated thereby;

the Investor having performed or complied in all material respects with all covenants and agreements required to be performed or complied with by it under the Securities Purchase Agreement at or prior to the Closing;

the Investor having delivered to the Company a certificate, dated as of the Closing and signed by an executive officer of the Investor, certifying to the effect that the conditions in the two bullets above have been satisfied; and

the Investor having delivered to the Company executed copies of the Registration Rights Agreement and the Stockholders Agreement.

The Investor’s obligations to complete the issuance, purchase and sale of the Convertible Preferred Stock are subject to the satisfaction or waiver by the Investor at or prior to the Closing of each of the following conditions:

the representations and warranties of the Company relating to due organization, authority, valid issuance of Convertible Preferred Stock and broker’s fees being true and correct at and as of the date of the Securities Purchase Agreement and as of the Closing as though made on the Closing, except for representations and warranties that relate to a specific date or time (which need only be true and correct in all material respects as of such date or time);

the representations and warranties of the Company related to capitalization of the Company being true in all butde minimis respects as of the date of the Securities Purchase Agreement and as of the Closing as though made on the Closing;

each other representation and warranty of the Company, without giving effect to any qualifications as to materiality or Company material adverse effect contained therein, being true and correct at and as of the date of the Securities Purchase Agreement and as of the Closing as though made on the Closing, except for representations and warranties that relate to a specific date or time (which need only be true and correct as of such date or time), except as has not had and would not reasonably be expected to have, individually or in the aggregate with all other failures to be true or correct, a Company material adverse effect;

the Company having performed and complied in all material respects with all covenants and agreements required to be performed or complied with by it under the Securities Purchase Agreement at or prior to the Closing;

the Company having delivered to the Investor a certificate, dated the Closing and signed by an executive officer of the Company, certifying to the effect that the conditions set forth in the first four bullets above have been satisfied;

the Company having delivered to the Investor a good standing certificate of the Company;

each member of the Board that is not a Company Designee (as defined below in the section entitled “Stockholders Agreement – Composition of the Board”) or the Chief Executive Officer having resigned from the Board effective as of the Closing;

the Board having caused each individual designated to the Board by the Company or the Investor, as applicable, to be appointed to the Board, effective as of the Closing;

the Company having filed the Certificate of Designations and BylawsPlans aligns with the Secretary of State of the State of Delaware and delivered to the Investor a copy of the Company’s certificate of incorporation and Bylaws, certified by the Secretary of the Company;

the Company having made any required filings and submitted any required certifications regarding the issuance or listing of additional shares with the NYSE; and

the Company having delivered to the Investor executed copies of the Registration Rights Agreement and the Stockholders Agreement.

Termination of the Securities Purchase Agreement

The Securities Purchase Agreement may be terminated at any time prior to the Closing by mutual written consent of each of the Company and the Investor, by action of their respective boards of directors.

In addition, either the Company or the Investor may terminate the Securities Purchase Agreement prior to the Closing, if:

approval of the Share Issuance by the Company’s stockholders has not been obtained upon a vote taken at the Special Meeting or any adjournments or postponements thereof;

if any court of competent jurisdiction or other governmental entity of competent jurisdiction has issued an order or taken any other action,change in each case, permanently restraining, enjoining or otherwise prohibiting, prior to the Closing, the consummation of the transactions contemplated by the Securities Purchase Agreement, and such order or other action will have become final andnon-appealable; provided that the right to terminate the Securities Purchase Agreement for this reason will be available only if the party seeking to terminate has complied with its covenants regarding competition laws before asserting the right to terminate and provided, further, that this right of termination will not be available to any party whose failure to comply with its obligations under the Securities Purchase Agreement has been the primary cause of or resulted in such order or action; and

the Closing has not occurred on or before the Outside Date; provided, however, that if all of the Closing conditions except those related to the PRC Approvals, CFIUS Clearance or related legal restraints have been satisfied or duly waived by all parties entitled to the benefit of such conditions, either the Company or the Investor may, by written notice delivered to such other party, extend the Outside Date to February 13, 2019; provided, further, that this right to terminate will not be available to any party whose material breach of any obligations of the Securities Purchase Agreement has been the primary cause of, or resulted in, the failure of the Closing to have occurred.

The Securities Purchase Agreement may also be terminated by the Investor, at any time prior to receipt of approval of the Share Issuance by the Company’s stockholders, if:

the Board has effected a Change of Board Recommendation or the Company has failed to include the Board’s recommendation in the proxy statement; and

the Company has entered into a merger agreement, stock purchase agreement, letter of intent or other similar agreement relating to an acquisition proposal;

provided, that the Investor’s right to terminate the Securities Purchase Agreement shall expire at 5:00 p.m. (New York City time) on the tenth calendar day following the date on which the event first permitting such termination occurred.

The Securities Purchase Agreement may also be terminated by the Investor, at any time prior to the Closing, if:

there has been a breach by the Company of the Company’s representations, warranties or covenants contained in the Securities Purchase Agreement, in either case, such that the mutual conditions to Closing or the Investor’s conditions to Closing are not reasonably capable of being satisfied while the Company’s breach is continuing;

the Investor has delivered to the Company written notice of such breach; and

such breach is not capable of cure in a manner sufficient to allow satisfaction of the mutual conditions to closing or the Investor’s conditions to Closing prior to the Outside Date or at least thirty days will have elapsed since the date of delivery of such written notice to the Company and such breach will not have been cured in all material respects; provided, however, that the Investor will not be permitted to terminate the Securities Purchase Agreement if there has been any material breach by the Investor of the Investor’s material representations, warranties or covenants contained in the Securities Purchase Agreement, and such breach will not have been cured in all material respects.

The Securities Purchase Agreement may also be terminated by the Company, at any time prior to receipt of approval of the Share Issuance by the Company’s stockholders, if the Board determines to accept a superior majority proposal, but only if the Company has complied in all material respects with its obligations under the Securities Purchase Agreement with respect to such superior majority proposal; provided that the Company pays a termination fee concurrently with such termination (as more fully described in the section entitled “ —Termination Fee; Effect of Termination”).

The Securities Purchase Agreement may also be terminated by the Company, at any time prior the Closing, if:

there has been a breach by the Investor of any of the Investor’s representations, warranties or covenants contained in the Securities Purchase Agreement, in either case, such that the mutual conditions to Closing or the Company’s conditions to Closing are not reasonably capable of being satisfied while the Investor’s breach is continuing;

the Company has delivered to the Investor written notice of such breach; and

either such breach is not capable of cure in a manner sufficient to allow satisfaction of the mutual conditions to Closing or the Company’s conditions to Closing prior to the Outside Date or at least thirty days will have elapsed since the date of delivery of such written notice to the Investor and such breach will not have been cured in all material respects; provided, however, that the Company will not be permitted to terminate the Securities Purchase Agreement if there has been any material breach by the Company of the Company’s material representations, warranties or covenants contained in the Securities Purchase Agreement, and such breach will not have been cured in all material respects.

The Company may also terminate, at any time, if all of the mutual conditions to Closing of the Company and the Investor (other than conditions that by their nature can only be satisfied on the Closing) have been satisfied, the Company has confirmed in writing that it is prepared to consummate the Closing, and the Investor fails to consummate the Closing within five business days following delivery of such written confirmation by the Company to the Investor.

Termination Fee; Effect of Termination

Under the Securities Purchase Agreement, the Company will be required to pay the Investor a “company termination fee” of $10 million under the following circumstances:

if the Securities Purchase Agreement is terminated by the Investor, at any time prior to the receipt of approval of the Share Issuance by the Company’s stockholders, because the Board has effected a Change of Board Recommendation or the Company has entered into a merger agreement, stock purchase agreement, letter of intent or similar agreement relating to an acquisition proposal;

if the Securities Purchase Agreement is terminated by the Company, at any time prior to the receipt of approval of the Share Issuance by the Company’s stockholders, because the Board determines to accept a superior majority proposal; or

if (i) the Securities Purchase Agreement is terminated by the Company or the Investor as a result of failure to obtain the approval of the Company’s stockholders for the Share Issuance, (ii) an acquisition

proposal for at least 40% of the consolidated assets or voting power of the Company has been publicly announced after the date of the Securities Purchase Agreement but before the Special Meeting, (iii) the Company enters into a definitive agreement with respect to any such acquisition proposal within nine months after such termination and (iv) a transaction with respect to such acquisition proposal is eventually consummated.

Under the Securities Purchase Agreement, the Company will be required to pay the Investor a “minority transaction termination fee” of $18 million under the following circumstance:

if the Securities Purchase Agreement is terminated by the Investor, at any time prior to the receipt of approval of the Share Issuance by the Company’s stockholders, due to a Change of Board Recommendation or the Company’s entrance into a definitive transaction agreement relating to an acquisition proposal; and

prior to such termination, the Board effects a Change of Board Recommendation with respect to a superior minority proposal.

In the event the Securities Purchase Agreement is terminated due to a failure to obtain approval of the Company’s stockholders, and the Board effects a Change of Board Recommendation with respect to a superior minority proposal, the Company shall also pay to the Investor reasonable documentedout-of-pocket costs, fees and expenses incurred by the Investor in connection with the negotiation and documentation of the Securities Purchase Agreement, up to $3,000,000 in the aggregate.

Under the Securities Purchase Agreement, the Investor will be required to pay Company an “investor termination fee” of $18 million under the following circumstances:

if the Securities Purchase Agreement is terminated, at any time prior to the Closing, by the Company due to an uncured breach of the Investor’s representations, warranties or covenants contained in the Securities Purchase Agreement or Investor’s failure to consummate the Closing for five business days despite the Closing conditions being satisfied;

if the Securities Purchase Agreement is terminated by either party because the conditions to Closing have not been satisfied by the Outside Date, where the Company could terminate the Securities Purchase Agreement in accordance with the bullet above; and

if the Securities Purchase Agreement is terminated by the Investor or the Company due to failure to obtain PRC Approvals or CFIUS Clearance prior to the Outside Date and all other conditions to closing have been satisfied or waived or if a court of competent jurisdiction issues an order related to the PRC Approvals or CFIUS Clearance that prohibits the Closing.

On March 6, 2018, the Investor caused the Guarantor to deposit an amount equal to the investor termination fee into an escrow account with JPMorgan Chase Bank, N.A., Hong Kong Branch (the “Escrow Agent”) and entered into an escrow agreement with respect to such account with the Guarantor, the Company and the Escrow Agent.

In circumstances where the parties’ respective termination fees are payable in accordance with the provisions of the Securities Purchase Agreement, either party’s receipt of the other party’s termination fee (if received) will be each party’s sole and exclusive remedy (whether based in contract, tort or strict liability, by the enforcement of any assessment, by any legal or equitable proceeding, by virtue of any statute, regulation or applicable laws or otherwise) against the other party and its subsidiaries and any of their respective former, current or future direct or indirect equity holders, general or limited partners, controlling persons, stockholders, members, managers, directors, officers, employees, agents, affiliates or assignees for all losses and damages suffered as a result of the transactions contemplated by the Securities Purchase Agreement to be completed, for any breach or failure to perform under the Securities Purchase Agreement or otherwise, and upon payment of such amount, no such

person will have any further liability or obligation relating to or arising out of the Securities Purchase Agreement or the transactions contemplated thereby, except in the event of a willful and material breach by the Investor.

Fees and Expenses

All fees and expenses incurred in connection with the Securities Purchase Agreement, the issuance, purchase and sale of the Convertible Preferred Stock and the other transactions contemplated by the Securities Purchase Agreement will be paid solely and entirely by the party incurring such fees or expenses, with certain exceptions expressly set forth in the Securities Purchase Agreement. These exceptions include certain expense reimbursements in the event of termination, as described in the section entitled “ —Termination Fee; Effect of Termination.”

Specific Performance

The Securities Purchase Agreement generally provides that the parties will be entitled, without posting a bond or other indemnity, to an injunction, specific performance and other equitable relief to prevent breaches of the Securities Purchase Agreement and to enforce specifically the terms and provisions of the Securities Purchase Agreement, in addition to any other remedy to which they are entitled at law or in equity.

Third Party Beneficiaries

The Securities Purchase Agreement provides that it will be binding upon, inure to the benefit of and be enforceable by the Company and the Investor and their respective successors and assigns. The Securities Purchase Agreement is not intended to and will not confer any rights, benefits or remedies of any nature whatsoever upon any person other than the Company and the Investor and their respective successors and assigns.

Amendments; Waivers

The Securities Purchase Agreement may be amended by mutual agreement of the parties to the Securities Purchase Agreement by action taken by or on behalf of their respective boards of directors at any time before or after receipt of the approval of the Share Issuance by the Company stockholders. However, after receipt of approval by the Company stockholders, no amendment may be made which, by law or in accordance with the rules of any relevant stock exchange, requires further approval by the Company’s stockholders, unless approval is again obtained from the Company stockholders with respect to the effectiveness of such amendment.

At any time prior to the Closing, the Company or the Investor may extend the time for performance of any obligations or acts of the other, waive any breach of the representations and warranties of the other or waive compliance by the other with respect to any of the agreements or covenants contained in the Securities Purchase Agreement. However, after receipt of approval by the Company stockholders, no extension or waiver may be made which, by law or in accordance with the rules of any relevant stock exchange, requires further approval by the Company’s stockholders, unless approval is again obtained from the Company stockholders with respect to the effectiveness of such extension or waiver.

Stockholders Agreement

In connection with the Securities Purchase Agreement, the Company will, at the Closing, enter into the Stockholders Agreement with the Investor. The following is a summary of selected provisions of the Stockholders Agreement.

Composition of the Board

At the Closing, the Board shall be comprised of eleven Directors. For so long as the Investor owns at least 15% of the outstanding Common Stock (on anas-converted basis), the Investor shall have the right to nominate up to five Directors (the “Investor Designees”), the Company shall have the right to nominate five or more Directors and the Company’s chief executive officer shall be entitled to be nominated as a Director (other than the Investor Designees, collectively, the “Company Designees”). The number of the Investor Designees will be adjusted from time to time, not to exceed five, in accordance with the Stockholders Agreement, to equal the Investor’s proportionate ownership of the Company. Upon the Investor’s material, uncured breach of certain material terms of the Stockholders Agreement or its ownership percentage of outstanding Common Stock (on anas-converted basis) decreasing below 15%, the Investor’s nomination right shall be terminated. Two of the initial Investor Designees shall be “independent”. However, if the Investor is only entitled to nominate four Investor Designees, only one shall be required to be “independent” and if the Investor is only entitled to nominate three Investor Designees, none shall be required to be “independent”. Each of the Investor Designees is required to be reasonably satisfactory to the Board’s Nominating and Corporate Governance Committee. Each of the Company Designees (other than the Company’s chief executive officer) shall be required to be an “independent” director.

In addition to the requirements above, each Investor Designee shall, among other requirements, (i) meet and comply in all material respects with any and all policies, rules, standards and guidelines of the Company applicable to allnon-employee Directors, (ii) meet and comply in all material respects with all applicable requirements of the NYSE for service as a director, (iii) not be an employee, officer or director of, or consultant to, a direct competitor of the Company, (iv) have demonstrated good judgment and have relevant international or other business experience and (v) have executed a confidentiality agreement with the Company.

Board Supermajority Voting

At the Closing, the Bylaws will be amended and restated to require thattwo-thirds of the Company’s Directors, including, for so long as the Investor owns at least 25% of the outstanding Common Stock (on anas-converted basis), at least onenon-independent Investor Designee, vote in favor of the following matters in order for them to be approved:

any alteration, amendment or repeal of any provision of the Company’s certificate of incorporation, Bylaws or other organizational documents;

any creation of a committee of the Board or delegation of authority to a committee of the Board (other than a committee constituted of independent Directors formed with respect to a matter for which one or more Directors has recused themselves due to a conflict of interest);

any extraordinary purchase, repurchase or redemption of capital stock, or any extraordinary dividend or other distribution thereon;

any appointment or removal of any Director, otherwise than in accordance with the Company’s organizational documents and the Stockholders Agreement;

any increase or decrease of the size of the Board;

the acceptance of any transaction or series of transactions that would (i) result in the stockholders of the Company immediately preceding such transaction beneficially owning less than 35% of the total outstanding equity securities of the Company (on anas-converted basis) in the surviving or resulting entity of such transaction (measured by voting power or economic interest), (ii) result in any person or group beneficially owning more than 35% of the outstanding equity securities of the Company (on anas-converted basis and measured by voting power or economic interest), or (iii) involve a disposition, directly or indirectly, of all or substantially all of the consolidated assets of the Company (any such, for

the purposes of the Stockholders Agreement, an “Acquisition”), other than with respect to a sale of 100% of the equity securities of the Company to a third party in a transaction in which all stockholders receive the same per share consideration;

any amendment or modification of that certain Convertible Notes Indenture that would cause the conversion price per share of Common Stock for the Company’s 1.5% Convertible Senior Notes, issued on August 10, 2015 pursuant to the Convertible Notes Indenture, in an original aggregate principal amount of $287,500,000, due in 2020 (the “Convertible Notes”) to be less than the Conversion Price for the Convertible Preferred Stock;

any conversion of the Convertible Notes into Common Stock, or repurchase or redemption of the Convertible Notes in exchange for Common Stock, at a conversion or purchase price per share of Common Stock that is less than the Conversion Price for the Convertible Preferred Stock;

any issuance of equity securities senior to or pari passu with the Convertible Preferred Stock; or

the commencement of bankruptcy or receivership proceedings, or the adoption of a plan of complete or partial liquidation.

Such voting standard shall also be required, for a period of three years after the Closing, for the Board to approve the matters set forth below:

the removal or replacement of the Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer or any other executive officer;

the incurrence of indebtedness of the Company in excess of $10 million in respect of any single transaction or in a series of related transactions; or

any other issuance of new equity securities in excess of $10 million in any single transaction or series of related transactions.

Voting Requirements

For so long as the Investor owns at least 15% of the outstanding Common Stock (on anas-converted basis), the Investor shall vote the shares it beneficially owns in stockholder elections of Directors (a) affirmatively in favor of the election of each Investor Designee, (b) except in a contested election, affirmatively in favor of the election of each Company Designee and (c) in a contested election, either (at the Investor’s election) consistent with the recommendation of the Board or in the same proportion as the voting securities of the Company not beneficially owned by the Investor are voted.

For so long as the Investor owns at least 15% of the outstanding Common Stock (on anas-converted basis), with respect to a stockholder vote on an Acquisition, the Investor shall vote the shares it beneficially owns either (at the Investor’s election) consistent with the recommendation of the Board or in the same proportion as the voting securities of the Company not beneficially owned by the Investor are voted. The Investor may vote the shares it beneficially owns in its sole discretion in any stockholder vote that occurs within one year of the Closing regarding an Acquisition in which the consideration per share of Common Stock is less than $5.35.

For all other matters, for so long as the Investor owns at least 15% of the outstanding Common Stock (on anas-converted basis), the Investor shall vote the shares it beneficially owns either (at the Investor’s election) consistent with the recommendation of the Board or in the same proportion as the voting securities of the Company not beneficially owned by the Investor are voted.

Transfer Restrictions

For two years after the Closing, the Investor shall not transfer any shares of Common Stock or Convertible Preferred Stock unless the transfer:

is approved in advance by a majority of the independent and disinterested members of the Board;

is to any Investor affiliate that becomes a party to the Stockholders Agreement;

is to the Company in connection with a “Fundamental Change” (as defined in the Certificate of Designations) or redemption pursuant to the Certificate of Designations;

is in connection with any Acquisition approved by the Board; or

the transfer constitutes a tender into a tender or exchange offer commenced by the Company.

After such two year restricted period and until the Investor owns less than 10% of the outstanding Common Stock (on anas-converted basis), the Investor may only transfer its shares of Common Stock or Convertible Preferred Stock, in accordance with certain customary restrictions to ensure an orderly market sell-down.

Right of First Refusal

For so long as the Investor owns at least 15% of the outstanding Common Stock (on anas-converted basis), the Investor shall have the right to purchase any new Common Stock or securities convertible into Common Stock, issued by the Company, except for those issued in the ordinary course of business (e.g. issuances pursuant to the Company’s compensation plans), in an amount necessary to allow the Investor to maintain the same percentage ownership of outstanding Common Stock (on anas-converted basis) as it had prior to such issuance. The Investor shall not have such a preemptive right if it intentionally breaches and does not cure within ten business days a material term of the Stockholders Agreement.

Standstill

For so long as the Investor owns at least 15% of the outstanding Common Stock (on anas-converted basis), the Investor and its affiliates shall not:

acquire, offer, agree to acquire or solicit an offer to sell, any beneficial interest in the Company, except for certain customary, de minimis exceptions (e.g., acquisitions due to stock splits or stock dividends) and pursuant to the Investor’s right of first refusal;

make any public announcement or public offer with respect to any merger, business combination, tender or exchange offer, recapitalization, reorganization, restructuring, liquidation, change of control or other similar extraordinary transaction involving the Company or any acquisition of all or substantially all the assets of the Company (unless such transaction is approved or affirmatively recommended by the Board);

make, knowingly encourage or participate in any “solicitation” of “proxies” to vote, or seek to advise or influence the voting of, the Company’s voting securities (except, in each case, in a manner that is consistent with the Board’s recommendation);

seek (or otherwise act alone or in concert with others) to place a representative on the Board, or seek a removal of any Director, in a manner not in accordance with the nomination and voting requirements in the Stockholders Agreement;

call a meeting of stockholders of the Company or initiate any stockholder proposal;

form, join or in any way participate in a “group” pursuant to Section 13(d)(3) of the Exchange Act, with respect to equity securities of the Company;

act alone or in concert with others, in any way, to seek to control, advise, change or influence the management or policies of the Company;

advise or knowingly assist or encourage any discussions, negotiations, arrangements or agreements with any other person in connection with the foregoing activities;

publicly disclose plans, intentions, proposals or arrangements inconsistent with the foregoing activities;

provide any financing for the acquisition of any securities or assets of the Company, subject to certain exceptions pertaining to debt financing for the transfer of such securities or assets to the Investor or its affiliates;

take any actions that the Investor knows or would reasonably be expected to know would require the Company to make a public announcement regarding the possibility of an acquisition;

deposit any equity securities of the Company into a voting trust; or

contest the validity of the foregoing.

Notwithstanding the foregoing, the Stockholders Agreement allows Investor to, among other things, make(i) non-public, confidential proposals to the Board for an Acquisition or (ii) if a definitive agreement with respect to an Acquisition has been publicly announced, public proposals for an alternative Acquisition. In addition, the Investor may make a public proposal for an Acquisition to acquire 100% of the outstanding shares of Common Stock in anall-cash tender offer (x) if the Company’s auditors issue an opinion containing a going concern qualification with respect to a full fiscal year of the Company, (y) if the Company is in material breach (which is not waived or cured) of any financial maintenance covenant in any of its debt instruments or (z) following the eighteen month anniversary of the Closing. However, before making any such proposal, the Investor must (A) engage in good faith in confidential negotiations with the Board for at least twenty days with respect to such proposal and (B) such proposal must be expressly conditioned upon the approval of either a majority of outstanding shares of Common Stock not beneficially owned by the Investor or an authorized independent special committee of the Board.

Other Provisions

The Stockholders Agreement also provides for:

the waiver of the corporate opportunity doctrine with respect to the Investor and its affiliates, including, in certain cases, the Investor Designees;

certain customary information rights;

customary confidentiality obligations;

customary representations and warranties by the Company and the Investor; and

termination on the date on which the Investor’s percentage ownership of outstanding Common Stock (on anas-converted basis) is less than 10%.

Registration Rights Agreement

In connection with the Securities Purchase Agreement, the Company will, at the Closing, enter into the Registration Rights Agreement with the Investor. The following is a summary of selected provisions of the Registration Rights Agreement.

The Investor shall have registration rights for the Underlying Shares, as well as any shares the Investor receives due to a stock split, dividend or other distribution (the “Registrable Securities”). After the expiration of thetwo-year lockupdefinition included in the Stockholders Agreement the Company is required to file a registration statement, including any prospectus, supplement, and amendments (“Registration Statement”), with the SEC registering the resale of the Underlying Shares, and use its reasonable best efforts to cause it to be declared effective by the SEC within thirty days if it is filed using a FormS-3, or within sixty days if the Company must initially file the Registration Statement on FormS-1.

The Investor shall have the right to deliver five written notices requiring the Company to register the requested number of Registrable Securities within thirty or sixty days, (“Demand Notices”)Company’s executive severance policy, established in connection with an offering,

whether or not consummated, involving the Company’s management’s participation in a customary “road show” (a “Marketed Offering”). In addition, the Investor shall have the right to deliver three additional Demand Notices in connection withnon-Marketed Offerings. The Investor shall not make more than four Demand Notices of any type in a365-day period. Unless the Investor requests to have registered all of its Registrable Securities, a Demand Notice for a Marketed Offering may only be made if the sale of the Registrable Securities is reasonably expected to result in cash proceeds in excess of $25 million.

The Company shall have the right to postpone the filing or initial effectiveness of a Registration Statement twice in any twelve-month period, for an aggregate period of not more than ninety days. The Company may enact such postponement or suspension only if the registration of the applicable Registration Statement would (i) require the Company to make a disclosure of material,non-public information that the Company has a bona fide business purpose for not disclosing or (ii) materially interfere with any bona fide material financing, acquisition, disposition or other similar transaction of the Company.

If the Company proposes to file a registration statement under the Securities Act with respect to an offering of the Common Stock, other than on a FormS-4 or FormS-8 or filed to effectuate an offering and sale to employees or Directors of the Company pursuant to an employee stock plan, then the Investor may elect to have the Company register a pro rata number of its Registrable Securities in such registration.

For certain registrations of Registrable Securities, the Company, its executive officers and Directors are subject to aninety-day lockup of sales of Common Stock and various customary restrictions for the registration procedures with the SEC. The Company shall be responsible for all expenses and fees in connection with the offering and sale of Registrable Securities, except for any underwriting discounts or commissions. The Company shall also indemnify the Investor, and its affiliates and representatives, from any and all losses, claims, damages, liabilities, costs (including reasonable attorneys’ fees), judgments, fines and penalties arising out of any untrue statement (or alleged untrue statement) or omission (or alleged omission) of material fact in any Registration Statement or related document incident to such registration, except for any untrue statement (or alleged untrue statement) or omission (or alleged omission) by the Investor, in which case, the Investor shall indemnify the Company, and its officers and Directors, against all losses, claims, damages, liabilities, costs (including reasonable attorneys’ fees), judgments, fines and penalties arising out such untrue statement (or alleged untrue statement) or omission (or alleged omission). The Investor may not assign the Registration Rights Agreement without the consent of the Company and any such assignee must execute a joinder addendum. The Registration Rights Agreement shall terminate (i) with respect to the Investor or any holder of Registrable Securities, on the date on which such person ceases to hold Registrable Securities and (ii) with respect to the Company, the earlier to occur of (x) the date on which all equity securities have ceased to be Registrable Securities or (y) the dissolution, liquidation or winding up of the Company.

China Joint Venture

Under the Securities Purchase Agreement, the Company and the Investor agreed to use reasonable best efforts to enter into definitive agreements for the Joint Venture in accordance with certain key terms that have been mutually agreed.

General

The Joint Venture would be the exclusive operator of the Company’s business in China (excluding Hong Kong, Taiwan and Macau) (the “Territory), including:

manufacturing and/or engaging a third party to contract manufacture vitamins, herbs, minerals, supplements and diet and sports nutrition products under the “GNC” brand or any othersub-brand owned by or exclusively licensed to the Company (“Products”) at facilities within the Territory (we refer to Products manufactured in local facilities within the Territory as “Local Products”);

purchasing Products wholesale from the Company for distribution within the Territory;

purchasing Products in bulk from the Company and repackaging them at facilities within the Territory for distribution within the Territory (we refer to Products purchased from the Company under this bullet and the bullet above as “Imported Products”);

promoting, marketing, selling and distributing Products, whether through offline or online channels, in the Territory; and

providing after-sale and other auxiliary services within the Territory.

In connection with the foregoing, the Company and the Investor would agree to cause the Joint Venture to enter into certain agreements with the Company, including:

an exclusive,sub-licensable license to use the Company’s PRC trademarks and all other trademarks owned by the Company used on the Products under a trademark license agreement (“Trademark License Agreement”);

an exclusive,sub-licensable license to use knowhow and other associated intellectual property rights necessary for conducting the Company’s business in the Territory and the Company’s provision of technical services and support to the Joint Venture regarding the manufacture of Local Products under a technical services agreement (“Technical Services Agreement”); and

a long-term supply agreement (the “Supply Agreement”), under which the Company would appoint the Joint Venture as the exclusive and sole distributor of Products in the Territory and supply the Joint Venture with Imported Products at a mutually agreed cost;

In connection with the Trademark License Agreement, the Joint Venture would pay a royalty to the Company based on the Joint Venture’s sale of Products within the Territory. Under the Joint Venture Term Sheet, the parties would agree that the royalty would meet certain minimum amounts for the first five years of the Joint Venture, and a portion of those royalties would be paid upon commencement of the Joint Venture. Services rendered by the Company under the Technical Services Agreement would be provided to the Joint Venture at cost.

Under the terms of the Supply Agreement, the Company would provide the Joint Venture with terms and conditions no less favorable to the Joint Venture than those provided by the Company in certain other exclusive supply arrangements outside the United States, subject to certain exceptions. In addition, the supply agreement would be subject to certain“take-or-pay” obligations based on agreed upon quarterly target purchase requirements.

Exclusivity

The Company would agree that the Joint Venture has exclusive jurisdiction of business over the Territory during the term of the Joint Venture, including sales through the Company’s existing Chinese online platform atwww.gnc.com.cn and other online platforms in the Territory (other than www.gnc.com). Other than the revenue arising from sales throughwww.gnc.com as described in the next paragraph, all revenue and income arising from orders shipped to consumers residing in the Territory or originated from consumers residing in the Territory, through whatever method (online or offline), would be considered the revenue of the Joint Venture.

For the first nine months following execution of definitive Joint Venture documentation, the Company could continuetosell Products on a passive basis to consumers based within the Territory throughwww.gnc.com. During such time, the Company would use commercially reasonable efforts to redirect consumers based within the Territory fromwww.gnc.com towww.gnc.com.cn and, if the Company is unable to redirect consumers based within the Territory, the Company would pay a royalty to the Joint Venture for any such sales to such consumers.

Valuation and Ownership

The Company’s initial contribution of its China business to the Joint Venture would be valued at approximately $50 million. Following the Investor’s contribution and a simultaneous sale of a portion of the Company’s initial interest in the Joint Venture to the Investor, the Joint Venture would be valued at approximately $80 million, and the Joint Venture would be held 65% by the Investor and 35% by the Company.

Term

The initial term of the Joint Venture would be 20 years, subject to extension upon approval of the Joint Venture’s board.

Corporate Governance

The Joint Venture would be governed by a Board of Directors (the “JV Board”), consisting of a total of five directors, three of whom would be elected by the Investor and two of whom would be elected by the Company. The JV Board would act by simple majority, except that the affirmative vote of both directors elected by the Company would be required for the following transactions:

any change of control of the Joint Venture, including any sale of a majority of the Joint Venture’s equity interests or a majority of its consolidated assets;

any public offering of the Joint Venture or any of its subsidiaries;

significant acquisitions and dispositions by the Joint Venture;

agreements, arrangements or understandings with either party or its affiliates, except those relating to ordinary course of business transactions with aggregate payments below a specified dollar amount or other threshold;

business plans;

capital calls on the parties; and

material changes in the nature or business of the Joint Venture.

In addition to the foregoing, the Investor would have the right to nominate the Chief Executive Officer of the Joint Venture and the Company would have the right to nominate the Chief Financial Officer of the Joint Venture, in each case after consultation with the other party.

Regulatory Matters

The Investor would use commercially reasonable efforts to assist the Joint Venture with the preparation work for registration applications with the PRC Food and Drug Administration for Local Products and Imported Products. The costs and expenses associated with such applications would be borne by the Joint Venture, and any such registrations obtained would be the property of the Joint Venture.

Termination; Effect of Termination

The Joint Venture could be terminated as follows:

by mutual agreement of the Company and the Investor;

at the end of the initial20-year term; or

by either party in the event of a material breach of the License Agreement, the Technical Services Agreement, the Supply Agreement or the definitive agreement governing the Joint Venture.

If the Investor or the Company has a right to terminate the Joint Venture pursuant to the third bullet above, thenon-breaching party would have the right to purchase the equity interests in the Joint Venture held by the breaching party.

2015. In the event of a termination of the Joint Venture for any other reason, each party’s equity interestchange in the joint venturecontrol, unvested stock-based awards generally would accelerate and become fully vested, or would be subject to cancellation for fair value or substituted for awards that substantially preserve the applicable terms of such stock-based awards, and with respect to the 2015 and 2018 Stock Plan, may provide for a customary“buy-sell” provision, whereby a party may make an offerlimited time tail period for awards to purchasebe exercised following the other party’s equity interestchange in the Joint Venture based on a proposed valuationcontrol event. We have assumed for purposes of the Joint Venture,above tables that upon a change in control, equity-based awards would not be accelerated, and instead would be substituted for awards that substantially preserve the other party could either accept the offer or elect to purchase the proposing party’s equity interest in the joint venture for a price based upon the same proposed valuation of the Joint Venture.

The Trademark License Agreement would survive for so long as the Joint Venture or its successor continues operation of the Joint Venture’s business in the Territory as a going concern, unless the license is terminated due to a material breach.

DESCRIPTION OF THE CONVERTIBLE PREFERRED STOCK

The following is a summary of the materialapplicable terms of the preferences, limitations, voting powers and relative rightsstock-based awards.

39

TABLE OF CONTENTS

Pay-Ratio Disclosure

For 2018, the median of the Series A Convertible Preferred Stockannual total compensation for all our employees, within the United States and Canada, other than Mr. Martindale, was $15,866.

Mr. Martindale’s annualized Annual Total Compensation for 2018 was $6,594,147 (see Paragraph 3 below for additional detail). The ratio of the Company as contained inAnnual Total Compensation of our Chief Executive Officer to the Certificate of Designations. While we believe that this summary covers the material terms and provisionsmedian of the Convertible Preferred Stock, we encourage youannual total compensation of the other employees included in this calculation is 415 to read the Certificate of Designations carefully and in its entirety,1, which is a reasonable estimate calculated consistent with applicable rules.

In order to (1) identify the total number of the Company’s employees, (2) determine the annual total compensation of our median employee, and (3) determine the Annual Total Compensation of our Chief Executive Officer, we did the following:

1.We selected November 1, 2018 as the date we would use to identify our median employee. As of that date, the Company’s employee population consisted of approximately 15,342 individuals with 14,266 employees located within the United States and 1,076 employees located in jurisdictions outside of the United States, of which 87, 49, and 940 were located in Ireland, China, and Canada, respectively. We excluded the employees in Ireland and China for this calculation. The total number of employees of the Company utilized for the purposes of the pay-ratio calculation was 15,206.
2.To determine the median of the annual total compensation of all of these employees, excluding Mr. Martindale, we used the amount of wages, salary, bonuses, and other taxable compensation from the payroll records for 2018, for United States Employees, as reported on Form W-2, and for Canadian employees, as reported on Form T4. We identified our median employee using this compensation measure, which was consistently applied to all our employees included in the calculation.
a.In order to most accurately reflect the pay-ratio, the Company annualized the compensation of approximately 1,143 full-time employees and 5,947 part-time employees who were hired in 2018 and employed on November 1, 2018. In order to convert the total annual compensation of the employees located in Canada, who are paid in Canadian dollars, to U.S. dollars, we used the conversion rate of 0.7329 as of December 31, 2018 provided by xe.com.
b.Next, we ranked the compensation for the applicable employees from highest to lowest. The median employee was a part-time sales associate located in the United States with taxable compensation of $15,866 for 2018 (the “Median Employee”).
c.With respect to our Median Employee, we added together all of the elements of such employee’s compensation for 2018 consistent with Item 402(c)(2)(x), resulting in annual total compensation of $15,866. The Median Employee was not paid, and did not otherwise earn or receive any of the compensation elements that are reported in the “Stock Awards”, “Option Awards”, “Changes in Pension Value and Nonqualified Deferred Compensation Earnings”, and “Other Compensation” columns of the Summary Compensation Table.
3.In calculating the “Annual Total Compensation” of Mr. Martindale, we used his salary and all other recurring compensation, each as presented in the Summary Compensation Table.

Additional Information. The required ratio was affected by the larger number, approximately 9,265 as an exhibitof November 1, 2018, of part-time associates whose total compensation is limited to our Current Report on Form8-K filedamounts paid for part-time work.

40

TABLE OF CONTENTS

RATIFICATION OF APPOINTMENT OF AUDITORS
(PROPOSAL 3)

In accordance with the SEC on February 13,Audit Committee’s charter, the Audit Committee is responsible for the appointment and retention of our independent registered accounting firm. In our fiscal years ended December 31, 2018 and is incorporated herein2017, all audit and non-audit services were pre-approved by reference. For more information about accessing the information we fileAudit Committee in accordance with the SEC, please see “Where You Can Find More Information” below.

Number of Shares in SeriesAudit Committee’s charter.

The Certificate of Designations will designate 1,000,000 initial shares of the Convertible Preferred Stock.

Ranking

The Convertible Preferred Stock will rank seniorAudit Committee has appointed PricewaterhouseCoopers LLP (“PwC”) to the Common Stock and to all other junior securities, but junior to the Company’s existing indebtedness, with respect to dividends and rights on the liquidation, dissolution or winding up of the Company.

Stated Value

The Convertible Preferred Stock has a per share stated value of $1,000,serve as our independent registered public accounting firm for our fiscal year ending December 31, 2019, subject to increaseratification by our stockholders. Representatives of PwC will be present at the Annual Meeting to answer questions and will also have the opportunity to make a statement if they desire to do so. For fiscal 2018, PwC rendered professional services in connection with the paymentaudit of dividends in kindour financial statements, including review of quarterly reports and other filings with the SEC, and also provided tax and other services. PwC is knowledgeable about our operations and accounting practices and well qualified to act as described below (the “Stated Value”).

Dividends

Holders of shares of Convertible Preferred Stockour independent registered public accounting firm, and the Audit Committee has appointed PwC as such for fiscal 2019. If the proposal to ratify PwC’s appointment is not approved, other certified public accountants will be entitled to receive cumulative preferential dividends, payable quarterly in arrears, at an annual rate of 6.50% of the Stated Value. Dividends are payable, at the Company’s option, in cash from legally available funds or in kind by issuing additional shares of Convertible Preferred Stock with the Stated Value equal to the amount of payment being made or by increasing the Stated Value of the outstanding Convertible Preferred Stockconsidered by the amount per share of the dividend, or a combination thereof.Audit Committee.

ConversionFees Paid to PricewaterhouseCoopers LLP

Each share of Convertible Preferred Stock will be convertible at any time at the option of the holder into a number of shares of Common Stock equal to (i) the Stated Value plus any accumulatedFees disclosed below include fees billed and unpaid dividends (the “Liquidation Preference”) divided by (ii) a conversion price of $5.35, subject to adjustment. The Conversion Price will be subject to customary antidilution adjustments.

Antidilution Adjustments

The formula for determining the conversion rate and the number of shares of Common Stockexpected to be delivered upon conversion of the Convertible Preferred Stock willbilled for professional services rendered by PwC for our fiscal years ended December 31, 2018 and 2017. Amounts disclosed for 2018 may be adjusted in future filings to reflect actual amounts that were ultimately approved and paid, as appropriate.

Audit Fees, Audit Related Fees, Tax Fees and All Other Fees
 
2018 ($)
2017 ($)
Audit Fees(1)
 
1,622,570
 
 
1,432,100
 
Audit Related Fees(2)
 
10,000
 
 
80,000
 
Tax Fees(3)
 
157,000
 
 
15,000
 
All Other Fees(4)
 
2,700
 
 
1,800
 
 
 
1,792,270
 
 
1,528,900
 
(1)Includes services related to the audit of the Company’s financial statements and internal controls over financial reporting, statutory audits of subsidiaries, and various other filings with the SEC.
(2)Principally includes review of implementation of new accounting pronouncements and franchise disclosure documents.
(3)Includes services related to Federal tax planning and advice, and certain individual tax compliance services.
(4)Represents license fees for access to technical accounting information.

The Audit Committee has concluded that the eventprovision of certain dividends or distributions in shares of Common Stock or subdivisions, splits and combinations of our Common Stock, among other events. If any such event occurs, the number of shares of Common Stock issuable upon conversion may be higher or lower than the initial number of shares designated under the Certificate of Designations.

Optional Redemptionforegoing services is compatible with maintaining PwC’s independence.

The Company has the right to redeem the Convertible Preferred Stock, in whole or in part at any time (subject to

certain limitations on partial redemptions) following the fourth anniversary of the issue date if the last reported sale price of the Common Stock equals or exceeds 130% of the Conversion Price for each of at least twenty consecutive trading days in any thirty trading day period. The Company can make such redemption at a price per share equal to the Liquidation Preference. The Convertible Preferred Stock is perpetual and is not mandatorily redeemable at the option of the holders, except upon the occurrence of a Fundamental Change (as defined in the Certificate of Designations) as described below.

Fundamental Change

Upon the occurrence of a Fundamental Change, each holder of shares of Convertible Preferred Stock will have the option to either (i) cause the Company to redeem all of such holder’s shares of Convertible Preferred Stock for cash in an amount per share equal to the Liquidation Preference, or (ii) continue to hold such holder’s shares of Convertible Preferred Stock, subject to any adjustments to the Conversion Price or the number and kind of securities or other property issuable upon conversion resulting from the Fundamental Change and to the Company’s or its successor’s optional redemption rights described above.

A Fundamental Change is defined in the Certificate of Designations to include, subject to certain exceptions, (i) any person or group becoming a beneficial owner of more than 50% of the voting power of the Company, or if the Company consummates a transaction whereby the existing stockholders of the Company own less than 50% of the Company following such transaction, (ii) the stockholders of the Company approve a liquidation, dissolution or winding up of the Company, or (iii) the Common Stock ceases to be listed on a national securities exchange.

Liquidation Preference

Upon any liquidation, dissolution or winding up of the Company, holders of shares of Convertible Preferred Stock will be entitled to receive, prior to any distributions on the common stock or other capital stock of the Company ranking junior to the Convertible Preferred Stock, an amount in cash per share of Convertible Preferred Stock equal to the greater of (i) the Liquidation Preference and (ii) the amount such holder would receive in respect of the number of shares of Common Stock into which a share of Convertible Preferred Stock is then convertible.

Voting Rights

Holders of shares of Convertible Preferred Stock will be entitled to vote on an as-converted basis with the holders of shares of Common Stock, as a single class, on all matters submitted for a vote of holders of shares of Common Stock. When voting together with the Common Stock, each share of Convertible Preferred Stock will entitle the holder to a number of votes equal to the number of shares of Common Stock issuable upon the conversion of such Convertible Preferred Stock to which such share is entitled as of the applicable record date.

The Certificate of Designations provides that, as long as any shares of Convertible Preferred Stock are outstanding, the Company may not, without the prior affirmative vote or prior written consent of the holders of a majority of the outstanding shares of Convertible Preferred Stock, amend the Company’s articles of incorporation, bylaws or other organizational documents, including the Certificate of Designations in any manner that adversely affects any rights, preferences, privileges or voting powers of the Convertible Preferred Stock or holders of shares of Convertible Preferred Stock.

PROPOSAL – THE SHARE ISSUANCE

On February 13, 2018, the Company entered into the Securities Purchase Agreement with the Investor, pursuant to which the Company agreed to issue and sell to the Investor, and the Investor agreed to purchase from the Company, 299,950 shares of newly created Convertible Preferred Stock for a purchase price of $1,000 per share, or an aggregate purchase price of approximately $300 million. The transaction is subject to customary closing conditions, as well as receipt of all necessary regulatory and governmental approvals, approval of our stockholders and entry into the Joint Venture. The Convertible Preferred Stock will be convertible into shares of the Company’s Common Stock at an initial conversion price of $5.35 per share, subject to customary antidilution adjustments, and will accrue cumulative preferential dividends, payable quarterly in arrears, at an annual rate of 6.50% of the Stated Value. The terms of the Convertible Preferred Stock will be set forth in the Certificate of Designations to be filed by the Company with the Secretary of State of the State of Delaware prior to the closing of the transaction.

Our Common Stock is listed on the NYSE and we are subject to the NYSE rules and regulations. Section 312.03(c) of the NYSE Listed Company Manual requires stockholder approval prior to any issuance of common stock, or of securities convertible into common stock, in any transaction or series of related transactions if (1) the common stock to be issued has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such stock or of securities convertible into or exercisable for common stock, or (2) the number of shares of common stock to be issued is, or will be upon issuance, equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of the common stock or of securities convertible into or exercisable for common stock.

At the closing of the Share Issuance, the Convertible Preferred Stock to be sold to the Investor will be convertible, at the option of the Investor, into 56,065,421 shares of Common Stock (subject to adjustment), which represents greater than 20% of both the voting power and number of shares of our Common Stock outstanding prior to the issuance. Because the sale of the Convertible Preferred Stock to the Investor exceeds 20% of both the voting power and number of shares of our Common Stock outstanding prior to the issuance and would implicate Section 312.03(c) and, since the NYSE rules do not define “change of control,” possibly 312.03(d), we must seek stockholder approval prior to making such issuance. Further, we are obligated to seek such stockholder approval pursuant to the Securities Purchase Agreement.

Certain Effects of the Share Issuance

While our Board believes that the sale of the Convertible Preferred Stock to the Investor is advisable and in the best interests of the Company and our stockholders, you should consider the following factors, together with the other information included in this proxy statement, in evaluating this proposal.

Dilution

If our stockholders approve the Share Issuance, upon the Closing, the Convertible Preferred Stock will initially be convertible into 56,065,421 shares of our Common Stock (subject to adjustment). On anas-converted basis, this would represent approximately 40% of our Common Stock outstanding. As a result, our current stockholders would experience substantial dilution of earnings per share, as well as of ownership percentage and voting rights.

Substantial Stockholder

If our stockholders approve the Share Issuance, upon the Closing, the Investor would hold approximately 40% of the outstanding voting power of the Company. As a result, the Investor will have significant voting power as well as significant influence over our business and affairs.

Market Price

Upon the issuance of the Convertible Preferred Stock, a substantial number of shares of our Common Stock will become issuable upon conversion thereof. This issuance could have an adverse effect on the market price of our Common Stock. Further, pursuant to the Registration Rights Agreement, we will agree to register the resale of the Underlying Shares with the SEC, which means that such shares would become eligible for resale in the public markets. Any sale of such shares, or the anticipation of the possibility of such sales, could create downward pressure on the market price of our Common Stock.

Consequences ofNon-Approval of the Share Issuance

Approval of the Share Issuance is a condition to closing the transactions contemplated by the Securities Purchase Agreement. If the Share Issuance is not approvedvotes cast by our stockholders the Securities Purchase Agreement may be terminated and the transactions contemplated thereby cannot be completed. See the section entitled “Description of the Transaction Documents—Securities Purchase Agreement— Termination of the Securities Purchase Agreement” above for more details.

Vote Required

Pursuant to the rules of the NYSE, the approval of the Share Issuance requires the affirmative vote of a majority of the shares present (inin person or represented by proxy)proxy at the Annual Meeting and entitled to vote atis required to approve this Proposal 3.

Pre-Approval Policies and Procedures

All of the Special Meeting. This meansservices performed for us by PwC during 2018 were pre-approved by the Audit Committee. The Audit Committee’s policy, as reflected in its charter, requires that there mustthe Audit Committee pre-approve on an engagement-by-engagement basis all audit and non-audit services to be more votes “FORperformed by our independent registered accounting firm, provided that the proposal thanAudit Committee may delegate the aggregateauthority to pre-approve such services to a subcommittee of votes “AGAINSTthe proposal plus abstentions atAudit Committee.

Recommendation

THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE RATIFICATION OF THE APPOINTMENT OF PWC AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2019.

41

TABLE OF CONTENTS

AUDIT COMMITTEE REPORT

The following Report of the Special Meeting.Audit Committee does not constitute soliciting material and should not be deemed filed or incorporated by reference into any other Company filing under the Securities Act of 1933 or the Exchange Act, except to the extent the Company specifically incorporates this Report by reference therein.

Abstentions willThe Board has determined that each member of the Audit Committee meets the SEC and the NYSE independence and financial literacy requirements. The Board has also determined that each of Messrs. Berger, Hines and Mallott qualifies as an “audit committee financial expert.”

The Audit Committee has reviewed and discussed our audited financial statements for the year ended December 31, 2018 with both management and the independent auditors. The Audit Committee discussed the auditors’ review of our quarterly financial information with the auditors prior to the release of such information and the filing of our quarterly reports with the SEC.

Further, the Audit Committee discussed with the independent auditors the matters required to be counted as votes “AGAINSTdiscussed by Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard No. 1301 (Communications with Audit Committees), received the proposal. Broker“non-votes” will have no effect onwritten disclosures and the outcomeletter from the independent auditors required by applicable requirements of this vote.

Pursuantthe PCAOB regarding the independent accountant’s communications with the Audit Committee concerning independence and discussed with the auditors the auditors’ independence. The Audit Committee also discussed with the auditors financial management matters related to our Bylaws, eitherinternal control over financial reporting.

Based on these discussions, the ChairmanAudit Committee’s review of our audited financial statements for the year ended December 31, 2018 and the written disclosures received from the independent auditors, the Audit Committee recommended that the Board orapprove the presiding personinclusion of the Special Meeting hasCompany’s audited financial statements in our Annual Report on Form 10-K for the power to recess and/or adjournfiscal year ended December 31, 2018 for filing with the meeting, for any or no reason, to another place, date and time. We intend to adjourn the Special Meeting to solicit additional proxies if there are insufficient votes at the Special Meeting to approve the Share Issuance.SEC.

Recommendation of the Board

THE BOARD

AUDIT COMMITTEE
Michael F. Hines (Chairperson)
Philip E. Mallott
Jeffrey P. Berger

42

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table below sets forth information regarding the beneficial ownership of our Common Stock as of March 20, 2018the Record Date by: (i) each person, or group of affiliated persons, known by us to beneficially own more than 5%five percent of our Common Stock; (ii) each of our named executive officers;the Named Executive Officers; (iii) each of our directors;directors and nominees for director; and (iv) all of our current directors and executive officers as a group, based on information furnished by each person.

Beneficial ownership is determined in accordance with the Exchange Act and includes voting and investment power with respect to our Common Stock. The following table includes Common Stock issuable within 60 days of March 20, 2018the Record Date upon the exercise of all options and other rights beneficially owned by the indicated stockholders on that date. Percentage of beneficial ownership is based on 83,661,96583,966,049 shares of Common Stock outstanding as of March 20, 2018.25, 2019. Except as otherwise noted below, each person or entity named in the following table has sole voting and investment power with respect to all shares of our Common Stock that he, she or it beneficially owns.

Unless otherwise indicated, the address of each beneficial owner listed below is c/o GNC Holdings, Inc., 300 Sixth Avenue, Pittsburgh, PA 15222.

Name of Beneficial Owner

  

Position

  Shares  Percentage 

Kenneth A. Martindale

  

Chief Executive Officer and Director

   455,001 (1)   * 

Tricia K. Tolivar

  

Executive Vice President, Chief Financial Officer and Interim Chief Marketing Officer

   67,513 (2)   * 

Timothy A. Mantel

  

Former Executive Vice President and Chief Merchandising Officer

   110,308 (3)   * 

Guru Ramanathan

  

Senior Vice President and Chief Innovation Officer

   156,589 (4)   * 

Gene E. Burt

  

Executive Vice President, Chief Merchandising Officer and Chief Supply Chain Officer

   11,091 (5)   * 

Michael D. Dzura

  

Former Executive Vice President, Operations

   6,980 (6)   * 

Jeffrey R. Hennion

  

Former Chief Marketing and e-Commerce Officer

      * 

Robert F. Moran

  

Director and Former Interim Chief Executive Officer

   1,019,888 (7)   1.22

Jeffrey P. Berger

  

Director

   96,429 (8)   * 

Alan D. Feldman

  

Director

   62,102 (9)   * 

Michael F. Hines

  

Director

   220,674 (10)   * 

Amy B. Lane

  

Director

   62,254 (11)   * 

Philip E. Mallott

  Director   51,837 (12)   * 

Richard J. Wallace

  Director   63,754 (13)   * 
All directors and executive officers as a group (14 persons)     2,298,275   2.75

Name of Beneficial Owner
Position
Shares
Percentage
Kenneth A. Martindale
Chief Executive Officer and Director
 
606,467
(1) 
 
 
*
Tricia K. Tolivar
Executive Vice President, Chief Financial Officer
 
114,676
(2) 
 
 
*
Gene E. Burt
Former Executive Vice President, Chief Merchandising Officer and Chief Supply Chain Officer
 
22,182
(3) 
 
 
*
Joseph Gorman
Former Executive Vice President of Operations
 
29,066
(4) 
 
 
*
Steven Piano
Senior Vice President, Chief Human Resources Officer
 
5,750
(5) 
 
 
 
Robert F. Moran
Director
 
1,256,631
(6) 
 
1.50
%
Jeffrey P. Berger
Director
 
128,038
(7) 
 
 
*
Hsing Chow
Director
 
0
 
 
 
*
Alan D. Feldman
Director
 
93,711
(8) 
 
 
*
Michael F. Hines
Director
 
227,283
(9) 
 
 
*
Amy B. Lane
Director
 
63,363
(10) 
 
 
*
Philip E. Mallott
Director
 
83,446
(11) 
 
 
*
Michele S. Meyer
Director
 
0
 
 
 
 
Richard J. Wallace
Director
 
95,363
(12) 
 
 
*
Yong Kai Wong
Director
 
0
 
 
 
*
All directors and executive officers as a group (16 persons)
 
 
2,905,806
 
 
3.41
%
*Less than 1% of the outstanding shares of Common Stock.
(1)Consists of (i) 173,186245,549 shares directly held, and (ii) 281,815187,876 shares of time-vested restricted stock.
(2)Consists of (i) 17,637 shares directly heldstock and (iii) 49,876173,042 shares issuable upon the exercise of options that are currently exercisable or will become exercisable within 60 days following March 20, 2018.the Record Date. Does not include 118,045 shares underlying performance based RSUs for which performance results have been certified, that will be settled in stock on December 31, 2020, provided Mr. Martindale remains employed by the Company on such date.
(3)(2)Consists of (i) 77,00427,363 shares directly held and (ii) 33,30487,313 shares issuable upon the exercise of options that are currently exercisable or will become exercisable within 60 days following March 20, 2018.the Record Date. Does not include 26,905 shares underlying performance based RSUs for which performance results have been certified, that will be settled in stock on December 31, 2020, provided Ms. Tolivar remains employed by the Company on such date.
(4)(3)Consists of (i) 57,5674,682 shares directly held and (ii) 99,022 shares issuable upon exercise of options that are currently exercisable or will become exercisable within 60 days following March 20, 2018.

(5)Consists of (i) 2,341 shares directly held and (ii) 8,75017,500 shares issuable upon the exercise of options that are currently exercisable or will become exercisable within 60 days following the Record Date. Does not include 20,179 shares underlying performance based RSUs for which performance results have been certified, that will be settled in stock on December 31, 2020. Mr. Burt resigned from the Company effective March 20, 2018.15, 2019.
(6)Consists of 6,980 shares directly held.
(7)(4)Consists of (i) 919,8885,565 shares directly held and (ii) 100,00023,501 shares issuable upon exercise of options that are currently exercisable or will become exercisable within 60 days following the Record Date. Does not include 20,179 shares underlying performance based RSUs for which performance results have been certified, that will be settled in stock on December 31, 2020. Mr. Gorman resigned from the Company effective March 15, 2019.
(5)Does not include 6,726 shares underlying performance based RSUs for which performance results have been certified, that will be settled in stock on December 31, 2020, provided Mr. Piano remains employed by the Company on such date.

43

TABLE OF CONTENTS

(6)Consists of (i) 936,579 shares directly held, (ii) 31,609 shares of time-vested restricted stock, and (iii) 288,443 shares issuable upon the exercise of options that are currently exercisable or will become exercisable within 60 days following March 20, 2018.the Record Date.
(8)(7)Consists of (i) 67,66482,429 shares directly held, (ii) 14,76531,609 shares of time-vested restricted stock and (iii) 14,000 shares issuable upon the exercise of options that are currently exercisable or will become exercisable within 60 days following March 20, 2018.the Record Date.
(9)(8)Consists of (i) 47,33762,102 shares directly held and (ii) 14,76531,609 shares of time-vested restricted stock.
(10)(9)Consists of (i) 168,989183,754 shares directly held, (ii) 14,76531,609 shares of time-vested restricted stock and (iii) 36,92011,920 shares issuable upon the exercise of options that are currently exercisable or will become exercisable within 60 days following March 20, 2018.the Record Date.
(11)(10)Consists of (i) 16,989 shares directly held, (ii) 14,765 time-vested restricted stock and (iii) 30,500 shares issuable upon the exercise of options that are currently exercisable or become exercisable within 60 days following March 20, 2018.
(12)Consists of (i) 37,07231,754 shares directly held and (ii) 14,76531,609 shares of time-vested restricted stock.
(13)(11)Consists of (i) 13,98951,837 shares directly held and (ii) 31,609 shares of time-vested restricted stock.
(12)Consists of (i) 28,754 shares directly held, (ii) 14,76531,609 shares of time-vested restricted stock and (iii) 35,000 shares issuable upon the exercise of options that are currently exercisable or will become exercisable within 60 days following March 20, 2018.the Record Date.

As of March 20, 2018, basedBased on filings made under Section 13(d) and 13(g) of the Exchange Act reporting ownership of shares and percent of beneficial ownership, as of December 31, 2017,March 25, 2019 the only persons known by us to be beneficial owners of more than 5% of our Common Stock were as follows:

Beneficial Owners of 5% or More of Our Outstanding Common
Stock
  Shares  Percentage 

FMR LLC and certain affiliated parties

245 Summer Street

Boston, MA 02210

   7,172,255 (1)   10.394

BlackRock, Inc.

55 East 52nd Street

New York, NY 10055

   4,633,563 (2)   6.7

The Vanguard Group, Inc.

100 Vanguard Blvd.

Malvern, PA 19355

   5,590,081 (3)   8.10

Beneficial Owners of 5% or More of Our Outstanding Common Stock
Shares
Percentage
Harbin Pharmaceutical Group Co., Ltd.
No. 68, Limin West Fourth Street
Limin Development Zone
Harbin, People’s Republic of China
 
56,065,420
(1) 
 
40.1
%
FMR LLC and certain affiliated parties
245 Summer Street
Boston, MA 02210
 
7,877,006
(2) 
 
9.390
%
BlackRock, Inc.
55 East 52nd Street
New York, NY 10055
 
6,124,028
(3) 
 
7.3
%
(1)Based on the Schedule 13D filed with the SEC on November 19, 2018 by Harbin Pharmaceutical Group Co., Ltd., (“Harbin”) in which Harbin reports it has sole voting power and sole dispositive power over 56,065,420 shares. On February 13, 2018, the Company entered into a Securities Purchase Agreement (the “Original Purchase Agreement”) with Harbin Pharmaceutical Group Holdings Co., Ltd., whose rights and obligations under the Original Purchase Agreement were subsequently assigned to Harbin. On November 7, 2018, the Company and Harbin entered into an amendment to the Original Purchase Agreement (the “Amendment to the Purchase Agreement” and, together with the Original Purchase Agreement, the “Purchase Agreement”). Pursuant to the terms of the Purchase Agreement, Harbin purchased 100,000 shares of the Issuer’s Series A Convertible Preferred Stock, par value $0.001 per share (the “Convertible Preferred Stock”) from the Company on November 8, 2018 at a purchase price per share equal to $1,000.00 for a total purchase price of $100,000,000 (the “Initial Issuance”). Furthermore, pursuant to the terms of the Purchase Agreement, Harbin agreed to purchase (i) 50,000 shares of Convertible Preferred Stock from the Issuer on, or, at the election of Harbin, prior to, December 28, 2018 at a purchase price per share equal to $1,000.00 for a total purchase price of $50,000,000 (the “First Subsequent Issuance”) and (ii) 149,950 shares of Convertible Preferred Stock from the Issuer on, or, at the election of Harbin, prior to, February 13, 2019 at a purchase price per share equal to $1,000.00 for a total purchase price of $149,950,000 (the “Second Subsequent Issuance”). The Convertible Preferred Stock may at any time and from time to time be converted into a number of shares of Common Stock calculated in accordance with the formula contained in the Certificate of Designation.
(2)Based on Amendment No. 56 to Schedule 13G filed with the SEC on February 13, 20182019 by FMR LLC, a parent holding company, Abigail P. Johnson, a Director, the Chairman and Chief Executive Officer of FMR LLC and Fidelity Series Intrinsic Opportunities Fund (the “FSIO”). In the Amendment No. 56 to Schedule 13G, (i) FMR LLC discloses it has sole voting power over 339,158307,168 shares and sole dispositive power over 7,172,2557,877,006 shares, (ii) Ms. Johnson discloses that she has sole dispositive power over 7,172,2557,877,006 shares and (iii) FSIO discloses that it has sole voting power over 5,939,600 shares. Members of the Johnson family are the predominant owners, directly or through trusts, of the Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC, and through a shareholders’ voting agreement, members of the Johnson family may be deemed to form a controlling group with respect to FMR LLC.
(2)(3)Based on the Amendment No. 56 to Schedule 13G filed with the SEC on February 8, 20184, 2019 by BlackRock, Inc. (“BlackRock”) in which BlackRock discloses that it has sole voting power over 4,409,3285,770,322 shares and sole dispositive power over 4,633,5636,124,028 shares.
(3)Based on the Amendment No. 5 to Schedule 13G filed with the SEC on February 9, 2018 by The Vanguard Group, Inc. (“Vanguard”). In the Amendment No. 5 to Schedule 13G, Vanguard reports it has sole voting power over 77,664 shares, sole dispositive power over 5,516,126 shares, shared voting power of 4,100 shares and shared dispositive power over 73,955 shares.

44

TABLE OF CONTENTS

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Our directors, executive officers and holders of more than 10% of our Common Stock are subject to the reporting requirements of Section 16(a) of the Exchange Act, which requires them to file reports with the SEC on Forms 3, 4 and 5 with respect to their ownership and change of ownership of our Common Stock.

Based solely upon a review of the copies of these forms or written representations, which we have received from such persons or entities for transactions in our Common Stock and their Common Stock holdings for our fiscal year ended December 31, 2018, we believe that all reporting requirements under Section 16(a) for such fiscal year were met in a timely manner by our directors, executive officers and holders of more than 10% of our Common Stock, except that there was a failure to timely file Forms 4 on behalf of certain of our Named Executive Officers in connection with exempt tax withholding transactions occurring upon the vesting of awards in 2018 as follows: Messrs. Martindale, Mantel and Burt (one tax withholding transaction each), Mr. Gorman (two tax withholding transactions), and Ms. Tolivar and Dr. Ramanathan (three tax withholding transactions). Each of these filings was made as soon as practicable after discovery that the reporting obligation had been missed.

STOCKHOLDER PROPOSALS FOR FUTURE2020 ANNUAL MEETINGSMEETING

Stockholder proposals submitted pursuant to Rule14a-8 of the Exchange Act for our 2018 Annual Meeting must have been received by us no later than December 12, 2017 to be presented at the 2018 Annual Meeting or to be eligible for inclusion in the proxy materials related thereto under the SEC’s proxy rules. Stockholder proposals submitted pursuant to Rule14a-8 of the Exchange Act for our 20192020 Annual Meeting must be received by us no later than December 11, 201810, 2019 to be presented at the 20192020 Annual Meeting or to be eligible for inclusion in the proxy materials related thereto under the SEC’s proxy rules. Such proposals can be sent to us at GNC Holdings, Inc., 300 Sixth Avenue, Pittsburgh, Pennsylvania 15222, Attention: Secretary.

Our Sixth Amended and Restated Bylaws (the “Bylaws”) prescribe the procedures that a record stockholder must follow to nominate directors for election at an Annual Meetingannual meeting or to bring other business before an Annual Meetingannual meeting (other than matters submitted pursuant to Rule14a-8 under the Exchange Act). The following summary of these procedures is qualified by reference to our Bylaws, a copy of which can be obtained, without charge, upon written request to GNC Holdings, Inc., 300 Sixth Avenue, Pittsburgh, Pennsylvania 15222, Attention: Secretary.

Pursuant to Article II, Section 5(b) of our Bylaws, a record stockholder must provide timely notice of any stockholder proposal (including director nomination(s)) other than those submitted pursuant to Rule14a-8 of the Exchange Act to be properly brought before anthe 2020 Annual Meeting. To be timely, such notice must have been received by February 22, 2018 for our 2018 Annual Meeting, or must be received by February 21, 2019 for our 2019 Annual Meeting, in each case by our secretary at our principal executive offices at 300 Sixth Avenue, Pittsburgh, Pennsylvania 15222.15222 between the opening of business on January 21, 2020 and the close of business on February 20, 2020. The notice must contain the information specified in our Bylaws regarding the stockholder giving the notice and the business proposed to be brought before the meeting. For director nominations, the notice must also contain the information specified in our Bylaws regarding each person whom the stockholder wishes to nominate for election as director and be accompanied by the written consent of each proposed nominee to serve as director if elected. Such stockholder proposals must also be in compliance with the additional requirements set forth in the Bylaws.

WHERE YOU CAN FIND MORE INFORMATION

The SEC allows us to “incorporate by reference” into this proxy statement documents we file with the SEC. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this proxy statement, and later information that we file with the SEC as specified below will update and supersede this information. Except to the extent that information is deemed furnished and not filed pursuant to securities laws and regulations, we hereby incorporate by reference the following filings:

Our Annual Report on Form10-K for the year ended December 31, 2017, filed with the SEC on March 1, 2018;

Our Proxy Statement on Schedule 14A, filed with the SEC on April 11, 2017;

Our Current Reports on Form8-K filed with the SEC on February 13, 2018 (Item 1.01, 2.03, 3.02, 5.02 and 8.01 disclosures only), February 14, 2018, February 23, 2018, February 28, 2018, and March 21, 2018; and

Any documents filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this proxy statement and before However, if the date of the Special Meeting.

This proxy statement incorporates important2020 Annual Meeting is more than 30 days before or more than 70 days after May 21, 2020, to be timely, such notice must be received no earlier than the 120th day prior to the date of the 2020 Annual Meeting and not later than (i) the close of business and financial information abouton the Company from other documents that are90th day prior to the date of the 2020 Annual Meeting or (ii) the tenth day following the day on which the public announcement of the date of the 2019 Annual Meeting was first made.

With respect to stockholder proposals not included in or delivered with this document. This information is available to you without charge upon your written or oral request. You can obtain the documents incorporated by reference in thisour proxy statement throughfor the 2019 Annual Meeting, the persons named in the Board’s proxy for the 2020 Annual Meeting will be entitled to exercise the discretionary voting power conferred by such proxy under the circumstances specified in Rule 14a-4(c) under the Exchange Act.

OTHER INFORMATION

Annual Report on Form 10-K

Copies of our website, www.gnc.com, or from the SEC at its website, www.sec.gov, orAnnual Report on Form 10-K can be obtained free of charge upon request to GNC Holdings, Inc., 300 Sixth Avenue, Pittsburgh, Pennsylvania, 15222, Attention: Secretary. Stockholders may also read and copy materials that

45

TABLE OF CONTENTS

ANNEX A

Calculation of Non-GAAP to GAAP financial metric

Operating income (EBIT) including certain specified adjustments disclosed in our quarterly earnings reports, was used as a performance metric under the 2018 Stock Plan. Below we file withhave set forth a reconciliation of the SEC atadjusted EBIT to the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549.

HOUSEHOLDING

The SEC permits companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process,GAAP financial metric, which is commonly referredbased upon reported EBIT from the Company’s audited financial statements.

GNC HOLDINGS, INC. AND SUBSIDIARIES

Reconciliation of Operating Income to as “householding,” potentially means extra convenience for stockholders and cost savings for companies. Stockholders who hold their shares through a nominee, such as a broker, bank, broker-dealer or similar organization may receive notice from that nominee regarding the householding of proxy materials. As indicated Adjusted Operating Income
(in the notice, a single proxy statement will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from an affected stockholder. Once a stockholder has received notice that a nominee will be householding, householding will continue until the stockholder is notified otherwise or until the stockholder has revoked consent by notifying the nominee. If you hold your shares in “street name” and would prefer to receive separate copies of a proxy statement for other stockholders in your household, either now or in the future, please contact your nominee. If you are record holder of your shares and would prefer to receive separate copies of a proxy statement for other stockholders in your household, either now or in the future, please contact: GNC Holdings, Inc., 300 Sixth Avenue, Pittsburgh, Pennsylvania 15222, Attention: Secretary. Stockholders who currently receive multiple copies of the proxy statement at their addresses and would like to request “householding” of their communications should contact their broker or the Company, as applicable.

OTHER MATTERSthousands, except per share data)

Pursuant to our Bylaws, only such business as is specified in this proxy statement will be conducted at the Special Meeting.

 
Year ended
December 31,
2018
Reported
$
(112,353
)
Gains on refranchising
 
(513
)
Long-lived asset impairments
 
438,236
 
Joint Venture start-up costs
 
1,624
 
Retention
 
6,971
 
Selling, general and administrative(1)
 
2,162
 
Adjusted
$
160,833
 
By Order(1)Includes severance expenses associated with the organizational realignment to more effectively align the structure in support of the Boardkey growth areas of Directors

LOGO

Kenneth A. Martindale
Chief Executive Officerthe Company, as well as a legal-related charges.

A-1

TABLE OF CONTENTS


Annex I

LOGO

February 12, 2018

GNC Holdings, Inc.

300 Sixth Avenue

Pittsburgh, Pennsylvania 15222

LadiesTHIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.KEEP THIS PORTION FOR YOUR RECORDSDETACH AND RETURN THIS PORTION ONLYTO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) DateTo withhold authority to vote for anyindividual nominee(s), mark “For AllExcept” and Gentlemen:

GNC Holdings, Inc. (“GNC” orwrite the Company”) has engaged Valuation Research Corporation (“VRC”) as independent financial advisor to provide certain valuation advisory services to GNC’snumber(s) of thenominee(s) on the line below.0 0 00 0 00 0 00000417065_1 R1.0.1.18For Withhold For AllAll All ExceptThe Board of Directors (the “Board”) with respect to a potential transaction in which the Company will sell to prospective investors on or about the date hereof preferred sharesrecommends you vote FORthe following:1. Election of the Company (the “Convertible Preferred Shares”) that are convertible into common shares of the Company (the “Common Shares”) at a conversion price of $5.35 per Common Share (the “Conversion Price”). On a primary share basis, the Convertible Preferred Shares will be convertible into approximately 40.2% of the Company’s outstanding Common Shares. The Company’s sale of Convertible Preferred Shares and all related sources and uses of funds, collectively, are referred to herein as the “Transaction.

In connection with the Transaction, the Company has requested that VRC render to the Board this opinion letter (the “Fairness Opinion”) expressing VRC’s view as to whether the Conversion Price of the Convertible Preferred Shares in the Transaction is fair from a financial point of view to the Company.

The Fairness Opinion does not address (i) the fairness of the Transaction, in whole or in part, or any terms associated therewith, in each case to the Company’s or any other person’s or entity’s creditors or other parties not expressly addressed in the Fairness Opinion; (ii) the relative risks or merits of the Transaction, or any other business strategies or transactional alternatives that may be available to the Company or any other person or entity; (iii) the underlying business decisions of the Company or any other person or entity to enter into or consummate the Transaction; (iv) any specific legal, tax, accounting, or financial reporting matters related to or associated with the Transaction; (v) the fair value of the Transaction in each case under any state, federal, or international laws relating to appraisal rights or similar matters; (vi) the book value of the assets and liabilities of, or otherwise associated with or comprising, the Company; (vii) the projections provided by the Company or the Company’s management for periods before or after the consummation of the Transaction; (viii) any employment or other agreements entered into in connection with the Transaction; or (ix) any matters relating to fees paid by the Company or any other person or entity in connection with the Transaction.

In rendering the Fairness Opinion, VRC conducted only such reviews, analyses, and inquiries, and considered such information, data and other material as are, in VRC’s judgement, customary for evaluation of transactions similar to the Transaction and otherwise for engagements of this type and necessary and appropriate based on the facts and circumstances of the Transaction and the engagement. In conducting its reviews and analyses, and as a basis for arriving at the opinion expressed herein, VRC utilized methodologies, procedures and considerations it deemed relevant and customary under the circumstances; and took into account its assessment of general economic, industry, market, financial and other conditions, which may or may not prove to be accurate, as well as its experience as a valuation financial advisor in general. Further, in rendering the Fairness Opinion, VRC did not conduct any due diligence whatsoever on the prospective investors or participants in the Transaction or the purchasers of any securities or interests involved in the Transaction.

Without limiting the generality of the foregoing, we have reviewed, among other things, the form of Securities Purchase Agreement to be entered into by and among the Company and the prospective investor, together with

Valuation Research Corporation    312 Walnut Street Suite 1700    Cincinnati, OH 45202    Phone 513.579.9100    valuationresearch.com

the other documents related to the Transaction and referred to therein; annual reports to stockholders and Annual Reports on Form10-K of the Company for the five fiscal years ended December 31, 2011 and December 31, 2016 respectively; certain interim reports to stockholders and Quarterly Reports on Form10-Q of the Company; certain other communications from the Company to their respective stockholders; certain publicly available research analyst reports for the Company; certain internal financial analyses and forecasts for the Company for the four full years ended 2021, both stand-alone and pro forma for the Transaction, prepared by Company management and approved for our use by the Company and the Board (collectively, the “Forecasts”); the reported price and trading activity for the Common Shares; and the financial terms of certain recent business combinations in the same industry as the Company and in other industries. We have also held discussions with members of the senior management of the Company regarding their assessment of the past and current business operations, financial condition and future prospects of the Company and the strategic rationale for, and the potential benefits to the Company of, the Transaction; compared certain financial and stock market information for the Company with similar information for certain other companies the securities of which are publicly traded, including a review of the current and historical market prices and trading volume for the Company’s publicly traded securities, and the historical market prices and certain financial data of publicly traded securities of certain other companies that we deemed to be relevant; and performed such other financial studies, inquiries and analyses, and considered such other factors and information, as we deemed appropriate.

With your permission, VRC assumed and relied upon, without independent verification or independent appraisal, the accuracy and completeness of all information provided to VRC by or on behalf of the Company or the Board (collectively, “Information”), and all other information, data and other material (including, without limitation, financial forecasts and projections) furnished or otherwise made available to, or discussed with or reviewed by, VRC in connection with the Fairness Opinion, or that was publicly available.

In addition, VRC assumed and relied upon the assumption, without independent verification, that any financial forecasts and projections provided to VRC by or on behalf of the Board or the Company in connection with the Fairness Opinion have been reasonably and prudently prepared in good faith and were based upon assumptions that are reasonable and reflect the best then currently available estimates and judgments of the Company’s management as to the matters covered thereby. VRC further assumed that any Information provided by or on behalf of the Board or the Company in connection with the Fairness Opinion did not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in light of the circumstances under which such statements were made.

With your permission, VRC assumed, without independent verification, (i) the accuracy and adequacy of the legal advice given by counsel to the Board or the Company on all legal matters with respect to the Transaction; (ii) that all procedures required by law to be taken in connection with the Transaction have been, or will be, duly, validly and timely taken and that the Transaction will be consummated in a manner that complies with all applicable laws and regulations and that conforms in all material respects to the description thereof set forth herein; (iii) that the Transaction is consummated in a timely manner in accordance with the terms and conditions set forth in the related definitive agreements and other documents provided to VRC; (iv) that each of the Board and the Company is in compliance in all material respects (and will remain in compliance in all material respects) with any and all applicable laws, rules or regulations of any and all relevant legal or regulatory authorities; and (v) that the Transaction will be consummated in a manner that complies in all material respects with any and all applicable laws, rules and regulations of any and all legal or regulatory authorities.

VRC did not make any independent evaluation of the Company’s (or any other party’s) solvency or creditworthiness nor did we make any physical inspection or independent appraisal or evaluation of any of the assets, properties or liabilities (contingent or otherwise) of the Company or any other party. VRC does not express herein any opinion regarding the liquidation value of any entity or business. In addition, VRC did not undertake any independent analysis of any potential or actual litigation, regulatory action, possible unasserted claims or other contingent liabilities to which the Company is or may be a party or of which it may be the subject, or of any governmental investigation of any possible unasserted claims or other contingent liabilities to which the Company is or may be a party or otherwise may be subject.

VRC relied upon and assumed, without independent verification, that, other than as expressly disclosed to VRC in writing by the Board or the Company, there was no material change in the assets, liabilities, financial condition, results of operations, business or prospects of the Company between the date of the most recent financial statements of or relating to the Company provided to VRC by or on behalf the Board or the Company in connection with the Fairness Opinion and the date of the Fairness Opinion; and that there are no facts or other information that would make any of the information (including, without limitation, the Information) reviewed by VRC incomplete or misleading. VRC further assumed that there will be no subsequent events that would materially affect the views set forth in the Fairness Opinion.

The Fairness Opinion is not intended to constitute a recommendation to the Board, the Company or any other party as to how they should vote, approve, disapprove, or act with respect to any matters relating to the Transaction. The Fairness Opinion does not represent an assurance, warranty, or guarantee that the price to be paid in the Transaction is the highest or best amount that can be obtained in connection with the Transaction or any other transaction.

VRC did not initiate any discussions, or solicit any indications of interest, with any third parties with respect to the Company or the Transaction. The Fairness Opinion speaks only as of the date thereof and addresses only the Transaction, and does not speak to or address any period thereafter or any subsequent business transaction, acquisition, dividend, share repurchase, debt or equity financing, recapitalization, restructuring or other actions, transactions or events not specifically referred to in the Fairness Opinion. Furthermore, the Fairness Opinion does not represent an assurance, guarantee, or warranty that the Company will not breach, or default on or under, any of its debt or other obligations or liabilities, nor does VRC make any assurance, guarantee, or warranty that any covenants, financial or otherwise, associated with any financing or existing indebtedness will not be breached in the future.

The Fairness Opinion is necessarily based on economic, industry, market, financial and other conditions and circumstances as they exist and to the extent that they can be evaluated by VRC as of the date hereof. VRC assumes no responsibility to update or revise the Fairness Opinion based upon any events or circumstances occurring subsequent to the date hereof.

VRC is continually engaged in performing financial analyses with respect to businesses and their securities in connection with mergers and acquisitions and other transactions for corporate and other purposes. Except for our engagement in connection with the Fairness Opinion, we have not acted as financial advisor to the Company in connection with the Company’s consideration of the Transaction and have not participated in the negotiations leading to the Transaction.We will receive a fee in connection with the delivery of this opinion. and the Company has agreed to reimburse certain of our expenses and indemnify us against certain liabilities arising out of our engagement. No portion of our fee is contingent upon either the conclusion expressed in this Opinion or whether or not the Transaction is successfully consummated. We may provide valuation advisory services to the Company in the future, in connection with which we may receive compensation. From time to time, we and our affiliates have in the past provided services to the Company unrelated to the proposed Transaction, including valuation services for the Company for financial reporting purposes.

The Fairness Opinion is intended solely for the benefit, use, and reliance of the Board in connection with the Transaction, and may not be publicly disclosed without the express written consent of VRC.

Based upon and subject to the foregoing, it is our opinion that, as of the date hereof, the Conversion Price of the Convertible Preferred Stock in the Transaction is fair from a financial point of view to Company.

This Fairness Opinion has been approved by the opinion review committee of VRC.

Respectfully submitted,

LOGO

VALUATION RESEARCH CORPORATION

Engagement#18377

LOGO

GNCDirectorsNominees01 Alan D. Feldman 02 Michael F. Hines 03 Amy B. Lane 04 Philip E. Mallott 05 Kenneth A. Martindale06 Robert F. Moran 07 Hsing Chow 08 Yong Kai Wong 09 Michele S. MeyerGNC HOLDINGS, INC. 300INC.300 SIXTH AVENUE PITTSBURGH,AVENUEPITTSBURGH, PA 15222 Investor Address Line 1 Investor Address Line 2 Investor Address Line 3 Investor Address Line 4 Investor Address Line 5 John Sample 1234 ANYWHERE STREET ANY CITY, ON A1A 1A1 1 OF 2 VOTE15222VOTE BY INTERNET - www.proxyvote.com Usewww.proxyvote.comUse the Internet to transmit your voting instructions and for electronic delivery of information.ofinformation. Vote by 11:59 P.M. ET on 04/24/2018.05/20/2019. Have your proxy card in hand when youwhenyou access the web site and follow the instructions to obtain your records and to create ancreatean electronic voting instruction form. ELECTRONICform.ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS IfMATERIALSIf you would like to reduce the costs incurred by our company in mailing proxy materials,proxymaterials, you can consent to receiving all future proxy statements, proxy cards andcardsand annual reports electronically via e-mail or the Internet. To sign up for electronicforelectronic delivery, please follow the instructions above to vote using the Internet and,Internetand, when prompted, indicate that you agree to receive or access proxy materials electronicallymaterialselectronically in future years. VOTEyears.VOTE BY PHONE - 1-800-690-6903 Use1-800-690-6903Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on 04/24/2018.ETon 05/20/2019. Have your proxy card in hand when you access the web sitecall and then follow the instructions to obtain your records and to create an electronic voting instruction form. VOTEtheinstructions.VOTE BY MAIL Mark,MAILMark, sign and date your proxy card and return it in the postage-paid envelope we have providedhaveprovided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood,NY 11717. NAME THE COMPANY NAME INC. - COMMON THE COMPANY NAME INC. - CLASS A THE COMPANY NAME INC. - CLASS B THE COMPANY NAME INC. - CLASS C THE COMPANY NAME INC. - CLASS D THE COMPANY NAME INC. - CLASS E THE COMPANY NAME INC. - CLASS F THE COMPANY NAME INC. - 401 K CONTROL # SHARES 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 PAGE 1 OF 2 TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. The11717.The Board of Directors recommends you vote FOR the following proposal:proposals: For Against Abstain 1. To approve, in accordance with Section 312.03Abstain2. The adoption, by non-binding vote, of the NYSE Listed Company Manual,advisory resolution to approve the issuance by GNC Holdings, Inc. (the “Company”)compensation paid to Harbin Pharmaceutical Group Holdings Co., Ltd. (the “Investor”)theCompany's named executive officers in a private placement of 299,950 shares of a newly created series of convertible preferred stock (the “Convertible Preferred Stock”)2018, as disclosed in the proxy materials.3. The ratification of the Company, which will includeappointment of PricewaterhouseCoopers LLP as the right to (i) atindependent registered publicaccounting firm for the option ofCompany's 2019 fiscal year.NOTE: Such other business as may properly come before the Investor, convert such Convertible Preferred Stock into shares of the Company’s Class A common stock, par value $0.001 per share, and (ii) receive additional shares of Convertible Preferred Stockmeeting or an increase in the stated value of the Convertible Preferred Stock as a result of the payment of non-cash dividends. Pleaseany adjournment thereof.Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary,please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership,orpartnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date JOB # Signature (Joint Owners) Date SHARES CUSIP # SEQUENCE # 02 0000000000 0000370054_1 R1.0.1.17

TABLE OF CONTENTS



LOGO

Important Notice Regarding the Availability of Proxy Materials for the SpecialAnnual Meeting:The Notice & Proxy Statement isand Form 10-K are available at www.proxyvote.com GNCwww.proxyvote.comGNC HOLDINGS, INC. SpecialINC.Annual Meeting of Stockholders April 25, 2018StockholdersMay 21, 2019 8:3000 AM ET ThisEDTThis proxy is solicited by the Board of Directors TheDirectorsThe Stockholder(s) hereby appoint(s), Tricia K. Tolivar and Kevin G. Nowe, or either of them, as proxies, each witheachwith the power to appoint his or her substitute, and hereby authorize(s) them to represent and vote, as designatedasdesignated on the reverse side of this ballot, all of the shares of common stock of GNC HOLDINGS, INC. that the stockholder(s)thestockholder(s) is/are entitled to vote at the SpecialAnnual Meeting of Stockholders to be held at 8:3000 AM ETEDT, on April 25, 2018,May21, 2019, at the Omni William Penn Hotel, 530 William Penn Place, Sternwheeler Room, Pittsburgh, Pennsylvania 15219, and any adjournmentanyadjournment or postponement thereof. Thisthereof.This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made,ismade, this proxy will be voted in accordance with the Board of Directors’ recommendations. ContinuedDirectors' recommendations.Continued and to be signed on reverse side 0000370054_2 R1.0.1.17